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PART I: AN APPROACH TOWARD THE SYNTHESIS OF (±)-KOUMINE
Chapter I. General Introduction
A widely adopted characterization of secondary metabolites, known
collectively as natural products, defines them as substances that appear to be
nonessential to the plant, insect or microorganism producing them.These
natural products are thereby distinguished from those of the primary metabolism
such as fatty acids, sugars, amino acids and nucleotides that are indispensable
for cell growth and maintenance of the organism.
Natural products, in the form of crude plant extracts, have been used by
man since the dawn of time:primitive man found these extracts expedient as
medicines for the relief of pain or alleviation of the symptoms of disease, as
poisons for use in warfare and hunting, as effective agents for euthanasia and
capital punishment, and as narcotics, hallucinogens, or stimulants to alleviate
fatigue and hunger.
The term Alkaloids comprises a large class of natural products that are
biogenetically derived from amino acids and owe their behavior as bases to the
presence of nitrogen in their molecular structure. They principally occur in the
leaves, seeds, roots and the bark of higher plants, particularly those of the
families Papilonaceae (lupis), Papaverceae (poppies), Ranunculae (aconites)
and Solanaceae (tobacco, potato, tomato).
The biological activity of some alkaloids such as strychnine or yohimbine
is legendary.In fact, almost all plant alkaloids possess in varying degrees
interesting pharmacological activity. Although the number of medicinally useful2
alkaloids is restricted due to the toxicity that they frequently display, those
alkaloids that are in therapeutic use today constitutea very important group of
medicinal agents.
Organic chemists have long been fascinated by the complex structural and
synthetic puzzles posed by alkaloid chemistry. Total synthesis of alkaloid natural
products, aside from being the ultimate proof of structure, has been centralto the
development of new methods for synthesis and structure elucidation in organic
chemistry.While some alkaloids are still obtained from plantsources for
economic reasons even after their total synthesis has been achieved (for
example, reserpine, ergotamine, morphine), synthesis has largely replaced the
plant source in the supply of a number of other alkaloids importantto medicine
(for example, ephedrine or quinine).3
Chapter II:An Approach toward the Synthesis of (±)-Koumine.
History and Background
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(-)-Koumine (1) is the principle constituent of Gelsemium elegans
Bentham, a plant used in traditional folk medicine in China.1Reportedly, the
toxic plant (known locally as "Kou-Wen") also has a notorious reputation in
Chinese forensic medicine for its implication in homicides.
The first report available in the West of the isolation and purification of
koumine appeared in 1931.2While the Chinese plant Gelsemium elegans
over the centuries has found use for treatment of severe pain, the
pharmacological properties of (-)-koumine have not been systematically
studied outside of China.Crude preparations from Gelsemium elegans in
combination with aspirin are commonly used in China for the palliation of
various acute cancer pains, particularly hepatic cancer.Recent clinical
evaluation of (-)-koumine in the treatment of malignant tumors has given good
results.3=
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(-)-Koumine bears some structural resemblance to (+)-gelsemine (2),
the principal alkaloid isolated from various Gelsemium species suchas
Gelsemium sempervirens(Carolina jasmine). The latter plant is commonly
found throughout the southeastern United States and northern Mexico. Roots
of that plant are an ingredient in some Mexican liquors and extracts of its
flowers have been used by the perfume industry.4(+)-Gelsemine, a
compound with a long western medicinal history,5 was first isolated in 1870.It
is a strong central nervous system stimulant as wellas an analgetic and
antihypertensive agent, and its pharmacological properties have been quite
thoroughly explored.
Toxicity studies in rodents have shown that the acute toxicity of (-)-
koumine is comparable to that of (+)-gelsemine which hasa medium lethal
dose (MLD) of 180 mg/Kg, while other alkaloids of Gelsemium elegansare
much more toxic.6For example, humantenidine has a MLD of 185 jig/Kg.
Toxicity presents a serious limitation for the clinical application of these
alkaloids.The clinical symptoms of gelsemium poisoning in humans and
rodents have been described as closely resembling those of strychnine
poisoning.Intoxication produces powerful excitation of all parts of the central
nervous system, which does not result from direct synaptic excitation but rather
from selective blockage of inhibitory neurons.Strychnine is known to
antagonize the inhibitory neurotransmitter glycine which has its highest5
receptor density in the spinal cord, brain stem and thalamus.In the spinal
cord, the alkaloid suspends the reciprocal inhibition that exists between
antagonistic muscles.Minor sensory stimulation then induces violent
convulsions that follow a characteristic motor pattern.The pattern of the
convulsion is determined by the most powerful muscles acting at a given joint.
During these convulsions all skeletal muscles including those of the face are
in full contraction and the body is arched in hyperextension so that the crown
of the head and the heels may be touching the ground.If untreated, death
usually occurs after the second to fifth full convulsion.
Both (-)-koumine and (+)-gelsemine resisted structure elucidation by
chemical degradation and spectroscopic analysis for many years. Eventually,
both structures were solved through crystallographic studies.7'8 The absolute
stereochemistry of (-)-koumine was established through partial synthesis from
vobasin.9
A variety of structurally diverse alkaloids have been isolated from
Gelsemium sempervirensandGelsemium rankiniifound in the southeastern
United States as well as from the less explored Chinese species Gelsemium
elegans .6Recently, an alkaloid extract of the latter plant has afforded two
new koumine-related substances, (19R)-hydroxydihydrokoumine (3a) and
(19S)-hydroxydihydrokoumine (3b), whose structures and stereochemistry
were confirmed by X-ray diffraction analysis.1°Along with (-)-koumine-N-
oxide (4) and (+)-21-oxo-gelsemine (5)Gelsemium eleganshas yielded (-)-
taberpsychine (6), a compound believed to be a key biogenetic precursor for
both (-)-koumine and (+)-gelsemine.66
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Several alkaloids of the humantenine family have also been isolated.
Their oxindole skeleton is similar to that of gelsemine but is lacking a bond
between C-6 and C-20.It has been speculated that humantenine (7) may be
the immediate biogenetic precursor of gelsemine (scheme 1).1
scheme 1
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In addition, gelsedine (8), koumindine (9), and sempervirine (10)
represent examples of structurally interesting alkaloids obtained from
Gelsemiumspecies.1OH HO
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Zenk et al. proposed that the Gelsemium alkaloids are biosynthesized
by a route analogous to that leading to monoterpenoid alkaloids and which
follows the biological transformations of strictosidine (13) (scheme 2).11 This
was confirmed through incorporation of [6 -14C]- strictosidine into gelsemine
(0.47%). However, the detailed biogenetic relationship between the different
alkaloids in the series remains to be elucidated.
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Nevertheless, a "map of biogenetic speculation" has been proposed for
the origin of the Gelsemium alkaloids (scheme 2).12 According to this scheme
strictosidine, after being transformed to a coryantheine-type base 14, forms
the koumidine skeleton 15 by closure between C-5 and C-16.After N-
methylation, 15 is converted to (-)-taberpsychine (6).(-)-Taberpsychine (6)
has been proposed as the biogenetic precursor of the humantenine-type
alkaloids which in turn are transformed to the gelsemine skeleton (scheme 3).
(-)-Taberpsychine (6)
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scheme 3
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Research directed at a biomimetic synthesis of (-)-koumine has
confirmeditsrelationship to (-)-taberpsychine (6) (scheme 4).Thus,
taberpsychine was converted to koumine by oxidation with selenium dioxide9
in the presence of hydrogen peroxide in a sequence believed to mimic the
final steps in the biosynthesis of (-)-koumine.13This precedent had direct
bearing on the synthetic planning and execution of the first total synthesis of
(+)-koumine (1) (the unnatural enantiomer) by Magnus.14
18
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It was recognized thatif the taberpsychine structure possessed a
leaving group at C-18, a facile intramolecular SN2' process could lead to the
ring system of koumine.
H
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scheme 5
In fact, while the cyclization of natural (-)-taberpsychine (6) via allylic
oxidation with selenium dioxide provides (-)-koumine only in modest yield,10
treatment of (+)-18-hydroxytaberpsychine (16) under Mitsunobu conditions
was found to give (+)-koumine (1) smoothly in 72% yield (scheme 5).
The Magnus synthesis begins with the natural amino acid (S)-(-)-
tryptophane (17) which bears the same absolute configuration at C-5 as that
found in natural (-)-koumine (scheme 6).
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However, in the course of a Dieckmann condensation performed on the
intermediate 18 the C-5 stereocenter is inverted, resulting in the synthesis of
(+)-koumine, the unnatural enantiomer. Recently, Bailey15 reported that it is
possible to avoid this epimerization.Thus, a route to natural (-)-koumine is
formally available which does not require (R)-(+)-tryptophane as starting
material.17
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Dieckmann condensation of 18 afforded the tetracyclic compound 19
which, after selective debenzylation and decarboxylation,was converted to
the amino ketone 20 (scheme 7).N-alkylation of 20 with propargyl bromide
gave the alkyne 21.Treatment of 21 with tert- butyldimethylsilyltriflate
followed by acylation of the alkyne with methyl chioroformate producedthe
a,(3- unsaturated acetylenic ester 22. Cleavage of the silyl enol ether, followed
by treatment of the resulting ketone with pyrrolidine and trifluoroaceticacid,
promoted an intramolecular Michael addition yielding 23. The quinuclidinic
ketone 23 was subjected to Tebbe's reagent resulting in homologation ofthe
carbonyl group to give 24 (scheme 8).Hydroboration with diisoamylborane
introduced the hydroxymethyl group in a stereoselective fashion leadingto12
25. Reduction of 25 with diisobutylaluminum hydride followed by removal of
the remaining benzyl group with sodium in ammonia, afforded the allylic diol
26 (scheme 8).
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Fragmentation of 26 in the presence of methyl chloroformate is
presumed to occur via the extended iminium ion 27 to afford 28 which, after
reduction of the methyl carbamate, yielded (+)-18-hydroxytaberpsychine (28).
Finally, SN2' cyclization of (+)-18-hydroxytaberpsychine (29) in thepresence
of diethyl azodicarboxylate and triphenylphosphine afforded (+)-koumine (1)
in 72% yield (scheme 9).26
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Frequent reports of synthetic approaches toward gelsemine have
appeared ever since the structure elucidation of that alkaloidwas first
announced.However, only very recently have three separate accounts
claiming total syntheses of racemic gelsemine been published.16 Interms of
theirsynthetic plan, virtually all the approaches share thecommon feature
that the oxindole portion is elaborated from the tetracyclic ketone 30(scheme
10).
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Many different strategies have been employed for the assembly of 30
and the difficult problem of its oxindolization. The first synthesis of 30was
achieved by Fleming et al. in 1986 (scheme 11). However theseresearchers
were unable to complete the synthesis of gelsemine from 30.17OTHP
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The central feature of the Fleming synthesis is the rearrangement of the
bicyclo[2.2.2]octene system 33 to the bicyclo[3.2.1 loctane skeleton
embedded in the target ketone 30.A Diels-Alder reaction provided a
convenient entry to the bicyclo[2.2.2]octene 33 (scheme 12) which was
transformed to the rearrangement precursor 35 in six steps.After
rearrangement of 35 to 37, the pyran ring of 38 was installed and the latter
was taken on to the allyl silane 41. A Mannich reaction of 41, in which
advantage was taken of the carbon nucleophilicity of the ally! silane, yielded
30 (scheme 12).HO
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Other successful routes to the tetracyclic ring system of 30 have been
reported by the Hart, Johnson and Speckamp groups.16 Progress towarda
very efficient entry to this ring system has also been announced by
Overman.18This latter approach features the construction of the
azatricyclo[4.4.0.0.2,8]decane substructure of gelsemine froma readily
available bicyclo[2.2.2]octenylamine precursor.
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Thus, the Diels -Alder adduct was homologated to the diene 44
(scheme 13) by oxidation with selenium dioxide followed by Wittig
methylenation.Curtius rearrangement and reaction of the resultant amine
with chloroacetonitrile afforded 45 which was subjected to a base-catalyzed
aza-Cope rearrangement with excess potassium hydride in tetrahydrofuran.
Quenching of the resulting imine enolate 47 with ethyl chloroformate provided
48 (scheme 14).
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Bromination of 48 introduced functionality that could allow the eventual
elaboration of the hydropyran ring of gelsemine.In this connection, the 13-
bromo enamide 49 was found to readily undergo acid-catalyzed Mannich
cyclization to give 50 (scheme 14) in 85% yield.In contrast, imine enolate 47
did not undergo Mannich cyclization, perhaps due to fast retro-Mannich
fragmentation of the tricyclic product (scheme 15).KO =
47
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Although traditional oxindole syntheses such as the Brunner reaction
and its variations proved unsuccessful with 30, extensive investigations on
model systems by Fleming, Johnson and Overman have led to the
development of practical methods for this particular oxindolization.19
Over the last five years the Overman group has extensively explored
the scope of intramolecular palladium-catalyzed alkene arylations (Heck
reactions)to create congested quaternary carbon centers.20Heck
methodology has been successfully applied to this problem by conversion
ketone 50 to its enol triflate 51 which then underwent palladium-catalyzed
carbonylation in the presence of ortho-bromoaniline to afford the cyclization
precursor 52 (scheme 16).
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Protection of amide 52 and cyclization under standard Heck conditions
gave a stereoisomeric mixture of the pentacyclic oxindoles 53 and 54 with
low stereoselection (1.8:1) but in excellent chemical yield.Either of the
stereoisomers 53 or 54 could be prepared with high selectivity when the Heck
cyclizationconditionswerevaried. Thus,theuseof
tris(dibenzylideneacetone)dipalladium(Pd2(dba)2) yielded a 9:1 ratio of
53:54, whereas addition of silver phosphate under otherwise identical
conditions resulted in almost exclusive formation of the oxindole 54. The
former conditions were used by Speckamp et al. in their total synthesis of
gelsemine.16 a)
When confronted with this problem, Johnson21 designed an interesting
oxindole annelation based on a variation of an indole synthesis originally
developed by Wender.22 In this case, the final C-C bond formation takes place
by coupling of the two carbon radical centers in 57, a process which is
insensitive to steric hindrance due to the low activation barrier associated with
radical recombination (scheme 17).hv
- N2
56
MeO
57
scheme 17
When applied to 30 this method produced 21-oxogelsemine in low yield, but it
concluded a formal total synthesis of gelsemine (scheme 18).
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As mentioned previously, koumine bears a structural resemblance to
gelsemine. Koumine and gelsemine are in the same overall oxidation state,
and the two alkaloids could be interconverted in principle by a pair of two 1,2-
alkyl shifts and addition or loss of water (scheme 19).21
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Likewise, ketone 30 is structurally related to a potential koumine
precursor 61 (scheme 24) that provides a focal point for the synthetic studies
described in the following chapter.
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30
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61
Koumine22
Results and Discussion
The chemistry of alkaloids has been central to the development of
classical methods of synthesis and structure elucidation in organic chemistry.
Many well known name reactions such as the Hofmann elimination,23 the
Mannich reaction,24 and the Fischer indole synthesis25were discovered
during the era of chemical degradation of alkaloid natural products.The
development of these methods paved the way for the first major synthetic
achievements in alkaloid chemistry, including the total syntheses of quinine,26
strychnine,27 and reserpine.28 This has subsequently led organic chemiststo
design and carry out syntheses of increasingly complex members of the large
family of alkaloids.
Many different strategies have evolved to confront the syntheses of
polycyclic indole alkaloids.However it has often been convenient to usea
monoterpenoid subunit as a building block for condensation withan indole
moiety at a late stage in the synthetic sequence.For example, several
approaches toward reserpine (62) have followed this strategy (scheme 28).29
OMe
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Among the known methods of indolization, the Fischer indole synthesis
is recognized for its broad scope and general applicability.As a classical
method in alkaloid synthesis, this reaction has been used to transform many
functionalized aldehydes and ketones to indole alkaloids.Since the indole
moiety of these alkaloids is generally the most sensitive part of the structure,
its late introduction in a synthetic sequence has great strategic advantage.
Koumine, being an indolenine alkaloid cannot become directly
available through the indolization of a ketone precursor. However, a literature
survey reveals that several indolenine alkaloids of the Aspidosperma class
have been synthesized following a strategy that involves Fischer indolization
of a functionalized amino ketone.For example, Stork30 reportedtotal
syntheses of (±)-aspidospermine (63) and (±)-quebrachamine (68) which
were completed through Fischer indolization of the aminoketone 65 (scheme
OMe
64
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Under the reaction conditions of the indolization, equilibration involving
indolenine 66 takes place via a retro-Mannich process. The iminium species
67 can be reduced with potassium borohydride to yield quebrachamine (68)
(scheme 27).Essentially the same strategy has been extended to the
synthesis of other Vince alkaloids by Klioze.31OMe
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Our approach to (±)-koumine is based on a plan in which the final ring
closure to the koumine ring system is accomplished through intramolecular
alkylation of the indole nucleus at the 3-position. Therefore,we have focused
our attention on synthesis of the tricyclic ketone 61, which would be subjected
to a Fischer indole synthesis in the final stages of the sequence (scheme 24).
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The target ketone 61 bears a close structural resemblance to the
gelsemine precursor 30 (scheme 25), differing in thepresence of an
additional hydroxymethyl group and the absence of a carbon-carbon bond
between C-5 and C-6 (gelsemine numbering).----=H3C N
5
HO
61 30
H3C'
scheme 25
25
In an earlier approach to this synthetic problem an attemptwas made to
use a hetero-Diels-Alder reaction of the azadiene 70 as an entry into the
hydroisoquinoline system of 61. However, this approach was abandoned due
to a lack of reactivity of the azadiene (scheme 26).32
61
scheme 26
The strategy outlined in scheme 27 proposes that the carbocyclic ring of
61 can be constructed in a stereocontrolled fashion bya conventional Diels-
Alder reaction. A central feature of this plan is theuse of a furan synthon as
the source of carbons 3, 4, 11 and 12 in 61.
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This logic leads to the tricyclic hydroisoquinoline structure 71 as the
precursor of 61. The hydroisoquinoline nucleus of 71 can be envisioned as
the Diels -Alder adduct of the dienophilic furan derivative 72 and an
appropriate diene (scheme 27).
It was reasoned that a functionalized Diels -Alder adduct derived from
72 and a suitable diene would serve as a platform on which the additional
architecture needed for 61 could be erected.Specifically, it was hoped that
two important objectives could be achieved by this route.First, the
stereochemistry of the carbocyclic ring of 61 with respect to the ring fusion
and the a-alkoxy ketone could be established, and secondly the two
heterocyclic rings (piperidine and hydropyran) in 61 could be conveniently
elaborated using cyclization reactions involving the furan template.
A large number of simple furan derivatives are commercially available
at low cost and have served as starting materials for these synthetic studies.It
is known that the aromatic nature of the furan nucleus enhances the reactivity
of furoic aldehydes toward Knoevenagel type condensation reactions.33 This
provides easy and flexible access to compounds of the general formula 72,
which we have used as dienophiles in this approach.
Furan derivatives are susceptible to a number of hydrolytic and
oxidative ring-opening reactions.Depending on the reagents, reaction
conditions and the substitution pattern of the furan, 1,4-diketones or the
corresponding five-membered lactones, lactols, butenolides or anhydrides
can be obtained.34
Most of the methodological studies on furan oxidation have been carried out
on simple furan substrates which are devoid of multiple functionality.Hence,
the synthetic potential of furan derivatives as masked 1,4-diol equivalents is
not well developed in the context of natural product synthesis.27
Kuehne, during his work directed toward synthesis of Strychnos
alkaloids has described an interesting reaction of the furoic aldehyde 74 and
the tryptamine derivative 73 which afforded 75 as a single diastereomer
(scheme 28).35
Bn
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scheme 28
However, conversion of furan 75 to the structurally complex alkaloid
strychnine (76), remained elusive (scheme 29). As noted by Kuehne: "while
this product contains all but two, acetate derived ring F carbon atoms of
strychnine, its further elaboration required considerable exploration and
discovery of new methodology...".
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75
scheme 29
The bromination of furan derivatives in an alcohol solvent is a well
studied reaction that is known to involve cationic intermediates. This reaction
has been used primarily for the formation of new carbon-oxygen bonds at the28
furan nucleus. Thus, in their total synthesis of the Prelog-Djerassi lactone 79,
Martin et a1.36 utilized the furan 77 to create the pyranone skeleton 78
(scheme 30).
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A similar strategy has been employed by DeShong37 et al. in their total
synthesis of (±)-tirandamycin A (80) (scheme 31). The spiroketal portion 83 of
tirandamycin A was synthesized through epoxidation of the hydroxy furan
precursor 81 which yielded the pyranone structure 82.
81
82
OH
OBn
OTBDMS
HF, MeCN
70%
MCPBA
NH
M
M
HO
CH2Cl2, 0°CTBDMSO
90%
83
scheme 31
OBn
O
'Me
OBn
8229
Initial studies indicated that a Die Is-Alder reaction of the furan derivative
85 with 2-ethoxy-1,3-butadiene proceeded in high yield to give adduct 86as
a single diastereomer (scheme 32).The dienophile 85 employed in this
cycloaddition was prepared by Knoevenagel condensation of 84 with ethyla-
cyanoacetate. A single olefin isomer was obtained from this condensation
which based on subsequent results (vide infra) can be assumed to have the E-
configuration shown.
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pyr, piperidine
84 85
/
EtO2C,
OEt
EtO
toluene, 180°C o
95%
scheme 32
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With 86 in hand, the reactivity of the furan towards electrophileswas
probed. The hope was that a cationic intermediate such as 87 generated by
bromination would result in cyclization with carbon-nitrogen bond formation
between the nitrile and furan (scheme 33). This process leading to lactam 88
is formally an intramolecular Ritter reaction and has good precedent. 38
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In the event, bromination of 86 in methanol did not yield 88 but instead
a complex mixture of products was formed which could not be further
elaborated.It appeared from a spectroscopic analysis of the crude reaction
mixture that the enol ether as well as the furan portion of 86 had reacted with
the bromine.
A possible solution to this problem was recognized in the work of Urabe
who showed that furan derivatives which were silylated in the 2-positioncan
be transformed regioselectively to butenolides under mild conditions with
peracetic acid (scheme 34).39
CI-13CqH,
s.../-3
TM O NaOAc,CH2C12
scheme 34
Butenolides (a,(3-unsaturated -y-lactones) are Michael acceptors that
react with many nucleophiles in a conjugate fashion.With this chemistry in
mind, our plan evolved toward building the piperidine ring throughan
intramolecular Michael addition.For this purpose a nitrogen nucleophile
derived from the cyano group and a butenolide Michael acceptor derived from
the furan (for example, compound 89, scheme 34) were needed.
First, 3-furoic acid (90) was silylated in the 2-position40 and then
reduced to the alcohol 91 (scheme 35).Benzylic oxidation of 91 yielded the
furoic aldehyde which was condensed with ethyl a-cyanoacetate to afford 92.
The cis ring fusion of the hydroisoquinoline in ketone 61 requires thata31
corresponding relationship exist between the furan andcyano group in the
Diets -Alder dienophile 92. Therefore, the geometry of the double bondin 92
was a critical issue.
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While spectroscopic analysis, including 1H and 13C NMR, of 92
indicated that a single isomer was obtained, the configuration of thedouble
bond could not be ascertained.Based on steric grounds it seemed
reasonable to assume that 92 was the E-isomer shown, and thiswas
subsequently confirmed by X-ray analysis of the Diets -Alder adduct 94 (vide
infra).
After considerable experimentation, 92 was found to give Diets -Alder
adduct 93 using 1,3-butadiene in great excess (scheme 36).Extensive
polymerization of the diene was the main side reaction.
EtO2C C N
T MS0 7 days, 87%
92
scheme 3632
With 93 in hand, efforts were undertaken to verify the assumed cis
relationship of the furan and cyano group in the Diels -Alder adduct.A
crystalline derivative 94 was obtained by selective reduction of the ester and
acylation of the resulting primary alcohol with p- nitrobenzoyi chloride (scheme
37).
93
1) LiAIH4,Et20, -78°C
2) C OCI
N02
D MAP,
Et3N,
C H2Cl2
scheme 37
X-ray diffractionanalysisof 94fully confirmed therelative
stereochemistry shown (Figure 1.1).The furan and the cyano group are
attached to the same face of the cyclohexene ring.33
Figure 2.1: ORTEP Representation from X-ray Structure of 94.
More complete reduction of 93 with lithium aluminum hydride gave an
amino alcohol 95 which was converted without purification to the cyclic
urethane 96 (scheme 38).
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Oxidation of 96 following Urabe's conditions gave the butenolide 97 in
modest yield. Much to our disappointment, 97 did not show any inclination to
undergo spontaneous cyclization, nor were we able to bring about the
intramolecular conjugate addition under any conditions that were tried.
scheme 39
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Due to the pronounced lability of 97 towards base, attempts to open the
butenolide ring by alkaline hydrolysis also met with failure.However, the
nitrogen of urethane 96 underwent smooth methylation with methyl iodide.
Subsequent oxidation of the N-methyl urethane 99 afforded butenolide 100
in good yield (scheme 40).oho oho 0
NH NMe NMe NaH, Mel C H3C 03H, NaOAc
87% CH2Cl2, 79%
scheme 40
H
0
100
35
Disappointingly, all attempts to cleave the cyclic carbamate of 100
were unsuccessful. Under conditions of basic hydrolysis, decomposition of
100 was observed as previously seen with 97.In the presence of acidic
reagents such as perchloric acid, Meerwein's salt or trimethylsilyl iodide,
urethane 100 displayed surprising stability.In light of this result, efforts were
undertaken to find alternative, more easily removed protection devices for the
amino alcohol 95. A tert-butoxycarbonyl group (BOC group) appeared to
satisfy this requirement and was introduced without incident to afford
compound 101. The protected nitrogen was then methylated with methyl
iodide to give 102.
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Oxidation of the furan nucleus of 102, unlike that of 99, turnedout to be
problematic, and only a small amount of lactone epoxide 103was isolated
along with unreacted starting material (scheme 41).It was thought that the
free primary hydroxyl group of 102 might have promotedepoxidation of the
cyclohexene through hydrogen-bonding to the peracid. Accordingly, several
attempts were made to block this sterically hindered alcohol but onlya
trifluoroacetate group could be introduced in practical yield, affording104.
Oxidation of 104 again yielded an inseparable mixture of 105 and106, albeit
in improved yield (scheme 42).
TM S
104
C H3C 03H, NaOAc
CH2Cl2, ca 66 %
scheme 42
O
°yC F3
BOC 0, BOC
NMe
O
105
+
H
0
O
106
Treatment ofthisunstable and base-sensitive mixture with
trifluoroacetic acid resulted in the expected removal of the BOCgroup but was
accompanied by unanticipated transfer of the trifluoroacetylgroup to form the37
trifluoroacetamide 107. The lability of compound 107 toward base again
precluded the removal of the trifluoroacetyl function from nitrogen (scheme
43).
105 106
scheme 43
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These discouraging results prompted us to search for a new approach
to 61 in which a potentially removable substituent is attached to nitrogen at
the outset. This plan required complete revision of our original strategy and
forced us to reevaluate the starting point of the synthesis.It was decided that a
more fruitful approach would lie in attachment of the nitrogen function to the j3-
position of the furan dienophile, so that construction of the piperidine ring of
61 would now take place in the reverse sense from that envisioned
previously.
vs.
The Curtius rearrangement came to mind as a convenientway to
introduce a protected amino functionality into a furan precursor.41Dimethyl
3,4-furandicarboxylate (108) was subjected to monohydrolysis42 and the38
resultant carboxylic acid was converted toitsacyl azide.Curtius
rearrangement of this azide in the presence of tert-butanol yielded the BOC-
protected 3-aminofuran 109 (scheme 44).
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During the N-methylation of 109 the adjacent methyl ester was partially
hydrolyzed to give the carboxylic acid 111. Both ester 110 and acid 111
were reduced to the alcohol 112, and the latter was oxidized under Swern39
conditions to the aldehyde 113. This aldehydewas condensed with dimethyl
malonate to afford 114. With an efficientroute to 114 at hand, the next step
was to identify an appropriate dienophile that wouldbe accessible from 114
for the projected Diels -Alder reaction.Removal of the BOC group from 114
resulted in spontaneous cyclization to the unstablea,13-unsaturated amide
115 (scheme 45).However, 115 did not display dienophilicreactivity with
1,3-butadiene, 2-ethoxy-1,3-butadieneor Danishefsky's diene (1-methoxy-3-
trimethylsilyloxy-1,3-butadiene).43 Hoping thattransformation of the furan
nucleus to an a,13-unsaturated lactone wouldenhance dienophilicity, 115was
oxidized with bromine in acetic acid44 to 116.Although the latter should,in
principle, be a more reactive dienophile than115 due to additional electron
withdrawal by the lactone carbonyl, it also failedto undergo cycloaddition with
1,3-butadiene, 2-ethoxy-1,3-butadieneor Danishefsky's diene.
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In contrast to 115 and 116, 114was reactive as a Diels-Alder
dienophile, although its dienophilicitywas found to be low, and only the highly40
reactive Danishefsky diene gave a cycloadduct 117 in good yield (scheme
46).
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Reduction of the enone 117 was examined under several conditions
with the goal of preparing an allylic alcohol of [3 configuration.It was found
that the use of L-Selectride produced a single allylic alcohol, 118, the relative
configuration of which was found to correspond to that required for the
hydropyran moiety of 61 (scheme 47). The assignment of configuration was
independently verified by X-ray analysis of a later intermediate.
CO2Me
CO2Me
N:
BOC
CH3
117
L-Selectride
THF, 93 %
scheme 47
H...
HO
118
02M e
CO2Me
4.1N,B0C
CH3
O41
Our plan for 118 was to use this intermediate to advance the synthesis
along three lines. These were:
a. Lactamization between the amino substituent of the furan and
one of the geminal esters.
b. Hydropyran construction using the allylic alcohol and furan.
c. Transformation of the allylic alcohol to an a-alkoxy ketone.
Removal of the BOC group from 118 did not result in spontaneous
lactamization as had been observed with compound 114. Instead the amino
alcohol 119 was isolated and could be characterized, although it provedto be
a very unstable species (scheme 48). Amino ester 119 was found to undergo
cyclization only very sluggishly to the stable 8-lactam 120. A single isomer
was formed in a reaction which proved to be very erratic with respect to yield.
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It was assumed that with the lactam 120 in hand the remaining
functional group transformations toward 61 could be addressed. The first
task, however, was to establish the ring fusion stereochemistry of 120.42
Proof of the cis ring fusion in 120, which itself did not give rise to a
crystalline derivative, was provided by X-ray analysis of 124.The crystalline
2,4-dinitrophenylhydrazone 124 was prepared from the minor byproduct 121
obtained from Luche reduction of 117 (scheme 49).Thus, 121 was
lactamized after removal of the BOC group, and the resulting hydroxy lactam
122 was oxidized with pyridinium chlorochromate to the 13-methoxy ketone
123.Treatment of 123 with 2,4-dinitrophenylhydrazine resultedin the
formation of 124.
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X-ray diffraction analysis of the 2,4- dinitrophenyihydrazone derivative
124 fully confirmed the stereochemistry shown (figure 1.2).
Figure 2.2: ORTEP Representation fromX-ray Structure of 124.44
The structures of 13-methoxy ketone 123 and allylic alcohol 120were
correlated by their conversion to the same enone 125 (scheme 50).Thus,
125 was obtained by straightforward oxidation of the alcohol 120 with
pyridinium dichromate while acid-catalyzed elimination of methanol from 123
also gave 125.
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Treatment of 120 with lithium aluminum hydride in an attempt to reduce
the 8-lactam to a piperidine ring and also reduce the angular ester
afforded a very polar and unstable amino diol which could not be further
characterized.It was therefore decided to defer the reduction of the 8-lactam
120 and study the furan opening next.
The reported use made of simple 2,5-dialkylfuran derivatives, for
example 2,5-dimethylfuran, as 1,4-diketone equivalents (scheme 51)45
suggested that the furan moiety of lactam 120 could be employed to generate
a dialdehyde by acidic hydrolysis.Although unsubstituted in the 2- and 5-
positions, it was assumed that the activating nitrogen substituent of 120 would
enhance the acid lability of the furan.H H
H+
OH
,--/
HO
CH3 H+
scheme 51
102
HO
45
Surprisingly, 120 proved to be quite stable toward acids, including
formic acid and trifluoroacetic acid, and no products of hydrolytic ring opening
were observed. An alternative means for opening the furan in 120 would be
through the use of oxidative conditions,46 buta disadvantage of this strategy
over the hydrolytic opening is that a tetrasubstituted double bond is invariably
formed when 3,4-disubstituted furans are oxidized (scheme 51).
Inspection of a molecular model of lactam 120 indicated that thereare
accessible conformations in which the distance between the allylic alcohol
and the C-12 atom of the furan is quite small.Since furans undergo rapid
nucleophilic attack following electrophilic activation of the aromatic nucleus,
the reaction of 120 with N-bromosuccinimide in methanolwas investigated in
the expectation that bromination of the furan would generatea cationic
intermediate 126 which would react in an intramolecular fashion with the
allylic alcohol and then with solvent to form 127 (scheme 52).Me0 C0
NCH3 Br2 NCH3Me0H
120
HO
H
0 Br
Br°
126
scheme 52
46
0 C H3
The tetracycle 127 was not observed when 120was reacted under
these conditions.Instead, dimethoxy adducts 128 were formed asa mixture
of stereoisomers.When this unstable mixture was treated withp-
toluenesulfonic acid, butenolide 129 was isolated in moderate yield (scheme
53).
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In order to determine whether there was any merit to the furan oxidation
strategy, the allylic alcohol 118 was reacted under the same conditionsas
120. To our pleasure, 118 underwent quantitative intramolecularacetal
formation between the allylic alcohol and C-12 of the furanto yield 130
(scheme 54). The proton NMR spectrum of 130 indicated thepresence of at
least two stereoisomers, but it was difficult to decide at this stage whetherthe
multiple signals were due to rotameric isomers of thetert-butoxycarbonyl
group or a diastereomeric mixture at the two newly formed acetal centers.HO
12
118
02Me
CO2Me
H N,B0C
O
C H3
CO2Me
NBS, Me0H CO2Me
BOC
100 % 0 N,
Me
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Subsequently, it was found that when the analogousreaction was
carried out in water, hemiacetal 131 was isolated in goodyield from 118.
Oxidation of 131 with pyridinium dichromategave the butenolide 132
(scheme 55).Again, multiple peaks were observed for both 131 and132 in
the proton NMR spectrum. Unfortunately,none of the three compounds 130,
131 or 132 were stable under the conditions required for removalof the BOC
group.
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Several attempts were made with 130, 131 and 132 to elaboratethe
pyran substructure of these acetals through reductiveor hydrolytic cleavage of
the acetal moiety but these too, were unsuccessful (scheme56).02Me
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It appears that the acetal carbon-oxygen bonds of thesestructures are
relatively weak and that cleavage occurs at the dihydrofuran rather thanthe
pyran.This is reflected in the high-yielding conversion of 131 to 134 with
sodium cyanoborohydride (scheme 57).
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In tandem with these studies, efforts were also directed toward
functionalization of the disubstituted double bond. Unfortunately, thetricyclic
compounds 130, 131 or 132 gave no useful result with either hydroboration,
epoxidation, or oxymercuration (scheme 58).
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After investigating several hydroborating reagents, including 9-
borabicyclo[3.3.1]nonane and thexylborane, it was discovered that the allylic
alcohol 118 reacted with borane-tetrahydrofuran complex.Subsequent
oxidation occurred with complete stereo- and regioselectivity to yield a triol.
The structure 135 a was tentatively assigned to this product (scheme 59).
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It was apparent from the proton NMR spectrum of the product that, in
addition to hydroboration-oxidation of the double bond, reduction of one of the
carbomethoxy groups had also occurred. High-resolution mass spectroscopy
established that the molecular composition of the product was that expected
for structure 135 a.It was clear from spectroscopic analysis that a single
diastereomer was formed and good precedent for formation of 135a existed
in the conversion of 136 to 137,47 (scheme 60).Ho.
HO 2) NaOH, H202,
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Convincing physical evidence for the structure of 135 a, however,was
still lacking.In particular, the important question of the regiochemistry of the
hydroboration, and hence the location of the newly formed secondary alcohol,
could not be ascertained by spectroscopic analysis.Therefore, the
regioisomeric structure 135 b had to be considered.
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We were nevertheless encouraged by the fact that acetal formation with
N-bromosuccinimide was unhampered by the additional hydroxyl groups in
135, yielding 138 (scheme 61).For the tricyclic compounds 130, 131, 132,
and 138 it was assumed that, regardless of the configuration of the newly
formed acetal moiety, the enamines produced upon cleavage of the nitrogen
protecting group would be difficult to cyclize to a 5-lactam due to the strain
associated with the tetrasubstituted double bond in 139 (see also scheme
52).However, the enamine function could, in principle, be reduced with
sodium cyanoborohydride to the corresponding saturated amine, which51
should be an excellent candidate for lactamization leading to 140 (scheme
62).
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Since it had not been possible to cleave the BOCgroup of 130, 131 or
132 in the presence of the acetal moiety,it was decided to modify this
approach by installing a different protection groupon nitrogen.
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A carbobenzyloxy group (Cbz group) was introduced througha
variation of the chemistry previously worked out for the preparation of
dienophile 114.Using benzyl alcohol instead of tert-butanol an analogous
sequence led to the dienophile 144 (scheme 63).
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The Diels-Alder reaction of 144 (scheme 64) with Danishefsky's diene
and reduction of the enone 145 proceeded uneventfully following the protocol
previously described for 118 (see also scheme 46).The resulting allylic
alcohol 146, in turn, gave rise to the tricyclic intermediates 147, 148 and
149 in analogy to the chemistry exhibited by 118 (scheme 65).NBS, Me0H
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In order to determine the stereochemistry of the acetal ring system, and
hence the prospects for lactamization, the crystalline p-nitrobenzoate
derivative 150 of lactol 148 was prepared (scheme 66).
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X-ray diffraction analysis of 150 fully confirmed the stereochemistry
shown (figure 1.3).
Figure 23: TELP Representation from X-ray Structure of 150.55
It can be seen that intramolecular addition of the allylic alcohol has
taken place to the face of the furan opposite to that required for the formation
of the tetracyclic lactam 127 (see schemes 52 and 62). The crystalstructure
also revealed the distance between the ester carbonyl and the protected
nitrogen to be 4.2 A (scheme 66).With this geometry, there is no reason to
expect spontaneous cyclization to a 6-lactam after cleavage of the Cbz group
of 148.
Although hydrogenolytic cleavage of the Cbz-group in 147, 148 and
149 was found to be straightforward, the disubstituted double bond in these
structures was sacrificed in the process.It was therefore decided to forego
deprotection of the nitrogen atom at this stage, and to reexamine the
disubstituted double bond as a locus for the regioselective installation of the
ketone which would be needed for indolization.
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Unfortunately, all attempts to bring about functionalization of the
cyclohexene double bond in these structures met with failure, presumably due
to the high degree of steric hindrance afforded by the tricyclic ring system
(scheme 67).This left only hydroboration of 146 as a viable option. The
alcohol 146 was hydroborated and oxidized using thesame conditions as
decribed for 118 (scheme 68).C, 02Me
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A triol was isolated which displayedvery similar chemical and
spectroscopic properties to those observed with 135 (scheme 59).Closer
examination of the triol, however, revealed that, contraryto our original
assignment for 135 a and to literature precedent,46 itwas the more hindered
carbon adjacent to the quaternary center that carried the hydroxylsubstituent
(scheme 68). The structure of the triol could therefore beassigned as 151.
The regiochemistry of the hydroboration of 146suggests that a directive
complexation of borane with one of the carbomethoxygroups may be
operative in the hydroboration step.In this way, the borane is delivered to the
proximal carbon of the olefin from the a-face of the cyclohexene,and one of
the carbomethoxy groups is reduced in theprocess leading to 146 (scheme
69).
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All attempts to reverse the regiochemical preferenceof the
hydroboration of 146 through the use of other hydroboratingreagents were
unsuccessful.Protection of the sterically hindered allylic alcohol 146 didnot
affect the outcome of the reaction. The acetate of 146, for example,could be
prepared in good yield but did not withstand the basicconditions of the
hydroboration-oxidation, and only the triol 151 could be isolated.The tert-
butyldirnethylsily1 ether of 146 was prepared in low yield andgave after
hydroboration-oxidation the monoprotected triol 152. Deprotection of thesilyl
ether again yielded 151.
TBDMSO
OH
CO2Me
NrCBz
CH3
152
H
0
Hu,
HO
1530
The ready formation of a cyclic carbonate 153 from 151clearly
supported the syn relationship of the two newly createdalcohols.
Furthermore, the regiochemical sense of the hydroboration issuggested by
the six-membered cyclic carbonate since seven-membered carbonatesare
very rare.
The structure of 151 was subsequently verified bycrystallographic
analysis. The lactone 154 could be isolated either directlyas a byproduct of
the hydroboration of 138, or through treatment of 146 withp -toluenesulfonic
acid (scheme 70).58
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Figure 2.4: TELP Representation from X-ray Structure of 155.59
When 154 was acetylated with acetic anhydride in the presence of 4-
dimethylaminopyridine the crystalline diacetate 155 was obtained. An X-ray
crystal structure of this substance confirmed that it had originated from 151
and that hydroboration-oxidation of 146 had taken place to give the alcohol
resulting from addition of boron to the more sterically congested terminus of
the cyclohexene double bond (figure 1.4).
The unfavorable outcome of the hydroboration-oxidation ledus to
explore other Diels -Alder reactions of the dienophile 144 in the hope that it
would allow for a more direct transformation of the Diels -Alder adduct to the
desired cc-alkoxy ketone.However, the poor dienophilic properties of 144
imposed a serious constraint on this endeavor, and it was recognized thatan
exceptionally reactive diene would be needed for a successful cycloaddition.
2,3-Bis(trimethylsiloxy)-1,3-butadiene (158) was selected for this purpose,
since itis readily available through acyloin condensation of diethyl succinate
(156) followed by pericyclic opening of the resulting 1,2-bis(trimethylsilyloxy)-
1,3-butadiene (157) (scheme 71).48
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The dienophile 144 reacted only very sluggishly with diene 158, but
the cycloadduct 159 could be obtained in modest yield (scheme 72).Me02C-.......,,,C 02Me
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i-r1CH3
0
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Unfortunately, although 159 bears oxygen substituents in the correct
position of the cyclohexane, selective conversion of the protected acyloin
functionality to the desired a-hydroxy ketone could not be achieved.After
removal of the silyl groups from 159, an inseparable and unstable mixture of
regiosomeric and diastereomeric a-hydroxy ketones 160 and 161was
obtained (scheme 73).
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Cleavage of the protected enediol of 159 with sodium fluoride, followed
by reduction of the mixture in situ with sodium borohydride,gave a
diastereomeric mixture of hydroxy y-lactones 162 whose stereochemistry
could not be defined (scheme 74).TMSO
TMSO
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" CO2Me
NJ"
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C H3
159
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scheme 74
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Attempts to elaborate the mixture of lactones 162 towards workable
compounds met with failure.Futhermore, although 159 could be epoxidized
to 163 with m-chloroperbenzoic acid, further transformation of this substance
to an a-diketone or an a-hydroxy ketone could not be accomplished (scheme
75).
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In summary, there are several features of the chemistry described
above that warrant comment. We were able to develop directaccess to
several functionalized Diels-Alder adducts that contain all butone of the
carbon atoms of the target structure 61.However, transformation of these
adducts to a substance which could lead to koumine remains to be completed.
In particular, the manipulation of the furan moiety in these adducts and the
elaboration of the a-alkoxy ketone in the carbocyclic ring were identifiedas
steps that will require extensive study.62
In light of the difficulties that were encountered with the installation of
the ketone needed for eventual Fischer indolization,it may be fruitful to
consider alternative indolization methods for the future.Along these lines,
some preliminary experiments have pointed at the possibility that the indole
moiety may be introduced by a Diels -Alder reaction of an indole diene suchas
164 with dienophile 144.49 Although the synthesis of dienes similar to 164 is
possible,50 the low dienophilic reactivity of 144 and potential problems of
regio and stereocontrol in the Diels -Alder reaction would have to beovercome
(scheme 76).
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An alternative strategy would entail introduction of the indole atsome
later stage through manipulation of an o-azidoaryl substituent connectedto
the p-carbon of an enone 166. Thermolysis of 166, for example, could yielda
reactive nitrene intermediate that would insert into the carbon hydrogen bond
of the enone to afford indole 167 (scheme 76).51CO2Me
CO2Me
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CH3
A
HN CO2Me
CO2Me
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CH3
166 167
scheme 76
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Synthesis of 166 can be envisioned through a Michael addition-
acylation sequence using enoate 144 as a substrate.Thus, conjugate
addition of acetone enolate, followed by acylation of the resulting enolate with
o-azidobenzoyl chloride, would yield diketone 168 which could undergo
intramolecular aldol condensation leading to 166 (scheme 77).
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Except for the o-azidophenyl group, structure 166 is identical to the
enone 145 obtainedinthe Diels-Alder reaction between 144 and64
Danishefky's diene (scheme 64).Thus, it is conceivable that the chemistry
worked out in that series may offer some valuable direction for synthetic efforts
toward koumine in the future.65
Experimental Section
General
Starting materials and reagents were obtained from commercial
sources and, unless stated otherwise, were used without further purification.
Solvents were dried by distillation from the appropriate drying agent
immediately prior to use. Toluene, tetrahydrofuran, and etherwere distilled
from potassium and benzophenone under an argon atmosphere.
Diisopropylamine, triethylamine, diisopropylethylamine, dimethylformamide,
acetonitrile, pyridine and dichioromethane were distilled from calcium hydride
under argon.All solvents used for routine isolation of products and
chromatography were reagent grade and glass distilled.Moisture and air
sensitive reactions were carried out under an atmosphere of argon.
Unless otherwise stated, the combined organic layers obtained during
the workup of a reaction were dried over magnesium sulfate. Concentration in
vacuo refers to the use of a rotary evaporator at water aspirator pressure.
Residual solvent was removed by vacuum pump at pressures less than 2 torr.
Reaction flasks were flame dried under a stream of argon.Syringes were
oven dried at 200 °C and cooled to room temperature in a desiccator over
anhydrous calcium sulfate.
Analytical thin layer chromatography (TLC) was conducted using E.
Merck precoated TLC plates (0.2 mm layer thickness of silica gel 60 F-254).
Spots were visualized by ultraviolet light, or by heating the plate after dipping
in a 3-5% solution of phosphomolybdic acid in ethanol, 10% ammonium66
molybdate, or a 1% solution of vanillin in 0.1M H2SO4 in methanol. Flash
chromatography was carried out using E. Merck silica gel 60 (230-400 mesh
ASTM).Radial chromatography was carried out on individually prepared
rotors with layer thickness of 1, 2 or 4 mm using a Chromatotron manufactured
by Harrison Research, Palo Alto, California.
Melting points were measured using a Biichi melting point apparatus.
Infared (IR) spectra were recorded with a Nicolet 5DXB FT-IR spectrometer.
Proton and carbon nuclear magnetic resonance (NMR) spectrawere obtained
using either a Bruker AC-300, or Bruker AM-400 spectrometer.All chemical
shifts are reported in parts per million (ppm) downfield from tetramethylsilane
using the 6 scale. 1H NMR spectral data are reported in the order: chemical
shift, multiplicity, (s = singlet, d= doublet, t = triplet, q = quartet, m = multiplet,
and br = broad), coupling constant (J) in Hertz, and number of protons.
Chemical ionization mass spectra MS(CI) were obtained usinga
Finnigan 4023 quadrupole GC-MS 4500 spectrometer witha source
temperature of 140 °C and a pressure of 0.7 torr.Electron impact mass
spectra MS(EI) were obtained using a Varian MAT311 spectrometer with an
ionization potential of 70 eV.High resolution mass spectra were obtained
using a Kratos MS-50 RF spectrometer.X-ray crystallographic data were
collected using a Rigaku AFC6R or a Siemens P4 diffractometer.Structures
were solved using the direct methods programs contained in the TEXAN
(VAXNMS) and SHELXTL (Silicon Graphics/UNIX) software packages.
Elemental analyses were performed by Desert Analytics, Tucson, Arizona.67
NCB C 02Et
O
3-(- Ethyl -2- cyano- 3- (furanyl)- acrylate(85).A mixture of 3-
furaldehyde (84) (100 mg, 1.0 mmol) and ethyl a-cyanoethyl acetate (226 mg,
2 mmol) and a catalytic amount of piperidine (10 pt) in pyridine (2.5 mL) was
stirred at room temperature for 12 h.The mixture was cooled to ice bath
temperature, 10% H2SO4 (10 mL) was added, and the mixture was extracted
with ether (3 x 10 mL). The separated organic layer was washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 10:1) afforded 165 mg (83%) of 85 as a white solid: mp
88°C;IR (KBr) 3190, 2996, 2226, 1717, 1645, 1292, 1162, 1105, 876, 759
cm-1; 1H NMR (300 MHz, CDCI3) 81.35 (3 H, t, J = 8.0 Hz); 4.30 (2 H, q, J = 8.0
Hz), 7.26 (1 H, s), 7.55 (1 H, s), 8.05 (1 H, s), 8.15 (1 H, s), 13C NMR (CDCI3,
75 MHz) 8 14.1, 62.5, 101.9, 108.5, 115.6, 120.8, 145.3, 145.4, 149.8, 162.4 ;
MS (El) m/z 191, 146, 135, 63.
EtO
Et°2C"C N
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1-Ethoxy-4-cyano-4-carboethoxy-5-(3-fu ranyl)cyclohexene
(86). A mixture of 85 (17 mg, 0.09 mmol) and 2-ethoxy-1,3-butadiene (130
mg, 2 mmol) in toluene (20 mL) was heated in a screw cap flask at 180°C for
20 h.Solvent and residual diene were removed in vacuo.Column
chromatography of the residue (hexane-ethyl acetate, 9:1) afforded 24 mg
(95%) of 86 as a yellow oil that slowly turned solid: mp 60 °C; IR (KBr) 2980,
2929, 1739, 1673, 1242, 1029, 657 cm-1; 1H NMR (300 MHz, CDCI3) 8 1.1568
(3H, t, J=8.0 Hz), 1.3 (3H, t, J=8.0 Hz), 2.39 (1H, dd, J=13.0, 5.6 Hz), 2.65 (2H,
m), 2.91 (1H, m), 3.40 (1H, dd, J=12.0, 5.6 Hz), 3.75 (2H, q, J= 8.0 Hz), 4.12
(2H, m), 4.60 (1H, d, J = 4.0 Hz), 6.50 (1H, s), 7.35 (2H, s); 13C NMR (CDCI3,
75 MHz) E. 13.7; 14.5, 32.1, 32.8, 36.7, 50.0, 62.4, 62.6, 88.4, 109.6, 118.0,
122.9, 140.2, 143.1, 153.4, 168.7; MS(EI) m/z 289 (M+, 100), 260, 164, 136;
HRMS m/z calcd for C16H1904N (M+): 289.1314. Found: 289.1314.
2-Trimethylsilylfuran-3-carboxylic Acid. A flame dried 50 mL
three-neck flask was charged with diisopropylamine (1.4 mL, 10 mmol). To
this was added via syringe 1.6 M butyllithium solution (5.3 mL) followed by
tetrahydrofuran (16 mL). The mixture was cooled to -78°C and 3-furanoic acid
(600 mg, 5.0 mmol) was added in tetrahydrofuran (10 mL) while stirring. The
mixture was kept at -78°C for 0.5 h after which chlorotrimethylsilane (1.6 mL)
was added. The mixture was allowed to warm to room temperature and then
water (6 mL) was added followed by 10% aqueous sulfuric acid (20 mL). The
resulting mixture was stirred for 0.5 h after which water (50 mL) was added
and the mixture was extracted with ether (4 x 30 mL portions). The combined
ether layers were washed with brine and dried over magnesium sulfate.
There was obtained 905 mg (91%) of the title compound as a white
amorphous powder: mp 88 °C (1it40: 89-90 °C); IR (KBr) 3450, 3444, 1685,
1682, 1673, 846 cm-1; 1H NMR (300 MHz, CDCI3) 8 0.36 (9H, s), 6.80 (1H, d, J
= 1.0 Hz), 7.26 (11-1, d, J = 1.0 Hz).
2- Trimethylsilyl- 3- furanmethanol (91). To a cold (0°C) solution of
2-trimethylsilylfuran-3-carboxylic acid (598 mg, 3.2 mmol) in tetrahydrofuran
(15 mL) was added 1.0 M borane-tetrahydrofuran complex in tetrahydrofuran
(6 mL). After 1 h the ice bath was removed and the mixture was stirred atroom
temperature for another 3h.Ammonium chloride solution (15 mL) was69
carefully added and the mixture was stirred for 0.5 h and extractedinto ether
(3 x 30 mL). The separated organic layerswere washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 1:1) yielded 450 mg (82%) of the title compound: IR (neat) 3327 (br),
3313, 2957, 1508, 1250, 1008, 841, 807, 630 cm-1; 1H NMR (300MHz,
CDCI3) 8 0.30 (9H, s), 4.6 (2H, d, J= 5 Hz), 6.45 (1H, d, J = 1 Hz), 7.57 (1H, d,
J = 1 Hz).
2- Trimethylsilyl- 3- furaldehyde.To a suspension of active
manganese (IV) oxide (2 g, 23 mmol) in hexane (30 mL) was added 2-
trimethylsilyI-3-furanmethanol (433 mg, 2.5 mmol) in hexane (1 mL). The
mixture was stirred at room temperature for 6h and then filteredover Celite.
The filter cake was thoroughly washed with ether and the solventcarefully
removed in vacuo.Column chromatography of the residue (hexane-ethyl
acetate, 20:1) afforded 260 mg (60 %) of the title compound: IR (neat) 3400
(br), 2957, 1668, 844, 762, 632 cm-1; 1H NMR (300 MHz, CDCI3) 80.39 (9H,
s),6.80 (1H, d, J = 0.5 Hz) 7.60 (1H, d, J= 1 Hz), 10.1 (1H, s).
NCB CO2Et
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3-(-Ethyl -2-cyano-3-(2-trimethylsily1-3-furany1)-acrylate(92).
A mixture of 2- trimethylsilyl -3- furaldehyde (180mg, 1.0 mmol), ethyl a-cyano
acetate (220 mg, 2 mmol), and a catalytic amount of piperidine in pyridine (2.5
mL) was stirred at room temperature for 10 h. The mixturewas cooled to 0°C,
10% aqueous sulfuric acid (10 mL) was added, and the mixturewas extracted
with ether (3 x 10 mL). The separated organic layerwas washed with brine,
dried, and concentrated in vacuo.Column chromatography of the residue70
(hexane-ethyl acetate, 20:1) afforded 230mg (80%) of 92 as a white solid: mp
106°C; IR (KBr) 3190, 2996, 2226, 1722, 1609, 1267, 840 cm-1; 1HNMR (300
MHz, CDCI3) 6 0.39 (9H, s), 1.40 (3H, t, J= 8.0 Hz) 4.40 (2H, q, J = 8.0 Hz),
7.40 (1H, d, J = 0.5 Hz), 7.68 (1H, d, J= 0.5 Hz), 8.30 (1H, s); 13C NMR
(CDCI3, 75 MHz) 8 -1.1, 14.1, 62.3,100.7,108.0,115.8,129.7, 146.4, 148.1,
162.8, 171.2; MS (El) m/z 263, 248,177,100, 75,73.HRMS m/z calcd for
C13H1703NSi: 263.0978. Found: 263.0978.
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4-Cyano-4-carboethoxy-5-(2-trimethylsily1-3-furanyl)
cyclohexene (93). To a solution of 92 (61 mg, 0.23 mmol) in toluene (3
mL) was added an undefined amount of 1,3-butadiene whichwas bubbled
through the solution in a gas stream. The mixturewas heated in a sealed flask
at 250°C for 7 days (progress of the reaction was monitored by TLC and 1,3-
butadiene was added to the reaction vessel several times). The mixturewas
poured into 5 mL of methanol and the polymeric materialwas removed by
filtration over Celite.Solvent and residual diene were removed invacuo.
Column chromatography of the residue (hexane-ethyl acetate, 20:1)afforded
63 mg (87%) of 93 as a colorless oil:IR (neat) 2958, 2929, 1741, 1281, 1261,
1252, 1230, 843, 764 cm-1; 1H NMR (300 MHz, CDCI3) 80.39 (9H, s), 1.03
(3H, t, J=8.0 Hz), 2.35 (2H, m), 2.58 (2H, m), 2.91 (1H, m), 3.35 (1H,dd, J=12,
5.6 Hz), 4.05 (2H, m), 5.8 (2H, m), 6.80 (1H, d, J= 0.5 Hz), 7.60 (1H, d, J = 0.5
Hz); 13C NMR (CDCI3, 75 MHz) 8 -1.0, 13.4, 31.5, 34.6, 37.3,48.4, 62.3, 108.6,
118.8, 121.9, 127.1, 133.3, 146.7, 156.1, 168.5; MS(EI) m/z 317 (M+),303,71
302, 274, 248, 230, 220, 73 ; HRMS m/z calcd for C17H2303N Si :317.1447.
Found: 317.1447.
4-Cyano-4-hydroxymethy1-5-(2-trimethylsily1-3-furanyI)-
cyclohexene. To a suspension of lithium aluminum hydride (20 mg, 0.5
mmol) in dry ether (8 mL) was added 93 (90 mg, 0.28 mmol) in ether (5 mL)
via cannula. The mixture was stirred at -78°C for 1.5 h after which water (20
4) was added followed by 10% aqueous sodium hydroxide (20 1.1L) and water
(60 gL). The resulting suspension was filtered over Celite and the filtercake
was washed with ether.The filtrate was dried and the solvent was
evaporated. Column chromatography of the residue (hexane-ethyl acetate,
1:1) afforded 54 mg (30%) of the title compound and 42 mg (21%) of 93was
recovered:IR (neat) 3400, 2920, 1250, 840, 763 cm-1; 1H NMR (300 MHz,
CDCI3) 8 0.39 (s, 9H), 1,85-2.4 (m, 4 H), 3.25 (dd, J=11Hz, 11 Hz, 1H), 3.58 (d,
J=11 Hz, 1H), 3.67 (d, J=11 Hz, 1H), 5.78 (m, 2 H), 6.80 (d, J= 0.7 Hz, 1 H),
7.61(d, J = 0.7 Hz, 1 H); 13C NMR (CDCI3, 75 MHz) 8 -0.8, 32.1, 33.5, 35.1,
42.6, 66.6, 108.3, 122.0, 123.0, 127.1, 134.6, 147.4, 155.5.
NO2
CN
H
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4-Cyan o-nitrobenzoy1-4-hydroxymethy1-5-(2-trimethyl-sily1-3-
furanyl)cyclohexene (94).To a solution of 4-Cyano-4-hydroxymethy1-5-
(2-trimethylsily1-3-furany1)-cyclohexene(50mg,0.17mmol)in
dichloromethane (5 mL) was added p-nitrobenzoyl chloride (40 mg, 0.2172
mmol), triethylamine (60 IlL, 0.6 mmol) anda catalytic amount of 4-
(dimethylamino)pyridine. The mixture was stirred atroom temperature for 15
h, after which 0.1 N hydrochloric acid (10 mL)was added and the mixture was
extracted with ether (3 x 5 mL). The combined organic layerswere washed
with brine, dried, and concentrated invacuo. Column chromatography of the
residue (hexane-ethyl acetate, 3:1) afforded 40mg (52%) of 94 as a yellow
solid and 10 mg (20%) of starting material was recovered:IR (KBr) 2920,
1732, 1529, 1347, 1269, 1100, 840, 718 cm-1; 1H NMR (300 MHz, CDCI3)8
0.39 (9H, s), 2.30-2.80 (4H, m), 3.05 (1H, dd, J=11Hz, 5 Hz), 4.22 (1H, d, J=11
Hz), 4.30 (1H, d, J=11 Hz), 5.78 (2H, m), 6.80 (1H, d, J=1 Hz), 7.59 (1H,d, J=1
Hz), 8.15-8.31 (4H, m); 13C NMR (CDCI3, 100 MHz) 8 -0.7,31.9, 34.5, 36.2,
40.6, 66.8, 108.3, 120.8, 122.0, 123.6, 127.7, 130.9, 133.4, 134.5,147.6,
150.8, 155.8, 164.0; Anal. calcd for C22H24N205Si C; 62.24; H; 5.70; N;6.60.
Found: C; 61.86; H; 5.63; N; 6.46.
Compound 94 crystallized in the monoclinic spacegroup c2/c with
a=30.400 (2) A, b=10.351(4) A, c=13.999 (6) A, 13=95.44 (7), V=4386 (4) A3,
Z=8, Dcalc=1.322 g/cm3. All 3111 nonequivalent reflection in therange of 3.5°
< 20 < 50° were measured on a Rigaku AFC6R diffractometer with graphite
monochromated Mo Ka radiation (X=0.71069 A). The structurewas solved
with direct methods (SHELXS) using 3052 unique reflections with F> 3 cr(F).
Full matrix least squares refinement with anisotropictemperature factors for all
non-hydrogen atoms and calculated hydrogen atom positions ledto the final
discrepancy indices of R=0.058 and Rw=0.065.73
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4-Aminomethy1-4-hydroxymethy1-5-(2-trimethylsily1-3-
furanyl)cyclohexene (95).To a suspension of lithium aluminum hydride
(20 mg, 0.5 mmol) inof dry ether (2 mL) was added a solution of Diels -Alder
adduct 93 (26 mg, 0.08 mmol) in ether (5 mL) via cannula. The mixture was
stirred at room temperature for 14 h, after which water (20 ilL) was added
followed by 10% aqueus sodium hydroxide (20 4) and water (60 ilL). The
resulting suspension was filtered over Celite and the filtercakewas washed
with ether and methanol. Due its very polar properties, 95 was used without
further purification: IR (KBr) 3030 (br), 2957, 2923, 2907, 1249, 840, 608 cm-1,
1H NMR (300 MHz, CDCI3) 8 0.39 (9H, s), 2.4-1.85 (4H, m), 2.70 (1H, d, 10
Hz), 2.80 (1H, d, 10 Hz), 3.25 (1H, dd, J=18Hz, 5.6 Hz), 3.62 (1H, d, 10 Hz),
3.69 (1H, d, 10 Hz), 5.72 (2H, m), 6.30 (1H, d, J = 0.5 Hz), 7.55 (1H, d, J= 0.5
H ).
4-Aminomethy1-4-hydroxymethylureido-5-(2-trimethylsily1-3-
furanyl)cyclohexene (96). To a solution of crude 95 (ca. 0.08 mmol) in
tetrahydrofuran (5 mL) was added 1,1'-carbonyldiimidazole (15mg, 0.09
mmol) in 3 mg portions over a period of 3h. The mixture was stirred for 12 h,
after which 5 mL of water were added and the mixture was extracted with ether
(3 x 10 mL). The combined organic layers were washed with brine, dried, and74
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 2:8) afforded 13 mg (54%, from 93) of 96 as a colorless oil:IR (KBr)
2899, 1715, 1487, 1250, 1115, 840, 762, 654 cm-1;1H NMR (300 MHz, CDCI3)
0.29 (9H, s), 2.1 (2H, m), 2.35 (2H, m), 2.95 (1H, m), 3.05 (1H, t, J=5Hz), 3.2
(1H, d, J=9Hz), 4.01 (1H, d, 11 Hz), 4.07 (1H, d, 11 Hz), 5.75 (2H, m), 6.32 (1H,
d, J = 1.5 Hz),7.55 (1H, d, J = 1.5 Hz); 13C NMR (CDCI3, 75 MHz) S -0.6, 29.5,
29.9, 32.2, 32.5, 47.1, 73.6, 109.6, 124.1, 126.0, 134.7, 147.0, 153.9, 155.7;
MS (CI) m/z 306 (M +1), 290, 59; HRMS m/z calcd for C16H2403NSi (M +1):
306.15255 Found: 306.15250.
4-Aminomethy1-4-hydroxymethylureido-5-(2-furanony1)-
cyclohexene (97). To a suspension of 96 (101 mg, 0.33 mmol) and sodium
acetate (50 mg) in dichloromethane (20 mL) was added 38% peracetic acid
(250 1.11_, 1.4 mmol). The resulting mixture was stirred at 9°C for 36 h.Solid
sodium thiosulfate (50 mg) was added, and the mixture was filtered over Celite
and the filtercake washed with ether. The filtrate was dried and the solvent
was evaporated.Column chromatography of the residue (ethyl acetate-
methanol, 1:4 ) afforded 56 mg (57%) of 97 as a colorless oil: IR (neat) 3400,
2899, 1746, 1724, 1702, 1692, 1686, 1582,1575, 1566,1490, 1443,1419
cm-1; 1H NMR (300 MHz, CDCI3) 8 1.95-2.45(4H, m), 2.91(2H, m), 3.28(1H,
d, J=15Hz), 4.07 (1H, d, 18 Hz), 4.10 (1H, d, 18 Hz), 4.81 (2H, m), 5.79 (2H, m),
6.00 (1H, s), 7.37 (1H, s); 13C NMR (CDCI3, 75 MHz) 8 28.0, 29.0, 32.3, 32.6,
47.0, 70.5, 72.8, 124.7, 125.1, 134.4, 147.0,153.7, 174.3; MS (CI) m/z 25075
(M +1), 232, 206, 189, 143; HRMS m/z calcd for C13H16N04 (M+1): 250.1079
Found: 250.1079.
f° -t---0".NMe
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N-Methy1-4-aminomethy1-4-hydroxymethylureido-5-(2-
trimethylsily1-3-furanyOcyclohexene(99). To a suspension of 60%
sodium hydride dispersion in mineral oil (15 mg, 0.37 mmol) indry
tetrahydrofuran (1.5 mL) was added 96 (44 mg, 0.14 mmol) in tetrahydrofuran
(3 mL) via cannula. The mixture was cooled to 0°C and iodomethane (300 gL,
5.3 mmol) was added via syringe.The mixture was stirred at room
temperature for 5 h, after which 0.1 N aqueous sodium hydroxide solution (5
mL) was added and the mixture was extracted with ether (3 x 10 mL). The
combined organic layers were washed with brine, dried, and concentrated in
vacuo. Column chromatography of the residue (hexane-ethyl acetate, 1:4)
afforded 40 mg (87%) of 99 as an amorphous white solid:IR (KBr) 2899,
1686, 1492, 1250, 1144, 840, 760 cm-1; 1H NMR (300 MHz, CDCI3) 6 0.29
(9H, s), 2.0-2.45 (4H, m), 2.35 (2H, m), 2.80 (1H, d, J = 11Hz), 2.88 (3H, s),
3.16 (1H, d, J = 18Hz), 3.96 (1H, d, 10.8 Hz), 3.98 (1H, d, 10.8 Hz), 5.75 (2H,
m), 6.32 (1H, d, J = 4 Hz), 7.50 (1H, d, J = 4 Hz); 13C NMR (CDCI3, 75 MHz) 6
-0.6, 29.5, 30.2, 32.6, 33.5, 36.8, 54.9, 73.1, 109.7, 124.1, 126.0, 134.9, 147.1,
153.4, 155.7; MS (El) m/z 319 (M±), 304, 238, 198, 73, HRMS m/z calcd for
C17H26NO3Si (M+1):320.1682. Found: 320.1680.76
N-Methy1-4-aminomethy1-4-hydroxymethylureido-5-(2-
furanonyl) cyclohexene (100).To a suspension of 99 (217mg, 0.68
mmol) and sodium acetate (50 mg) in dichloromethane(20 mL) was added
38% peracetic acid (250 4, 1.4 mmol). The resultingmixture was stirred at
9°C for 36 h.Solid sodium thiosulfate (50 mg)was added, the mixture was
filtered over Celite and the filtercakewas washed with ether. The filtrate was
dried and the solvent was evaporated.Column chromatography of the
residue (ethyl acetate-methanol, 1:4) afforded103 mg (57%, 79% based on
recovered starting material) of 100 and 61mg (28%) of 99: IR (neat) 3400,
2899, 1750, 1700, 1692, 1687, 1582, 1576, 1566,1490, 1443 cm-1; 1H NMR
(300 MHz, CDCI3) 8 1.95-2.45 (4 H, m), 2.80 (1H,d, J=15Hz), 2.90 (3H, s),
3.28 (1H, d, J=15Hz), 4.15 (2H, m), 4.80 (1H, d, 18Hz), 4.85 (1H, d, 18 Hz),
5.79 (2H, m), 7.39 (1H, s); 13C NMR (CDCI3, 75 MHz)8 28.0, 29.1, 32.2, 33.8,
36.8,54.6,70.4,72.2, 124.7, 125.1, 134.6, 147.0, 153.7, 174.2; MS (CI)m/z
264(M+1),117,59, 57, HRMS m/z calcd for C14H18N04(M+1):264.1236.
Found: 264.1235.
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N-tert-Butoxycarbony1-4-aminomethy1-4-hydroxymethyl-5-(2-
trimethylsily1-3-furanypcyclohexene (101). Toa solution of crude 95
(290 mg, 1.04 mmol) in dry tetrahydrofuran (8 mL)was added di -tent -butyl
dicarbonate (250 mg, 1.1 mmol). The mixturewas stirred at room temperature77
for 4 h, after which water (20 mL)was added and the mixture was extracted
into ether (3 x 50 mL). The combined organic layerswere washed with brine,
dried, and concentrated in vacuo. Column chromatographyof the residue
(hexane-ethyl acetate, 20:1) afforded 320mg (81%) of 101: IR (KBr) 3380,
3283, 2960, 1678, 1559, 1347, 1250, 1172, 840, 718 cm-1; 1HNMR (300 MHz,
CDCI3) 6 0.29 (9H, s), 1.43 (9H, s), 1.90 (3H, m),2.50 (1H, m), 2.90 (1H, dd, J
= 18Hz, 12Hz), 3.10 (1H, d, J=12 Hz), 3.41 (2H, m), 3.95 (1H, t, J=12Hz), 4.59
(1H, bt, J=8Hz), 5.75 (2H, m), 6.32 (1H, d, J= 0.5 Hz), 7.53 (1H, d, J = 0.5 Hz);
13C NMR (CDCI3, 75 MHz) S -0.6, 28.3, 28.4,29.7, 30.6, 40.6, 44.7, 64.3, 80.0,
110.2, 124.6, 125.5, 137.7, 147.0, 154.5, 157.7; MS (El)m/z 379 (M+), 308,
172, 102, 73, HRMS m/z calcd for C20H33NO4Si(M-9:379.2179 Found:
379.2180.
HO
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N-Methyl-N-tert-butoxycarbony1-4-aminomethy1-4-
hydroxymethy1-5-(2-trimethylsily1-3-furanypcyclohexene (102). To
a solution of 101 (222 mg, 0.59 mmol) in dry tetrahydrofuran (8 mL)was
added 60% sodium hydride dispersion in mineral oil (25mg, 0.65 mmol). The
mixture was cooled to 0°C and iodomethane (0.5 mL, 8.0mmol) was added
via syringe. The mixture was stirred atroom temperature for 8 h, after which
aqueous sodium bicarbonate (20 mL) was added and the mixturewas
extracted with ether (3 x 50 mL). The combined organiclayers were washed
with brine, dried, and concentrated invacuo. Column chromatography of the
residue (hexane-ethyl acetate, 20:1) afforded 320mg (80%) of 102: IR (KBr)
3734, 2960, 1701, 1505, 1250, 1172, 840, 718 cm-1; 1HNMR (300 MHz,
BOC
N_78
CDCI3) 0.29 (s, 9H), 1.40 (s, 9H), 1.85-2.40 (4H,m), 3.10 (2H, m), 3.25 (2H,
m), 3.30 (3H, s), 4.95 (1H, bs), 5.75 (2H, m),6.35 (1H, s), 7.52 (1H, s); 13C
NMR (CDCI3, 75 MHz) 8 -0.6, 28.4, 29.4, 30.4,32.9, 39.1, 45.3, 59.4, 78.7,
110.3, 125.1, 125.7, 136.6, 146.7, 154.8, 156.3; MS(El) m/z 393 (M+), 322,
216, 172, 159.1, 74, 73, HRMS m/z calcd forC21H35NO4Si (M +): 393.2335.
Found: 393.2336.
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N-Methyl-N-tert-butoxycarbony1-4-aminomethyl-
trifuoroacety1-4-hydroxymethy1-5-(2-trimethylsily1-3-furanyl)
cyclohexene (104). To a solution of the 102 (156mg, 0.39 mmol) in dry
dichloromethane (2 mL) was added triethylamine (0.5mL) and a catalytic
amount of 4-(dimethylamino)pyridine. The mixturewas cooled to 0°C and
freshly distilled trifluoroacetic anhydride (0.25mL) was added via syringe.
The resulting mixture was stirred for 1 h andwas diluted with cold water (30
mL) and extracted with ether (3 x 50 mL). Thecombined organic layers were
washed withbrine,dried,and concentratedinvacuo.Column
chromatography of the residue (hexane-ethyl acetate, 20:1)afforded 119 mg
(78%) of 104:IR (KBr) 3734, 2960, 1760, 1718, 1371, 1281,1255, 1198,
1127, 1101, 840, 718 cm-1; 1H NMR (300 MHz, CDCI3)8 0.29 (9H, s), 1.49
(9H, s), 3.02-3.12 (2H, m), 3.18 (3H, s), 3.22 (1H,d, J=9 Hz), 3.58 (1H, d,
J=14Hz), 4.02 (1H, d, J=14Hz), 5.75 (2H, m), 6.38 (1H,d, J=3 Hz), 7.56 (1H, d,
J=3 Hz); 13C NMR (CDCI3, 75 MHz) 8 -0.6, 27.5,29.4, 30.2, 33.7, 40.4, 50.0,
59.1, 85.4, 110.1, 125.0, 125.5, 136.0, 146.9, 151.9,155.2; MS (El) m/z 48979
(Mt), 374, 204, 203, 193, 143, 122, 118, 81, 75, 73; HRMSm/z calcd for
C23H34NO5SiF3 (M+):489.2158. Found: 489.2159.
0,--CF3 °)....0 F3
.,--0.B0C .,-0_BOG
N N
Me
+ Me
00 0
fixture
N-Methyl-N-tert-butoxycarbony1-4-aminomethyl-
trifuoroacety1-4-hydroxymethy1-5-(3-furanoypcyclohexene(105)
and its epoxide 106. To a solution of 104 in dichloromethane(2 mL) was
added sodium acetate (20 mg). The mixturewas cooled to 0°C and 38%
peracetic acid was added in two portions (80 pl, 0.08 mmol)over a period of 6
h.The resulting mixture was stirred for 12 h at 9°C, dilutedwith aqueous
sodium thiosulfate (10 mL) and aqueous sodium bicarbonatesolution (10 mL),
and was extracted with ether (3 x 15 mL). The combinedorganic layers were
washed withbrine,dried,and concentratedinvacuo.Column
chromatography of the residue (hexane-ethyl acetate, 4:1) afforded17 mg
(66%) of a mixture of 105 and 106: IR (neat) 3734, 2960,1756, 1714, 1283,
1198, 1131, 1101 cm-1; 1H NMR (300 MHz, CDCI3) 6 1.49 (s,9H), 2.01-2.31
(m, 4H), 2.91-3.22 (m, 6H), 3.65 (m, 1H), 4.02 (m, 2H),4.81 (m, 2H), 5.75 (m,
2H), 7.32 (s, 1 H); 13C NMR (CDCI3, 75 MHz) 625.7,27.5,28.1,29.7,29.9,
33.0, 34.2, 39.3, 40.9, 46.1,47.7, 50.3, 51.7, 58.8, 70.0,70.3,85.7,86.1,124.7,
125.6, 135.1, 145.5, 147.1, 151.8,174.6.80
N-Methyl-N-trifuoroacetamido-4-aminomethy1-4-
hydroxymethy1-5-(3-furanoyl)cyclohexene(107). To a solution of a
mixture of 105 and 106 (48 mg, 0.11 mmol) in dichloromethane (3 mL)was
added trifluoroacetic acid (0.75 mL) dropwise over a period of 1h. Aqueous
sodium bicarbonate (20 mL) was carefully added and the mixturewas
extracted into ether. The combined organic layerswere washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 4:1) afforded 20 mg (56%) of 107:IR (neat) 3349,
2923, 1724, 1447, 1209, 1159 cm-1; 1H NMR (300 MHz, CDCI3) 6 1.7 (1H, m),
1.92 (2H, m), 2.31(1H, m), 2.10 (1H, m), 2.75 (1H, dd, J=5Hz, 1Hz), 3.07 (1H,
dd, J=5Hz, 1Hz), 3.30 (3H, s), 3.41 (2H, m), 3.65 (1H, dd, J=14Hz, 8Hz), 4.81
(2H, m), 5.70 (2H, m), 7.39 (1H, s); 13C NMR (CDCI3, 75 MHz) 6 28.2, 28.9,
31.2, 39.2, 39.4, 44.7, 59.1, 70.7, 77.5, 124.8, 125.4, 135.7, 146.7, 175.5; 19F
NMR (CDCI3, 282 MHz) 8- 76.63; MS (CI) m/z 334 (M+1), 314, 302, 220, 207,
188, 175, 143, 129; HRMS m/z calcd for C15H19F3N04 (M+): 334.1266.
Found: 334.1267.
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Methyl -4 -N- tert - Butoxycarbonylamino -3- furoate(109). To a
solution of 4-carbomethoxy-3-furoic acid42 (718 mg, 4.22 mmol) in dry toluene
(7 mL) was added oxalyl chloride (0.4 mL, 4.3 mmol) via syringe. Themixture
was refluxed for 1 h and the toluene was removed in vacuo. The residuewas81
taken up in ether (10 mL), cooled to 0°C, anda solution of sodium azide (1g,
15.4 mmol) in water (10 mL) was added. The resultingtwo phase system was
stirred at 0°C for 2 h, after which the layerswere separated and the aqueous
layer was back extracted with ether (3x 15 mL). The combined organic layers
were washed with brine and aqueous sodium bicarbonate, dried,and
concentrated in vacuo. The crude acyl azidewas taken up in dry tert-butanol
(20 mL) and the solution was refluxed for 3 h. Evaporationof the tert-butanol
and column chromatography of the residue (hexane-ethylacetate, 20:1)
afforded 680 mg (66%) of 109: IR (KBr) 3399, 1709, 1705,1561, 1510, 1276
cm-1; 1H NMR (300 MHz, CDCI3) 1.50 (9H, s),3.85 (3H, s), 7.83 (1H, s), 7.91
(2H, bs); 13C NMR (CDCI3, 75 MHz) 6 28.2, 51.5, 80.6,109.9, 124.9, 131.5,
146.2, 152.2, 164.4; MS (El) m/z 241 (M+), 185, 168,154, 141, 109; HRMS m/z
calcd for C11 H15N05 (M+): 241.0950. Found: 241.0950.
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Methyl -4 -N- tert- Butoxycarbonyl -N- methylamino -3- furoate
(110). To a suspension of 60% sodium hydridedispersion in mineral oil (116
mg, 2.9 mmol) in dry tetrahydrofuran (4 mL) was addeda solution of 109 (470
mg, 1.93 mmol) in tetrahydrofuran (8 mL). The mixturewas cooled to 0°C and
iodomethane (0.5 mL, 8.05 mmol) was added via syringe.The mixture was
stirred at room temperature for 3 h after whichaqueous sodium hydroxide
solution (20 mL) was added and the mixturewas extracted with ether (3 x 25
mL).The combined organic layers were washed withbrine, dried, and
concentrated in vacuo. Column chromatography of the residue(hexane-ethyl
acetate, 20:1) afforded 253 mg (51%) of 110: IR (neat) 2960,1730, 1708,
1435, 1388, 1362, 1389, 1160, 1083 cm-1; 1H NMR (300MHz, CDCI3) 6 1.5082
(9H, s), 3.12 (3H, s), 3.79 (3H, s), 7.37 (1H, bs), 7.91 (1H, d, J=1Hz); 13C NMR
(CDCI3, 75 MHz) 8 28.1, 38.0, 51.5, 80.2, 116.3, 129.7, 139.2, 139.9, 145.8,
148.0, 154.9, 162.5.
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4-N-tert-Butoxycarbonyl-N-methylamino-3-furanmethanol
(112). Method A: The combined aqueous layers from the preparation of110
described above were carefully acidified with aqueous 1N hydrochloric acid
and extracted with ether (3 x 15 mL). The ether combined layerswere washed
with brine, dried, and concentrated in vacuo, and the residuewas taken up in
tetrahydrofuran (3 mL). To this solution was added 1.0 M borane-
tetrahydrofuran complex in tetrahydrofuran (0.6 mL). The mixturewas stirred
at room temperature for 3h. Saturated aqueous ammonium chloride (0.6 mL)
was carefully added and the mixture was stirred for 0.5 h and was extracted
into ether (3 x 15 mL). The separated organic layerswere washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 1:1) yielded 85 mg (20%, from 110) of 112.
Method B: To a suspension of lithium aluminum hydride (80mg, 2.1 mmol) in
dry ether (2 mL) was added 110 (253 mg, 0.98 mmol) in ether (5 mL) via
cannula. The mixture was stirred at 0°C for 1 h, after which water (80 !IL)was
added followed by 10% aqueous sodium hydroxide (80 4) and water (240
p.L). The resulting suspension was stirred at room temperature for 0.5 h and
filtered over Celite.The filtercake was washed with ether and the ether
evaporated. Column chromatography of the residue (hexane-ethyl acetate,
20:1) gave 151 mg (64%) of 112: IR (neat) 3464, 3457, 2977, 1701, 1686,
1476, 1368, 1362, 1251, 1160 cm-1; 1H NMR (300 MHz, CDCI3) 8 1.47 (9H, s),83
3.19 (3H, s), 4.35(2H, m), 7.37 (1H, s), 7.39 (1H, s); 13C NMR (CDCI3, 75
MHz) 8 28.0, 38.9,53.7,81.3,122.7, 130.3, 136.9, 141.0, 155.6; MS (El) m/z
227 (M+), 171, 154,127,109,108, 80.1, 66; HRMS m/z calcd for C11H17N04
(M +): 227.1158. Found: 227.1158.
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4-N-tert-Butoxycarbonyl-N-methylamino-3-furaldehyde (113).
To a solution of oxalyl chloride (0.14 mL, 1.6 mmol) in dry dichloromethane (2
mL) at -78°C was added a solution of dimethylsulfoxide (0.24 mL, 3.4 mmol) in
dichloromethane (3 mL).A solution of 112 (279 mg, 1.22 mmol) in
dichloromethane (8 mL) was added dropwise over a period of 0.5 h.The
mixture was stirred at -78°C for an additional 0.5 h, after which triethylamine
(0.85 mL, 6.1 mmol) was added and the mixture was allowed to warm to room
temperature. The mixture was diluted with aqueous 0.1N hydrochloric acid
(10 mL), the layers were separated, and the aqueous layer was back extracted
with ether (2 x 15 mL). The combined organic layers were washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 3:1) afforded 240 mg (86%) of 113: IR (neat) 2978,
1698, 1693, 1597, 1429, 1386, 1363, 1311, 1253, 1162, 1052, 869, 765 cm-1;
1H NMR (300 MHz, CDCI3) 8 1.50 (9H, s), 3.19 (3H, s), 7.45 (1H, bs),7.92 (1H,
d, J=1Hz), 9.89 (1H, s); 13C NMR (CDCI3, 75 MHz) 8 28.0, 37.95, 80.88, 124,4,
128.7, 139.1, 150.5, 154.4, 183.9; MS (CI) m/z 226 (M+1), 210, 198, 170, 133,
101; HRMS m/z calcd for CiiH15N04 (M+): 225.1001. Found: 225.1001.MeO
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Dimethy1-4-N-tert-Butoxycarbonyl-N-methylamino-3-
furylidenemalonate (114). To a solution of aldehyde113 (616 mg, 2.72
mmol) in toluene (30 mL) was added diethyl malonate(0.36 mL, 3.0 mmol)
and a catalytic amount of piperidine (50 4). Themixture was heated to reflux
for 3 h and the water formed during the reactionwas removed with a Dean-
Stark trap. The mixture was cooled to 0°C anddiluted with cold aqueous 2N
sulfuric acid (30 mL). The layerswere separated and the aqueous layer was
back extracted with ether (3 x 20 mL). The combinedorganic layers were
washed withbrine,dried, and concentratedinvacuo.Column
chromatography of the residue (hexane-ethyl acetate, 3:1) afforded860 mg
(92%) of 114: IR (neat) 2978, 1709, 1363, 1270,1230, 1162 cm-1; 1H NMR
(300 MHz, CDCI3) 6 1.40 (9H, s), 3.18 (3H, s), 3.81 (3H,s),3.86 (3H, s), 7.36
(1H, s), 7.40 (s, 1H), 7.72 (1H, s); 13C NMR (CDCI3,75 MHz) 6 28.0, 39.2,
52.6, 52.7, 81.2, 117.3,117.5,124.3, 131.0, 132.0,137.4, 143.6, 164.4, 166.8;
MS (CI) m/z 340 (M+1),312,298, 284, 277, 254,208, 187, 170; HRMS m/z
calcd for C16H21 N07 (M+): 339.1319. Found: 339.1319.
0
0
5- Carbomethoxy- 6- oxo -7 -N- methyl -3,8- pyridinefuran(115).
To a solution of (114) (30 mg, 0.09 mmol) indichloromethane (4 mL) was
added trifluoroacetic acid (1 mL). The mixturewas stirred at 0°C for 15 min
and diluted with cold aqueous sodium bicarbonate(10 mL). The layers were85
separated and the aqueous layer was back extracted with ether (3x 10 mL).
The combined organic layers were washed withbrine,dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 4:1) afforded 12 mg (62%) of 115: IR (neat) 2980, 1732, 1648, 1213
cm-1; 1H NMR (300 MHz, CDCI3) 3.89 (3H, s), 3.91 (3H, s), 7.39 (1H, s),7.85
(1H, s), 8.20 (1H, s); 13C NMR (CDCI3, 75 MHz) 8 30.9, 52.5, 112.5, 123.2,
123.8, 131.1, 132.0, 135.1, 140.8, 158.6, 166.4; MS (El) m/z 207 (M +), 190,
188, 177, 176, 175.
6- Carbomethoxy- 5- oxo -4 -N- methyl -3,8- pyridinefuranone
(116). To a solution of 115 (14 mg, 0.07 mmol) in glacial acetic acid (1 mL)
buffered with potassium acetate (30 mg) was added neat bromine (5 4, 0.07
mmol).The mixture was stirred at 0°C for 15 min and diluted with cold
aqueous sodium bicarbonate (10 mL) and chloroform (5 mL). The layers were
separated and the aqueous layer was back extracted with ether (3x 5 mL).
The combined organic layers were washed withbrine,dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 4:1) afforded 9 mg (60%) of 116: IR (neat) 2980, 1732, 1648, 1213
cm-1; 1H NMR (300 MHz, CDCI3) 3.89 (3H, s), 3.91 (3H, s), 7.39 (1H, s),7.85
(1H, s), 8.20 (1H, s); 13C NMR (CDCI3, 75 MHz) 8 30.9, 52.5, 112.5, 123.2,
123.8, 131.1, 132.0, 135.1, 140.8, 158.6, 166.4; MS (El) m/z 207 (M+), 190,
188, 177, 176, 175: IR (neat) 2980, 1765, 1741, 1715, 1664, 1217; 1H NMR
(300 MHz, CDCI3) 8 3.88 (3H, s), 3.95 (3H, s), 5.15 (2H, s), 8.11 (1H, s); 13C86
NMR (CDCI3, 75 MHz) 6 29.0, 29.7.53.0, 66.9, 126.3, 126.9, 133.6,135.6,
159.4, 164.2, 166.8.
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4,4-Dicarbomethoxy-5-[3-N-tert-butoxycarbonyl-N-
methylamino-4-furanyl]cyclohex-2-en-1-one (117).To a solution of
114 (272 mg, 0.80 mmol) in toluene (4 mL) was added 1-methoxy-3-
(trimethylsilyloxyl)-1,3-butandiene (0.60 mL, 2.8 mmol) and the mixturewas
heated in a sealed tube at 140°C for 18 h. After evaporation of the toluene the
residue was taken up with a 1:1 mixture of tetrahydrofuran andaqueous 0.1 M
hydrochloric acid and was stirred at room temperature for 0.5 h.Saturated
aqueous bicarbonate solution was added and the mixture was extracted with
ether (3 x 20 mL). The combined organic layers were washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 3:1) afforded 233 mg (75%) of 117: IR (neat) 2977,
1737, 1434, 1366, 1328,1310, 1257, 1237, 1214, 1154, 1091, 1057 cm-1; 1H
NMR (300 MHz, CDCI3) 8 2.76 (1H, m), 1.44 (9H, s), 3.06 (1H, d, J=6Hz), 3.12
(3H s), 3.60 (3H, s), 3.80 (3H, s), 4.05 (1H, m), 6.19 (1H, d, J=10Hz), 7.10 (1H,
s), 7.27 (1H, s), 7.30 (1H, d, J=10Hz); 13C NMR (CDCI3, 75 MHz) 8 27.6, 28.1,
34.2, 40.6, 53.0, 53.5, 58.0, 80.7, 121.6, 130.6, 137.7, 139.4, 142.9, 154.9,
163.1, 167.4, 168.0, 196.0; MS (El) m/z 407 (M+), 308, 307, 248, 216, 159,
109, 94, 85; HRMS m/z calcd for C201-125N08 (M+): 407.1581.Found:
407.1581.
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4,4-Dicarbomethoxy-5-[3-N-tert-butoxycarbonyl-N-
methylamino-4-furanyl]cyclohex-2-en-1-ol(118). To a solution of
117 (16 mg, 0.039 mmol) in tetrahydrofuran (1 mL) was added a 1.0 M
solution of L-selectride in tetrahydrofuran (45 4, 0.041 mmol). The mixture
was stirred at 0°C for 15 min, after which saturated aqueous ammonium
chloride (2 mL) was added and the mixture was extracted with ether (3 x 2
mL).The combined organic layers were washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 2:8) afforded 15 mg (93%) of 118: IR (neat) 2957, 1735, 1700, 1452,
1369, 1264, 1208, 1154, 1091, 1068, 874, 801, 730 cm-1; 1H NMR (300 MHz,
CDCI3) 8 1.44 (s, 9H), 2.25-2.38 (m, 2H), 3.14 (s, 3H), 3.58 (s, 3H), 3.65 (m,
1H), 3.71 (s, 3H), 4.12 (m, 1H), 6.09-6.28 (m, 2H), 7.21 (s, 1H), 7.30 (s, 1H);
13C NMR (CDCI3, 75 MHz) 8 28.2, 30.9, 33.7, 52.6, 53.0, 57.9, 64.1, 80.6,
123.9, 125.4, 130.4, 133.2, 136.9, 137.9, 140.0, 155.1, 169.5; MS (El) m/z 309
(M+-05H802, 65), 246, 216, 119, 103.
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4,4-Dicarbomethoxy-5-[3-N-methy1-4-furanyl]cyclohex-2-en-
1-01 (119). To a solution of 118 (52 mg, 0.127 mmol) in dichloromethane (2
mL) was added neat trimethylsilyl iodide (20 p,L, 0.13 mmol). After 5 min the
mixture was quenched with a few drops of 10% methanolic potassium
carbonate. The solvent was evaporated and the residue was taken up with88
deuterated chloroform (0.24 mL):IR (neat) 3400, 2977, 1729, 1450, 1444,
1435, 1267, 1245, 916, 880, 735 cm-1; 1H NMR (300 MHz, CDCI3) 5 1.90 (2H,
m), 2.45-2.68 (3H, s), 3.50 (3H, s), 3.65 (1H, m), 3.72 (3H, s), 4.12 (1H, m),
6.10 (2H, m),6.95 (1H, s), 7.15 (1H, s).
0
8a-Carbomethoxy-3,4-[3,4-furany1]-2-N-methyl-6-hydroxy
hexahydroisoquinolin-2-one (120). To a solution of the 118 (52mg,
0.127 mmol) in dichloromethane (2 mL) was added neat trimethylsilyl iodide
(20 !IL, 0.13 mmol). After 5 min the mixture was quenched witha few drops of
methanolic 10% potassium carbonate. The solventwas evaporated and the
residue was taken up with chloroform (2 mL) and triethylamine (0.1 mL) and
the solution was heated to reflux for 12 h. The mixture was allowed to cool to
room temperature and washed with aqueous 0.1 N hydrochloric acid(2 mL).
The layers were separated and the aqueous layer back extracted with ether (3
x 2 mL). The combined organic layers were washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 2:8) afforded 23 mg (63%) of 120: IR (neat) 3400, 2977, 1733, 1664,
1637, 1221, 1121, 1003, 915, 887, 804, 732 cm-1; 1H NMR (300 MHz, CDCI3)
5 2.10 (2H, m), 2.22-3.26 (3H, s), 3.64 (3H, s), 3.65 (1H, m), 3.68 (3H, s), 4.37
(1H, m), 6.07 (2H, m),7.11 (1H, s), 7.23 (1H, s); 13C NMR (CDCI3, 75 MHz) 5
26.1, 31.1, 31.7, 36.2, 53.2, 65.7, 115.1, 125.1, 126.3, 129.7, 133.5, 138.0,
166.2, 170.9; MS (El) m/z 277 (M+), 232, 218, 200, 176, 91, 69. HRMS m/z
calcd for C14H15N05 (M+): 277.0950. Found: 277.0949.Me0 CO2Me
CO2Me
KBOC
CH3
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HO
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4-4-Dicarbomethoxy-3-methoxy-5-[3-N-tert-butoxycarbonyl-N-
methylamino-4-furanyl]cyclohexan-1-ol (121).To a solution of 1 1 7
(317 mg, 0.77 mmol) in 0.4 M aqueous cerium chloride (1.5 mL)was added
sodium borohydride (57 mg, 1.4 mmol) in small portions. The mixturewas
stirred at room temperature for 15 min, treated with aqueous 0.1 N
hydrochloric acid and extracted with ether (3 x 15 mL). The combined organic
layers were washed with brine, dried, and concentrated invacuo. Column
chromatography of the residue (hexane-ethyl acetate, 1:1) afforded 209mg
(66%) of 118 (see above for the preparation of 118 asa single epimer) and
42 mg (12%) of 121.
121: IR (neat) 3398, 2957, 1758, 1729, 1697, 1435, 1368, 1258, 1205,
1154, 1068, 1066 cm-1; 1H NMR (300 MHz, CDCI3) 8 1.42 (9H, s), 1.55-2.38
(5H, m), 3.31 (6H, m), 3.70 (6H, m), 3.91 (1H, m), 4.02 (1H, m), 6.91 (1H, s),
7.26 (1H, s); 13C NMR (CDCI3, 75 MHz) 8 28.2, 31.1, 38.9, 39.0, 52.0, 52.0,
57.0, 57.8, 62.1, 65.7, 66.0, 80.0, 125.2, 131.0, 136.8, 139.3, 155.2, 169.4,
169.6; MS (El) m/z 441 (M+), 342, 341, 232, 200, 137.
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8a-Carbomethoxy-3,4-[3,4-furany1]-2-N-methy1-8-methoxy-6-
hydroxy-1-octahydroisoquinolin-2-one (122). To a solution of 121 (30
mg, 0.09 mmol) in dichloromethane (2.5 mL) was added trifluoroacetic acid
(0.5 mL).After 5 min the mixture was quenched with aqueous sodium90
bicarbonate (5 mL). The resulting mixture was diluted with tetrahydrofuran (3
mL) and stirred at room temperature for 0.5 h. The layers were separated and
the aqueous layer was back extracted with ether (3 x 2 mL). The combined
organic layers were washed with brine, dried, and concentrated in vacuo.
Column chromatography of the residue (hexane-ethyl acetate, 2:8) afforded
12.1 mg (43%) of 122: IR (neat) 3437, 2946, 1743, 1672, 1639, 1456, 1437,
1358, 1282, 1230, 1183, 1109, 1083, 1031 cm-1; 1H NMR (300 MHz, CDCI3) 8
0.91 (m, 1H) 1.38 (m, 1H), 1.55 (m, 1H), 2.05 (m, 1H); 3.26 (s, 3H), 3.33 (s, 3H),
3.47 (m, 1H), 3.65 (s, 3H), 3.70 (m, 1H), 4.0 (m, 1H), 4.50 (m, 1H), 7.06 (d,
J=1.5Hz, 1H), 7.20 (d, J=1.5 Hz, 1H); MS (El) m/z 309 (M+), 277, 251, 250,
219, 218, 208, 176, 147, 85.9, 83, 69.
Co
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8a-Carbomethoxy-3,4-[3,4-furany1] -2-N-methy1-8-methoxy-1-
octahydroisoquinolin-2,6-one (123).To a cold (0°C) suspension of
pyridinium chlorochromate (15 mg, 0.07 mmol) and sodium acetate (20 mg) in
dichloromethane (1 mL) was added a solution of 122 (12 mg, 0.038 mmol) in
dichloromethane (2 mL). The mixture was stirred at room temperature for 3 h,
after which the mixture was diluted with ether (5 mL) and filtered over Celite.
The filtercake was washed with ether and the filtrate was washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 3:1) afforded 10 mg (83%) of 123:IR (neat) 2925,
1743, 1725, 1675 cm-1; 1H NMR (300 MHz, CDCI3) 8 2.21-2.50 (2H, m), 2.80
(2H, m), 3.27 (3H, s), 3.32 (3H, s), 3.68 (3H, s), 4.11 (1H, dd, J=18.0, 6.0 Hz),91
4.71 (1H, m), 7.13 (1H, s), 7.22 (1H, s); MS (El) m/z 307 (M+), 275, 248, 216,
208, 176.1, 150, 134, 84, 77.
02N
8a-Carbomethoxy-3,4-[3,4-furany1]-2-N-methyl -8-methoxy-6-
[2,4-dinitrophenylhydrazinyl]-1-octahydroisoquinolin-2-one (124).
To a solution of 123 (2.8 mg, 0.009 mmol) in ethanol (0.2 mL) was added 2,4-
dinitrophenylhydrazine (2 mg, 0.01 mmol) and acetic acid (2 pt). The mixture
was stirred for 4 h and the solvent was evaporated. Chromatography of the
residue (hexane-ethyl acetate, 3:1) afforded 1 mg (22%) of 124: IR (neat)
2915, 1742, 1671, 1615, 1612, 1585, 1506, 1460, 1340, 1109, 1675 cm-1; 1H
NMR (300 MHz, CDCI3) 8 2.05 (m, 1H), 2.32 (m, 1H), 2.51 (m, 1H), 2.75 (m,
1H), 3.40 (s, 3H), 3.68 (s, 3H), 3.72 (s, 3H), 3.92 (m, 1H), 4.75 (m, 1H), 7.15 (s,
1H), 7.28 (s, 1H), 7.95 (d, J=1Hz, 10H), 8.30 (d, J=1Hz, 10H), 9.14 (d, J=1Hz,
1H).
Compound 124 crystallized in the triclinic space group P-1 with
a=11.975 (3) A, b=12.399 (4) A, c=8.308 (6) A, a=91.23 (6)°, (3=95.44 (7)°,
y=117.24 (5)°, V=1077.8 (8) A3, Z=2, Dcalc=1.19 g/cm3. There were 3381
reflections measured in the range of 2.0° < 20 < 45° using a Rigaku AFC6R
diffractometer with graphite monochromated Mo Ka radiation (X=0.71069 A).
Of the 1998 unique reflections 1000 were considered observed with F > 3
cy(F).The structure was solved with direct methods (SHELXS) and refined
using a full matrix least squares routine with anisotropic temperature factors92
for all oxygen and nitrogen atoms and calculatedhydrogen atom positions.
The final discrepancy indices were R=0.078 and Rw=0.084.
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8a-Carbornethoxy-3,4-[3,4-furany1]-2-N-methyl-6-one-1-
hexahydroisoquinolin-2,6-one (125).
Method A.: To a cold (0°C) suspension of pyridinium chlorochromate(20 mg,
0.06 mmol) and sodium acetate (20 mg) in dichloromethane(1 mL) was
added a solution of 120 (6 mg, 0.029 mmol) in dichloromethane(2 mL). The
mixture was stirred at room temperature for 3 h, after which itwas diluted with
ether (5 mL) and filtered was over Celite.The filtercake was washed with
ether and the filtrate washed with brine, dried, and concentratedin vacuo.
Column chromatography of the residue (hexane-ethylacetate, 3:1) afforded 7
mg (88%) of 125.
Method B.: To a solution of 123 (2 mg, 0.006 mmol) in toluene (2mL) was
added p-toluenesulfonic acid (ca. 0.2 mg) and the mixturewas heated to reflux
for 12 h.The mixture was allowed to cool toroom temperature and was
washed with 2 mL of aqueous sodium bicarbonate.The layers were
separated and the aqueous layer was back extracted with ether(3 x 2 mL).
The combined organic layers were dried and concentratedin vacuo. Column
chromatography of the residue (hexane-ethyl acetate, 3:1) afforded1 mg
(55%) of 125: IR (neat) 1739, 1672, 1638, 1244, 1150,1091, 1033, 884, 811
cm-1; 1H NMR (300 MHz, CDCI3) 8 2.68 (m, 2H),3.25 (3H, s), 3.83 (3H, s),
4.15 (1H, m), 6.13 (1H, d, J=10Hz), 6.82 (1H, d, J=10Hz),7.15 (1H, d,
J=1Hz),7.18 (1H, d, J=1Hz); 13C NMR (CDCI3, 75 MHz) 8 31.3,33.5, 34.2,93
39.7, 53.7, 65.7, 113.7, 125.9, 130.7, 138.4, 143.2, 166.1, 169.6, 195.0; MS
(El) m/z 277 (M+), 216, 188, 158, 123; HRMS m/z calcd for C14H13N05 (Mi:
275.0794. Found: 275.0794.
8a-Carbomethoxy-3,4-[3,4-furanony1]-2-N-methyl -6-hydroxy
hexahydroisoquinolin-2-one (129). To a solution 120 (15 mg, 0.05
mmol) in methanol (2 mL) was added solid sodium bicarbonate (5 mg) and N-
bromosuccinimide (9 mg, 0.05 mmol). The methanol was evaporated after 5
min and the residue was taken up with chloroform (3 mL).The resulting
solution was washed with aqueous sodium thiosulfate, dried over sodium
sulfate and heated at reflux with a catalytic amount of p-toluenesulfonic acid
for 4 h. The mixture was allowed to cool to room temperature, washed with
aqueous sodium bicarbonate (2 mL), dried over sodium sulfate, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 2:8) afforded 8.4 mg (53%) of 129: IR (neat) 3396, 2977, 1761, 1736,
1678, 1221, 1058, 915 cm-1; 1H NMR (300 MHz, CDCI3) 8 2.15 (2H, m), 3.45
(3H, s), 3.70 (1H, m), 3.76 (3H, s), 4.32 (1H, m), 4.90 (2H, m), 6.07 (2H, m); 13C
NMR (CDCI3, 75 MHz) 8 28.9, 31.9, 33.2, 53.7, 55.1,64.6, 68.0, 125.8, 126.2,
133.8, 139.4, 166.3, 166.4, 169.8; MS (El) m/z 293 (M+), 248, 234, 216, 160,
77; HRMS m/z calcd for C14H15N06 (Mt): 293.0899. Found: 293.0899.94
9,9-Dicarbomethoxy-6N-tert-butoxycarbonyl-N-methylamino-
-5-methoxytricyclo-2,4-dioxa[6.3.1.03,7]dodeca-6,10-diene(130).
To a solution of 118 (48 mg, 0.12 mmol) in methanol (3 mL)was added
sodium bicarbonate (10 mg) and N-bromosuccinimide (23mg, 0.13 mmol).
The mixture was stirred at room temperature for 5 min and the solventwas
evaporated. The residue was taken up with aqueous sodium thiosulfate (5
mL) and the mixture was extracted with ether (3x 15 mL). The combined
organic layers were washed with brine, dried, and concentrated invacuo.
Column chromatography of the residue (hexane-ethyl acetate, 1:1) afforded
51 mg (99%) of 130:IR (neat) 2959, 1737, 1698, 1437, 1153, 998 cm-1; 1H
NMR (300 MHz, CDCI3) 5 1.48 (9H, s), 2.11 (2H, m), 2.97-3.11 (3H, m),3.66-
3.78(6H, m), 4.38 (1H, m), 5.78-6.34 (4H, m); 13C NMR (CDCI3, 75 MHz) 5
28.3,31.5, 31.7, 33.9, 36.0, 36.8, 52.9, 53.1,54.1,54.7, 57.6, 57.8, 64.9, 65.4,
81.0,99.4, 100.4,106.2, 106.9, 127.9, 128.1,128.7,129.0, 135.2, 153.7, 168.2,
169.0, 169.7; MS (El) m/z 439 (M+), 308, 280, 279, 279, 278, 264. HRMS m/z
calcd for C21 H29 NOg (M+): 439.1843. Found: 439.1843.
OH
9,9-Dicarbomethoxy-6-N-tert-butoxycarbonyl-N-
methylamino-5-hydroxytricyclo-2,4-dioxa[6.3.1.03,7]dodeca-6,1 0-
diene (131).To a solution of1 1 8(52 mg, 0.13 mmol) in"wet"95
dichloromethane (3 mL) was added solid sodium bicarbonate (ca. 10 mg) and
N-bromosuccinimide (24 mg, 0.14 mmol). The mixture was stirred atroom
temperature for 5 min after which aqueous sodium thiosulfate (5 mL) was
added and the mixture was extracted with ether (3 x 15 mL). The combined
organic layers were washed with brine, dried, and concentrated invacuo.
Column chromatography of the residue (hexane-ethyl acetate, 1:1) afforded
46 mg (85%) of 131: IR (neat) 3330, 2959, 1737, 1714, 1262, 1153, 998 cm-1;
1H NMR (300 MHz, CDCI3) 8 1.48 (9H, s), 2.11 (2H, m), 3.04 (3H, m), 3.75 (6H,
m), 3.85 (1H, m), 4.95 (1H, m), 5.25-6.10 (2H, m), 6.20 (2H, m); 13C NMR
(CDCI3, 75 MHz) S 21.0, 28.2, 29.5, 29.6, 31.4, 34.0, 36.6, 53.0, 53.2, 57.7,
60.3, 81.5, 99.5, 100.4, 128.0, 129.0, 137.0, 171.1, 177.6.
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9,9-Dicarbomethoxy-6-N-tert-butoxycarbonyl-N-
methylamino-5-oxotricyclo-2,4-dioxa[6.3.1.03,7]dodeca-6,10-diene
(132). To a cold (0°C) suspension of pyridinium dichromate (177mg, 0.45
mmol) and crushed 4 A molecular sieves (100 mg) in dichloromethane (3 mL)
was added hemiacetal 131 (67 mg, 0.16 mmol) in dichloromethane (4 mL).
The mixture was stirred at room temperature for 3 h, after which itwas diluted
with ether (5 mL) and filtered over Celite. The filtercakewas washed with
ether and the filtrate was washed with brine, dried, and concentrated invacuo.
Column chromatography of the residue (hexane-ethyl acetate, 1:1) afforded
41 mg (60%) of 132:IR (neat) 2959, 1789, 1739, 1698, 1436, 1366, 1229,
1154, 1091, 1068, 942 cm-1; 1H NMR (300 MHz, CDCI3) S 1.46 (9H, s), 2.1896
(2H, m), 3.05 (3H, s), 3.75 (6H, m), 4.10 (1H, m), 4.50 (1H, m), 5.93 (1H, m),
6.30 (2H, m); 13C NMR (CDCI3, 75 MHz) 6 28.1, 31.1, 34.7, 35.4, 53.4, 53.5,
153.6, 166.9, 167.6, 168.9; MS (El)
136, 124; HRMS m/z calcd for (M-F):
57.5,60.4, 65.3,81.9,94.6, 127.3, 129.5,
m/z422 (M-1+),421,321, 277, 217, 152,
423.1529. Found: 423.1528.
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4,4-Dicarbomethoxy-5-[3-N-tert-butoxycarbonyl-N-
methylamino-4-dihydrofuranyl]cyclohex-2-en-1-ol(134).To a
solution of 131 (10 mg, 0.02 mmol) in glacial acetic acid (0.3 mL) was added
sodium cyanoborohydride (15 mg, 0.24 mmol) in small portions. The mixture
was stirred at room temperature for 0.5 h, treated with aqueous 1 N potassium
hydroxide (3 mL), and extracted with ether (4 x 5 mL). The combined organic
layers were washed with brine, dried, and concentrated in vacuo. Column
chromatography of the residue (hexane-ethyl acetate, 1:1) afforded 9 mg
(93%) of 134: IR (neat) 2957, 1735, 1706, 1702, 1452, 1259, 1155, 733 cm-1;
1H NMR (300 MHz, CDCI3) 6 1.44 (9H, s), 2.11
s), 3.35 (1H, m), 3.71 (3H, s), 3.72 (3H, s), 4.31
(1H, m), 2.30
(1H, m), 4.40
(1H, m), 2.92
(1H, m), 4.55
(3H,
(1H,
m), 4.75 (1H, m), 5.99 (2H, m); 13C NMR (CDCI3, 75 MHz) 6 28.4, 35.1, 35.1,
52.9, 57.1, 65.3, 71.6, 75.0, 80.6, 125.0, 126.3, 131.5, 133.8, 164.7, 169.5.HO,
HO
/OH
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4-Carbomethoxy-4-hydroxymethy1-3-hydroxy-5-[3-N-tert-
butoxycarbonyl-N-methylamino-4-furanyl]cyclohexan-1-01(135).
To a solution of 118 (90 mg, 0.22 mmol) in tetrahydrofuran (1 mL) was added
1.0 M borane-tetrahydrofuran complex in tetrahydrofuran (0.7 mL).The
mixture was heated at reflux for 0.5 h, cooled to 0°C and aqueous 1M sodium
hydroxide (1 mL) followed by 30% Hydrogen peroxide (0.3 mL) were added.
The resulting mixture was stirred at 0°C for 1.5 h, diluted with water (6 mL) and
extracted into ether and ethyl acetate (5 x 15 mL). The combined organic
layers were washed with brine, dried over sodium sulfate, and concentrated in
vacuo. Column chromatography of the residue (hexane-ethyl acetate, 2:8 to
ethyl acetate-methanol 9:1) afforded 10 mg (11%) of recovered starting
material and 28 mg (33%) of 135: IR (neat) 3330, 2932, 1709, 1660, 1438,
1368, 1343, 1251, 1197, 1156, 1063, 1043, 1010 cm-1; 1H NMR (300 MHz,
CDCI3) 8 1.44 (9H, s), 1.95 (2H, m), 2.20 (2H, m), 3.16 (3H, s), 3.65-3.80 (5H,
m), 3.85 (1H, m), 4.01 (1H, m), 4.22 (1H, m, ), 4.59 (m, 1H), 7.39 (s, 1H),7.41 (s,
1H); 13C NMR (CDCI3, 75 MHz) 6 28.1, 38.9, 39.1, 39.4, 52.0, 54.9, 65.7, 65.8,
97
66.4,81.9,123.0, 130.7,137.3, 137.5, 142.0, 156.4, 173.0; MS (El) m/z 309
(M+),326,300, 299, 268,204, 115; HRMS m/z calcd for C191-129N08 (M +):
399.1893. Found: 399.1892.98
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Acetal 138. To a solution of 135 (18 mg, 0.045 mmol) in methanol (2
mL) was added sodium bicarbonate (10 mg) and N-bromosuccinimide (9 mg,
0.05 mmol). The mixture was stirred at room temperature for 5 min and the
solvent was evaporated. Column chromatography of the residue (hexane-
ethyl acetate, 2:8 to ethyl acetate-methanol 9:1) afforded 16 mg (83%) of 138:
IR (neat) 3379, 2937, 1704, 1661, 1437,
cm-1; 1H NMR (300 MHz, CDCI3) 8 1.48
1369, 1337, 1250,
(9H, s, ), 2.11-2.42
1208, 1157,
(3H, m), 3.05
1043
(3H,
m), 3.45 (5H, m), 3.75 (3H, s), 3.78 (1H, m, ), 4.10 (2H, m), 4.41 (1H, m),5.45
(2H, m), 5.67 (1H, m); 13C NMR (CDCI3, 75 MHz) 8 28.1, 35.9, 39.1, 39.4, 52.0,
138.0, 139.8, 173.5;
268, 238, 220, 176,
53.1, 54.4, 54.5, 54.7,55.0,66.1,66.4, 82.0, 107.1, 125.1,
MS (El) m/z 429 (M+),373,330,329, 312, 300, 298, 270,
154.
Methyl -4-N-Carbobenzyloxyamino-3-furoate(141). To a
solution of 4-carbomethoxy-3-furoic acid42 (2.40 g, 14 mmol) in dry toluene (7
mL) was added oxalyl chloride (1.2 mL, 15 mmol) via syringe. The mixture
was refluxed for 1 h and the toluene was removed in vacuo. The residue was
taken up in ether (40 mL) and cooled to 0°C. A solution of sodium azide (4.0
g, 61 mmol) in water (20 mL) was added and the resulting two phase mixture
was stirred at 0°C for 2 h after which the layers were separated and the
aqueous layer was back extracted with ether (3 x 40 mL). The combined99
organic layers were washed with brine andaqueous sodium bicarbonate,
dried, and concentrated in vacuo. The crude acyl azidewas taken up in
toluene ( 40 mL) and benzyl alcohol (1.6 mL, 16 mmol) and the solutionwas
refluxed for 3 h. Evaporation of the solvent and recrystallisation of theresidue
from hexane afforded 3.91 g (71%) of 141 asa colorless solid; mp 65°C: IR
(KBr) 3390, 2996, 1731, 1717, 1561, 1513, 1263, 1042, 742, 698 cm-1, 1H
NMR (300 MHz, CDCI3) 8 3.84 (3H, s), 5.21 (2H, s), 7.38 (5H, m), 7.84 (1H, s),
7.97 (1H, s), 8.15 (1H, bs); 13C NMR (CDCI3, 75 MHz) 8 51.6, 67.3, 110.0,
124.7, 128.1, 128.3, 128.5, 131.9, 135.8, 146.3, 153.2, 164.2; MS (El) m/z 275
(M+), 231, 136, 92, 91; HRMS m/z calcd for C14H13N05 (M+): 275.0794.
Found: 275.0793. Anal. Calcd for C14H13N05 C; 61.09; H; 4.76; N;5.09.
Found: C; 61.12; H; 4.63; N; 5.17.
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4-N-Carbobenzyloxy-N-methylamino-3-furanmethanol(142).
To a suspension of 60% sodium hydride dispersion (460mg, 12 mmol) in dry
tetrahydrofuran (20 mL) was added a solution of 141 (1.60g, 5.8 mmol) in
tetrahydrofuran (30 mL) via cannula. The mixturewas cooled to 0°C and
iodomethane ( 2 mL, 60 mmol) was added via syringe. The mixturewas
stirred at room temperature for 5 h, after which aqueous 3 N sodium hydroxide
(50 mL) was added and the mixture was stirred for 4 h atroom temperature.
The mixture was diluted with ether and acidified withaqueous 10% sulfuric
acid. The layers were separated and the aqueous layerwas back extracted
with ether (3 x 20 mL). The combined organic layerswere washed with brine,
dried, and concentrated in vacuo. The residual crude acidwas taken up in
tetrahydrofuran (50 mL), cooled to 0°C, and reduced with 1.0 M borane-100
tetrahydrofuran complex in tetrahydrofuran (10 mL). The mixturewas stirred at
room temperature for another 3 h. Aqueous ammonium chloride (30 mL) was
carefully added and the mixture was stirred for 0.5 h, after which itwas
extracted with ether (3 x 50 mL). The separated organic layerswere washed
with brine, dried, and concentrated in vacuo. Column chromatography of the
residue (hexane-ethyl acetate, 1:1) yielded 1.21 g (77%) of 142:IR (neat)
3300, 2988, 1705, 1476, 1163, 1013, 759, 699 cm-1; 1H NMR (300 MHz,
CDCI3) 5 3.26 (s, 3H), 4.35 (d, 2H, J=6Hz), 5.20 (s, 2H),7.37 (m, 7H); 13C NMR
(CDCI3, 75 MHz) S 39.9, 53.9, 62.6, 70.8, 128.1, 128.3, 128.6, 136.0, 137.1,
137.8, 141.0, 156.2; MS (El) m/z 261 (M+), 108, 92, 91, 64; HRMS m/z calcd
forC14F115N04(M+): 261.1001. Found: 261.1001; Anal. calcd for C14H Nn155
C; 64.36; H; 5.79; N; 5.36. Found: C; 64.19; H; 5.64; N; 4.98.
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4-N-Carbobenzyloxy-N-methylamino-3-furaldehyde (143). To
a solution of oxalyl chloride (4.9 mL, 30 mmol) in dry dichloromethane (4 mL)
at -78°C was added a solution of dimethyl sulfoxide (2.8 mL, 69 mmol) in
dichloromethane (5 mL).A solution of 142 (7.50 g, 29 mmol) in
dichloromethane (40 mL) was added dropwise over a period of 0.5 h. The
mixture was stirred at -78°C for an additional 0.5 h, after which triethylamine
(20 mL, 150 mmol) was added and the mixture was allowed towarm to room
temperature. The mixture was diluted with aqueous 10% sulfuric acid (40 mL),
the layers were separated, and the aqueous layer was back extracted with
ether (2 x 30 mL). The combined organic layers were washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 3:1) afforded 0.50g (7%) of recovered 142 and 6.0g101
(87%) of 143:IR (neat) 2951, 1721, 1715, 1705, 1693, 1597, 1545, 1447,
1369, 1216, 1162, 870, 764 cm-1; 1H NMR (300 MHz, CDCI3) 8 3.24 (3H, s),
5.13 (2H, s), 7.30 (6H, m), 7.97 (1H, s), 9.85 (1H, s); 13C NMR (CDCI3,75
MHz) 8 38.3, 67.7, 124.4, 127.8, 128.0, 128.4, 136.1, 139.8, 151.2,155.4,
183.6; MS (El) m/z 259 (M+), 92, 91, 65; Anal. Calcd for C14H13N04 C;64.86;
H; 5.05; N; 5.40. Found: C; 64.81; H; 5.48; N; 5.02.
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Dimethy1-4-N-Carbobenzyloxy-N-methylamino-3-furylidene
malonate (144). To a solution of 143 (478 mg, 1.80 mmol) in toluene (30
mL) was added diethyl malonate (0.30 mL, 3.6 mmol) anda catalytic amount
of piperidine (50 ML). The mixture was heated at reflux for 3 h andthe water
produced during the reaction was removed with a Dean-Stark trap.The
mixture was cooled to 0°C and diluted with aqueous cold 2N sulfuric acid (30
mL). The layers were separated and theaqueous layer was back extracted
with ether (3 x 20 mL). The combined organic layerswere washed with brine,
dried, and concentrated in vacuo. Column chromatography of the residue
(hexane-ethyl acetate, 3:1) afforded 545 mg (80%) of 144: IR (neat) 2964,
1719, 1604, 1438, 1363, 1270 cm-1; 1H NMR (300 MHz, CDCI3) 8 3.23 (s, 3H),
3.74 (3H, s), 3.79 (3H, s), 5.12 (2H, s), 7.28 (1H, s), 7.43 (1H, s), 7.74 (1H, s);
13C NMR (CDCI3, 75 MHz) 8 38.8, 52.5, 52.7, 67.8, 125.1, 127.9,128.4, 131.2,
142.0, 143.9, 155.4, 164.2; MS (El) m/z 373 (M+), 180, 120, 92, 91, 66,65;
HRMS m/z calcd for C19H19N07 (M+): 373.1161. Found: 373.1161.Anal.
calcd for C19l--119N07 C; 61.12; H; 5.13; N; 3.75. Found: C; 61.46; H; 5.11; N;
3.84.Me02C
N.
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4,4-Dicarbomethoxy-5-[3-N-carbobenzyloxy-N-methylamino-
4-furanyl]cyclohex-2-en-1-one (145).To a solution of 144 (463 mg,
1.24 mmol) in toluene (4 mL) was added 1-methoxy-3-(trimethylsilyloxyl)-1,3-
butadiene (0.60 mL, 2.8 mmol) and the mixture was heated in a sealed tube at
140°C for 18 h. After evaporation of the toluene the residuewas taken up with
a 1:1 mixture of tetrahydrofuran and 0.1 M hydrochloric acid (50 mL) and was
stirred at room temperature for 0.5 h. Saturatedaqueous bicarbonate (30 mL)
was added and the mixture was extracted with ether (3 x 30 mL).The
combined organic layers were washed with brine, dried, and concentrated in
vacuo. Column chromatography of the residue (hexane-ethyl acetate, 3:1)
afforded 423 mg (83%) of 145: IR (neat) 2954, 1749, 1737, 1705, 1694, 1643,
1436, 1351, 1271, 1257, 1217, 1154, 1094, 1054, 915, 817, 762 cm-1; 1H
NMR (300 MHz, CDCI3) 5 2.43 (m, 1H), 2.96 (m, 1H), 3.20 (s, 3H), 3.52 (s, 3H),
3.77 (s, 3H), 4.02 (m, 1H), 5.19 (m, 2H), 6.19 (d, J=10Hz, 1H), 7.10 (s, 1H),
7.11 (s, 1H), 7.30 (m, 6H); 13C NMR (CDCI3, 75 MHz) 8 34.2, 39.2, 40.8, 53.1,
53.5, 53.6, 58.3, 67.7, 121.8, 127.0, 128.1, 128.5, 130.7, 136.2, 137.9, 139.8,
143.0, 155.8, 167.4, 168.1, 196.0; MS (El) m/z 441 (M+), 382, 338, 306, 94, 91;
HRMS m/z calcd for C23H23N08 (M+): 441.1424. Found: 441.1423.
102Me02C, c
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4,4-Dicarbomethoxy-513-N-carbobenzyloxy-N-methylamino-
4-furanyl]cyclohex-2-en-1-ol(146).To a cold (-78°C) solution of 145
(740 mg, 1.63 mmol) in tetrahydrofuran (18 mL)was added a 1.0 M solution of
L-selectride in tetrahydrofuran (2 mL). The mixturewas stirred at -78°C for 30
min, after which it was allowed to warm to room temperature andsaturated
aqueous ammonium chloride (20 mL) was added. The mixture was then
extracted with ether (3 x 20 mL), and the combined organic layerswere
washed withbrine,dried,and concentratedinvacuo.Column
chromatography of the residue (hexane-ethyl acetate, 2:8) afforded 720mg
(96%) of 146:IR (neat) 2953, 1733, 1706, 1452, 1336, 1391, 1354, 1326,
1208, 1106, 1091, 1106, 1060 cm-1; 1H NMR (300 MHz, CDCI3) 8 2.01 (2H,
m), 3.22 (3H, s), 3.52 (3H, s), 3.67 (3H, s), 3.87 (1H, m), 4.30 (1H, m), 5.10 (2H,
m), 6.10 (2H, m), 7.30 (7H, m); 13C NMR (CDCI3, 75 MHz) 8 31.0, 34.2,39.0,
52.5, 52.9, 58.2, 64.3, 67.5, 123.8, 125.4, 128.1, 128.4, 137.6, 140.4, 155.8,
196.5; MS (El) m/z 443 (M+), 340, 308, 306, 92, 91; HRMS m/z calcd for
C23H25N08 (M+): 443.1580. Found: 443.1580. Anal. calcd for C23H25N08 C;
62.30; H; 5.68; N; 3.16. Found: C; 62.15; H; 5.44; N; 2.97.
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9,9-Dicarbomethoxy-6-N-carbobenzyloxy-N-methylamino-5-
methoxytricyclo-2,4-dioxa[6.3.1.03,7]dodeca-6,10-diene (147).To
a solution of 146 (108 mg, 0.24 mmol) in methanol (3 mL)was added sodium
bicarbonate (20 mg) and N-bromosuccinimide (45mg, 0.25 mmol). The
mixture was stirred at room temperature for 5 minand the solvent was
evaporated. The residue was taken up withaqueous sodium thiosulfate (10
mL) and the mixture was extracted with ether (3x 20 mL). The combined
organic layers were washed with brine, dried, andconcentrated in vacuo.
Column chromatography of the residue (hexane-ethylacetate, 1:1) afforded
90 mg (75%) of 147:IR (neat) 2955, 1720, 1437, 1394, 1331, 1267,1165,
968, 736 cm-1; 1H NMR (300 MHz, CDCI3) S 1.88 (1H, m),2.01 (1H, m), 3.03
and 3.13 (3H, 2s), 3.30 and 3.48 (3H, 2s, ), 3.72 (6H, m), 3.85 (1H, m), 4.35
(1H, m), 5.18 (2H, m), 5.74 (1H, m), 5.94 (1H, m),6.20 (2H, m), 7.35 (5H, m);
13C NMR (CDCI3, 75 MHz) 5 53.1, 54.4,54.6, 57.6, 57.8, 64.9, 65.4, 67.7,
99.6, 100.4, 105.8, 107.1, 127.9, 128.0, 128.1, 128.3,128.5, 128.7, 129.0,
132.3,134.1, 135.9, 154.5, 167.0, 168.1, 196.0, 196.6; MS (El) m/z473 (M+),
382, 383, 214, 169, 91, 91, 84; HRMS m/z calcd for C24H27N09(M+):
473.1686. Found: 473.1685.105
OH
9,9-Dicarbomethoxy-6-N-carbobenzyloxy-N-methylamino-5-
hydroxytricyclo-2,4-dioxa[6.3.1.03,71dodeca-6,10-diene(148). To
a solution of 146 (184 mg, 0.41 mmol) in n wet" dichloromethane (6 mL)was
added sodium bicarbonate (10 mg) and N-bromosuccinimide (75mg, 0.42
mmol). The mixture was stirred at room temperature for 5 min, after which
aqueous sodium thiosulfate (5 mL) was added. The mixture was extracted
with ether (4 x 20 mL) and the combined organic layerswere washed with
brine, dried, and concentrated in vacuo.Column chromatography of the
residue (hexane-ethyl acetate, 1:1) afforded 130mg (68%) of 148: IR (neat)
3404, 2955, 1733, 1437, 1393, 1332; 1266, 1231, 1210, 1074, 1007, 873,
763, 733, 700 cm-1; 1H NMR (300 MHz, CDCI3) 8 1.91 (m, 2H), 3.11 (3H, s),
3.54 (3H, s), 3.80 (1H, s), 4.32 (1H, m), 4.75 (3H, s), 5.15 (2H, m), 6.01 (4H, m),
7.35 (5H, m); 13C NMR (CDCI3, 75 MHz) 8 34.0, 36.4, 36.6, 52.9, 53.2, 57.7,
60.4, 65.0, 65.5, 67.9, 68.1, 99.7, 100.1, 101.2, 127.9, 128.1, 128.4, 128.6,
128.9, 129.1, 134.9, 135.7, 155.1, 168.0, 169.2; MS (El) rniz 459 (M+), 306,
274, 216, 186, 105, 91, 77; HRMS m/z calcd for C23H25N09 (M÷): 459.1529.
Found: 459.1528.106
9,9 -Di carbomethoxy-6-N- carbobenzyloxy -N- methylamino -5-
oxo-tricyclo-2,4-dioxa[6.3.1.03,7]dodeca-6,10-diene(149). To a
cold (0°C) suspension of pyridinium dichromate (80 mg, 0.18 mmol) and
crushed 4 A molecular sieves (50 mg) in dichloromethane (1.5 mL)was added
a solution of hemiacetal 148 (28 mg, 0.06 mmol) in dichloromethane (3 mL).
The mixture was stirred at room temperature for 3 h, after which itwas diluted
with ether (5 mL) and filtered over Celite. The filtercakewas washed with
ether and the filtrate was washed with brine, dried, and concentrated invacuo.
Column chromatography of the residue (hexane-ethyl acetate, 1:1) afforded
26 mg (92%) of 149:IR (neat) 2972, 1786, 1732, 1326, 1267, 1230, 1150,
1042cm-1, 1H NMR (300 MHz, CDCI3) 8 2.01 (2H, m), 3.14 (3H, s), 3.62 (3H,
s), 3.77 (3H, s), 4.01 (1H, s), 4.40 (1H, s), 5.15 (2H, m), 5.89 (1H, s), 6.25 (2H,
m), 7.34 (5H, m); 13C NMR (CDCI3, 75 MHz) 8 30.4, 34.8, 35.4, 53.3, 53.4,
57.5,65.4, 68.4, 94.6, 127.3, 127.8, 128.4, 128.6,129.4, 135.5, 154.1, 154.3,
166.8, 167.4, 168.8; MS (El) m/z 457 (M+), 366, 322, 278, 158, 91, 65; HRMS
m/z calcd for C23H23N09 (M +): 457.1373. Found: 457.1372.107
9,9-Dicarbomethoxy-6-N-carbobenzyloxy-N-methylamino-5-
bromobenzyloxy-2,4-dioxa[6.3.1.03,7]dodeca-6,10-diene (150). To
a solution of 148 (5 mg, 0.01 mmol) in dichloromethane (5 mL) was added p-
bromobenzoyl chloride (10 mg, 0.045 mmol), triethylamine (10 4L, 0.1 mmol)
and a catalytic amount of 4-(dimethylamino)pyridine. The mixturewas stirred
at room temperature for 15 h, after which aqueous 0.1 N hydrochloric acid (10
mL) was added and the mixture was extracted with ether (3x 5 mL). The
combined organic layers were washed with brine, dried, and concentrated in
vacuo. Column chromatography of the residue (hexane-ethyl acetate, 3:1)
afforded 3 mg (46%) of 150 as a yellow solid: IR (KBr) 2920, 1733, 1269, 718
cm-1; 1H NMR (300 MHz, CDCI3) 8 2.04 (2H, m), 3.16 (3H, s),3.50 (3H, s),
3.75 (3H, s), 3.92 (1H, m), 4.40 (1H, m), 5.15 (2H, m), 5.91-6.40 (4H, m), 7.06
(1H, s), 7.34 (5H, m), 7.55 (2H, d, J=8Hz), 7.84 (2H, d, J=8Hz); 13C NMR
(CDCI3, 100 MHz) 6 34.0, 36.4, 36.6, 52.9, 53.2, 57.7, 60.4, 65.0, 65.5, 67.9,
68.1, 99.7, 100.1, 101.2, 127.9, 128.1, 128.4, 128.6, 128.9, 129.1, 134.9,
135.7, 155.1, 168.0, 169.2, 172.9.
Compound 150 crystallized in the monoclinic spacegroup C2/C with
a=26.140 (5) A, b=10.389 (2) A, c=24.814 (5) A, p=117.94° (3), V=5953.23 A3,
Z=8, Dcalc=1.434 g/cm3.All 4454 non equivalent reflections in therange of
3.5° < 20 < 95° were measured on a Siemens P4 diffractometer with graphite
monochromated Cu Ka radiation (X=1.54178 A). The structurewas solved by108
direct methods (SHELXTL) using 3411 unique reflections of which2253 were
considered observed with F > 4 a(F). Full matrix leastsquares refinement with
anisotropic temperature factors for all non-hydrogenatoms and calculated
hydrogen atom positions led to the final discrepancy indices ofR=0.054 and
wR =0.051.
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1-Hydroxymethy1-2-oxo-3-oxa-6-hydroxy-7-[3-N-
carbobenzyloxy-N-methylamino-4-furanyl]bicyclo[2.2.2]octane
(146)and4-Carbomethoxy-4-hydroxymethy1-3-hydroxy-543-N-
carbobenzyloxy-N-methylamino-4-furanyl]cyclohexan-1-01(154).
To a cold (-78°C) solution of 146 (601mg, 1.36 mmol) in tetrahydrofuran (60
mL) was slowly added 1.0 M borane-tetrahydrofurancomplexin
tetrahydrofuran (10 mL).The mixture was allowed to warm toroom
temperature and was stirred for 12 h.The mixture was cooled to 0°C and
aqueous 3M sodium hydroxide (3 mL), followed by 30% hydrogen peroxide
(0.5 mL) were added. The resulting mixturewas stirred at 0°C for 3 h and
poured into aqueous ammonium chloride (60 mL). The mixturewas extracted
with ether (4 x 15 mL) and ethyl acetate (6x 15 mL)and the combined organic
layers were washed with brine, dried over sodium sulfate, andconcentrated in
vacuo. Column chromatography of the residue (hexane-ethyl acetate, 2:8to
ethyl acetate-methanol 9:1) afforded 123 mg (23%) of 154and 251 mg (43%)
of 151.
154: IR (neat) 3448, 3434, 2945, 1727, 1709, 1686,1471, 1455, 1436,
1394, 1354, 1322, 1212, 1153, 1082, 1022, 914, 754, 699,615, 604 cm-1; 1H109
NMR (300 MHz, CDCI3) 8 1.59 (1H, m), 1.85 (1H, m), 2.38 (1H, m), 2.42 (1H,
m), 3.19 (3H, s), 3.60 (2H, m), 3.85 (1H, m), 4.39 (1H, m), 4.67 (1H, m), 5.19
(2H, m), 7.35 (7H, m); 13C NMR (CDCI3, 75 MHz) S 33.7, 36.1, 39.3, 49.6, 57.9,
60.4, 65.3, 67.6, 73.3, 123.8, 128.3, 128.5, 136.3, 137.5, 139.9, 155.6, 171.2;
MS (El) m/z 401 (M+), 342, 134, 91; HRMS m/z calcd for C21 H23N07(W):
401.1474. Found: 401.1474.
151: IR (neat) 3402, 3395, 3391, 3368, 2945, 1694, 1444, 1438, 1394,
1352, 1211, 1160, 1088, 1048,764, 735, 699, 612 cm-1; 1H NMR (300 MHz,
CDCI3) 8 1.70 (2H, m), 2.01 (2H, m), 3.19 (3H, s), 3.65 (5H, m),3.85 (1H, m),
4.45 (1H, m), 4.91 (1H, m), 5.20 (2H, m), 7.31 (7H, m); 13C NMR (CDCI3, 75
MHz) 8 14.1, 18.8, 20.9, 29.6, 38.6, 50.3, 60.3, 62.4, 67.8, 69.5, 123.1, 128.01,
128.1, 128.5, 130.0, 135.9, 137.0, 139.8, 141.8, 155.7, 171.1; MS (El) m/z 433
(M+), 404, 342, 91; HRMS m/z calcd for C22H27N08 (M+): 433.1737 Found:
433. 1736.
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4-Carbomethoxy-4-hydroxymethy1-3-hydroxy-513-N-
carbobenzyloxy-N-methylamino-4-furanyl]cyclohexane-1-01(153).
To a solution of triol 151 (3 mg, 0.006 mmol) in tetrahydrofuran (1 mL)was
added triethylamine (3 p.L, 0.03 mmol) and triphosgene (3 mg, 0.011 mmol).
The mixture was heated to reflux for 20 min after which the mixturewas
allowed to cool to room temperature and water (3 mL) was added and the
mixture extracted with ether (3 x 3 mL). The combined organic layerswere
washed withbrine,dried,and concentratedinvacuo.Column110
chromatography of the residue (hexane-ethyl acetate, 3:1) afforded 1.6mg
(56%) of 153:IR (neat) 3396, 2945, 1772, 1731, 1707, 1450, 1157 cm-1; 1H
NMR (300 MHz, CDCI3) 8 1.90-2.61 (5H, m), 3.21 (3H, s), 3.70 (3H, s),4.12
(1H, m), 4.42 (2H, m), 4.80-5.25 (3H, m), 7.33 (1H, s), 7.34 (7H, m),7.44 (1H,
s).
6-Acetoxy-1-acetoxymethy1-2-oxo-3-oxa-7-[3-N-
carbobenzyloxy-N-methylamino-4-furany1]-bicyclo[2.2.2]octane
(155). To a solution of 154 (20 mg, 0.05 mmol) in dichloromethane (2 mL)
was added acetic anhydride (10 mg, 0.10 mmol), triethylamine (20 0.2
mmol) and a catalytic amount of 4-(dimethylamino)pyridine. The mixturewas
stirred at room temperature for 5 h, after whichaqueous 0.1 N hydrochloric
acid (10 mL) was added and the mixture was extracted with ether (3x 5 mL).
The combined organic layers were washed withbrine,dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 3:1) afforded 16 mg (66%) of 155: IR (neat) 2945, 1751, 1708, 1450,
1432, 1364, 1319, 1239, 1151,1125, 1083, 1046, 599 cm-1; H NMR (300
MHz, CDCI3) 15 1.50 (1H, m), 1.69 (1H, m), 1.81 (1H, m), 2.03 (3H, s), 2.07 (3H,
s), 2.65 (1H, m), 3.28 (3H, s), 3.95 (1H, m), 4.12 (1H, m), 4.65 (1H, m), 4.92
(1H, m), 5.20 (2H, m), 5.26 (2H, m), 7.36 (7H, m); 13C NMR (CDCI3,75 MHz) ö
20.7, 22.0, 33.7, 36.1, 39.3, 49.6, 57.9, 60.4, 65.3, 67.6, 73.3, 123.8, 128.3,
128.5, 136.3, 137.5, 139.9, 155.6, 169.6, 170.5, 171.2; MS (El) m/z 485 (M+),
338, 248, 91; HRMS m/z calcd for C25H27N09 (M+): 485.1686.Found:
485.1685.111
Compound 155 crystallizedin the orthorhombic space group
P2(1)2(1)2(1) with a=15.779 (3) A, b=8.880 (2) A, c=17.227 (3) A, V=2413.80
A3, Z=4, Dcalc=1.434 g/cm3. All 1792non equivalent reflections in the range of
3.5° < 2e < 95° were measured on a Siemens P4 diffractometer with graphite
monochromated Cu Ka radiation (X=1.54178 A). The structure was solved
with direct methods (SHELXTL) using 1482 unique reflections with F> 4a(F).
Full matrix least squares refinement with anisotropic temperature factors for all
non-hydrogen atoms and calculated hydrogen atom positions led to the final
discrepancy indices of R=0.032 and wR =0.030.
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1,2-Bistrimethylsilyloxy1-4,4-dicarbomethoxy-5-[3-N-carbo
benzyloxy-N-methylamino-4-furanyl]cyclohexene(159).To a
solution of 144 (820 mg, 2.20 mmol) in toluene (4 mL) was added 2,3-
bis(trimethylsilyloxy)-1,3-butadiene (1.0 g, 4.94 mmol) and the mixture was
heated in a sealed tube at 240°C for 4d. After evaporation of the toluene the
residue was chromatographed (hexane-ethyl acetate, 3:1) to afforded 264 mg
(32%) of recovered 144 and 643 mg (48%) of 159:IR (neat) 2958, 1735,
1711, 1436, 1390, 1350, 1307, 1255, 1220, 1154, 1054, 912, 887, 843, 697
cm-1; 1H NMR (300 MHz, CDCI3) 5 0.15 (m, 18H), 2.04 (1H, m), 2.50 (1H, m),
2.80 (2H, m), 3.20 (3H, s), 3.46 (1H, s), 3.61 (3H, s), 3.64 (3H, s), 5.15 (2H, m),
7.34 (7H, m); 13C NMR (CDCI3, 75 MHz) 5 0.71, 1.3, 15.2, 32.9, 33.4, 34.2,
39.1, 52.6, 52.7, 57.2, 60.3, 65.8, 67.5, 122.8, 127.8, 128.0, 128.4, 129.0,
130.4, 136.3, 136.8, 140.9, 155.8, 169.6, 170.4; MS (El) m/z 603 (M+), 404,112
378, 304, 149, 94, 91; HRMS m/z calcd for C29H41NO9Si2 (M+): 603.2320.
Found: 603.2319.
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1-Carbomethoxy-243-N-carbobenzyloxy-N-methylamino-4-
furany11-4-hydroxy-6-oxa-7-oxo-bicyclo[3.2.1]octane(162). To a
solution of 159 (30 mg, 0.05 mmol) in methanol (2 mL)was added sodium
fluoride (15 mg, 0.35 mmol) and sodium borohydride (5mg, 0.13 mmol). The
mixture was stirred for 1h at room temperature and themethanol was
evaporated. The residue was taken up with water (5 mL) and the solutionwas
extracted with ether (3 x 5 mL). The combined organic layerswere washed
with brine, dried, and concentrated invacuo. Column chromatography of the
residue (hexane-ethyl acetate, 3:1) afforded 12mg (56%) of 162: IR (neat)
3520, 3477, 2958, 1785, 1732, 1704, 1436, 1393, 1354, 1331,1299, 1256,
1154 cm-1; 1H NMR (300 MHz, CDCI3) 8 2.51-2.90 (5H, m),3.19 (3H, s), 3.31
(3H, s), 3.40 (1H, m), 3.51 (3H, s), 3.61 (3H, s), 3.75 (3H,s), 4.65 (1H, m), 5.15
(2H, m), 7.33 (1H, s), 7.34 (7H, m), 7.44 (1H, s); 13C NMR(CDCI3, 75 MHz) 8
33.9, 36.2, 37.6, 39.0,39.2,40.7, 52.3, 52.6, 54.5,58.6,67.5, 69.0, 79.2, 122.8,
128.3, 128.6, 136.5,136.9,139.6, 142.7, 155.9,168.6,170.2, 172.3; MS (El)
m/z 429 (M+), 91; HRMS m/z calcd for C22H23N08 (M +):429.1424. Found:
429.1423.Me0
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Epoxide163. To a solution of 159 (10 mg, 0.016 mmol) in
dichloromethane (1 mL) was added m-chloroperbenzoic acid (4mg, 0.017
mmol) and the mixture was stirred at 0°C for 4h. The mixturewas diluted with
water (3 mL) and extracted with ether (3 x 2 mL). The combined organic
layers were washed with brine, dried, and concentrated invacuo. Column
chromatography of the residue (hexane-ethyl acetate, 3:1) afforded 7mg
(71%) of unstable 163: IR (neat) 2958, 1731, 1711, 1436, 1391,1352, 1289,
1253, 1204, 1121, 1042, 993, 845, 740, 696 cm-1; 1H NMR (300 MHz, CDCI3)
6 0.15 (m, 18H), 2.60 (2H, m), 2.90 (1H, m), 3.50 (1H, m), 3.61 (3H, s),5.15
(2H, m), 7.34 (7H, m), 7.51 (1H, s); 13C NMR (CDCI3, 75 MHz) 81.5, 1.8, 2.2,
2.3, 39.1, 39.9, 52.0, 52.5, 57.5, 67.3, 96.7, 97.5, 120.9, 127.7, 128.3, 129.6,
129.8, 132.6, 133.3, 136.5, 143.7, 155.9, 170.1, 171.0; MS (El) m/z 619 (M+),
593, 529, 438, 394, 366, 330, 213, 91.
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PART II: AN APPROACH TOWARD THE SYNTHESIS OF (±)-MORPHINE
Chapter III. An Approach toward the Synthesis of (±)-Morphine
Background and History
The opium poppy(Papaver somniferum)has been known since prehistoric
times as the source of opium, an air dried milky exudate from the incised unripe
capsules of the plant. Due to its sedative and euphoriant properties opium has
had a prominent position as a therapeutic and recreational drug since antiquity.
Opium contains more than twenty alkaloids, of which (-)-morphine (1), (-)-codeine
(2) and (-)-thebaine (3) are the most important.
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After morphine was isolated as a pure substance by Serturmer in 1806 the
use of the pure alkaloid rather than crude opium preparations began to spread
throughout the medical world. With the invention of the hypodermic syringe in
the eighteenth century, morphine could be administered by a route that allowed a
far better expression of its potent analgetic and euphoriant activity. This also led
to very severe compulsive drug abuse, and the drug's propensity to cause
profound physical dependence became widely recognized.The abuse of
morphine-based narcotics, especially heroin, is still a serious problem today.118
The now accepted structure of morphine was first proposed by Robinson1
in 1925, and it was confirmed by a total synthesis of (±)-morphine reportedby
Gates in 1952.2The absolute configuration of natural (-)-morphinewas
established in 1968 by X-ray crystallographic analysis.3
The search for analgetic drugs and their synthetic preparation has long
represented an important area of research within the pharmacological sciences.
In this context, the total synthesis of morphine has beenan alluring goal since the
days of Liebig.In 1870 the Prussian Academy of Science in Berlin held outa
prize of 100 ducats for a solution to this problem, and in 1925a rich manufacturer
in New York offered $ 100,000 for the same purpose.4 Today, after decades of
research, a practical route to synthetic morphine has yet to be discovered.
The structural complexity of morphine, particularly thepresence of the
nitrogen-containing ring which bridges the phenanthrene nucleus, has frustrated
many attempts at the total synthesis of this molecule and its close relatives. For
this reason the search for clinically useful analgesics has focused mainlyon the
derivatization of morphine alkaloids obtained from plant sources. Thebaine is still
the most important starting material in the synthesis of more recent analgetic
drugs based on the full morphine nucleus. Oxymorphone (4 ), for example, has
between six and eight times the activity of morphine in man.5 Etorphine (5), also
obtained from thebaine, is among the most potent opiates. Owing to its high
potency it is used primarily for the immobilization of large zoo animals, suchas
elephants.
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In the absence of a practical total synthesis, medicinal chemists have
developed a long-standing interest in "simplifying" the morphinestructure to
identify the minimum pharmacophore necessary for analgetic activity.Research
towards this end was started in the 1880's following the observation thatthe
reduction of morphine (1) with zinc dust yielded phenanthrene (6) (scheme 1).6
6
Phenanthrene was unsuccessfully used as a starting material in this
endeavor.It was discovered serendipitously in the 1940's that meperidine (7),a
compound originally designed as an antispasmodic agent, showedpotent
analgetic activity. This led the way to the preparation ofnew synthetic analgetic
agents with structural complexity far below that of morphine.5
=
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Acyclic analgesics such as methadone representa further "simplification"
of the morphine structure. Methadone (8) is used today primarilyas a treatment
for heroin addiction.Unlike meperidine, methadone is chiral and has been
resolved. Most, but not all of the analgesic activity of theracemate is associated120
with the S-form.Its enantiomer, R-methadone lacks significantrespiratory-
depressant action and addiction liability.
In 1954 Beckett and Casy7 formulateda set of empirical rules which
attempted to define the structural elements required for analgeticactivity. The
structural requirements were
1. an aromatic ring, preferably axially disposed; if connected toa piperidine
2. ring, a quaternary carbon center connected via the equivalent ofan
3. ethylene chain to a basic amine.
The assumption underlying these rules was that, in order fora drug to be
analgetic, it must bind to a specific receptor located in thecentral nervous
system. More recently, binding studies with radiolabelled opioid drugs inbrain
and other tissue such as mouse vas deferens have suggested theexistence of
distinct populations of receptors that can interact with opioiddrugs or
endogenous opioid peptides.The latter are natural opioid receptor ligands
produced in the body in response to extreme stress and pain.
In the mammalian central nervous system, three major classes ofopioid
receptors can be distinguished based on their pharmacological profile.These
are ji,-K and 6 -types.8 These are proteins of about 60 kDa which belong toa
broader class of receptors that are coupled to G proteins and haveseven
transmembrane segments.About 80% of all known receptors belong to this
family, for which extensive homology in the amino acidsequence has been
reported.9Functional and regulatory homology within this family ofreceptors
seems very likely. For example, all G protein-coupled receptors havea common
mechanism of desensitization that is caused by reversible phosphorylationof the
receptor by regulatory kinases such as protein kinase C. Thedesensitization of
opioid receptors is responsible for the gradual increase in drugconsumption
typically seen with morphine addicts.121
The overall effect of opioid drugs on thenervous system is determined by
which cells express 11,K. or 6 -receptors. The receptor distributionshave been
extensively mapped by autoradiography.1° Since morphine ismainly selective
for p-receptors, the distribution of i_t-receptors largelycorresponds to the
spectrum of its pharmacological action such as analgesia, drowsiness,change of
mood, respiratory depression and decreased gastrointestinalmotility.Since
other sensory modalities, such as touch, are not affected bythe drug, the
mechanism of opiate induced analgesia must involve theselective inhibition of
nociceptive reflexes in the spinal cord and the substantiagelatinosa.At the
cellular level, the potassium and calcium ion channels andthe enzyme adenylyl
cyclase are the immediate targets of opioid action. Adenylylcyclase produces
cyclic AMP (cAMP), a common secondmessenger. Opiates reduce the levels of
cellular cAMP through inhibition of adenyl cyclase.After prolonged opiate
exposure, the cell responds by increasing the production of acetylcholine which
in turn raises the cAMP levels in order to maintain normalcell functions.If the
use of the drug is interrupted, there is a sudden surge in the cellular cAMP-
production which precipitates a multitude of serious withdrawalsymptoms.
Although the mechanism of opiate induced analgesia isnot completely
understood, changes in the ion channel conductivity of the affectednerve tissue,
and the reduction of neurotransmitter release from thosenerve cells appear to be
the main functional consequences of morphine administration.For pain therapy
it is therefore important to distinguish between pain that iscaused by stimulation
of nociceptive nerve cells which is transmittedover intact neural pathways and
pain that is caused by damage to neural structures.Morphine is reportedly
ineffective for treatment of the latter type of pain.11
In addition to its analgesic properties, morphineacts as a powerful
respiratory depressant even at subtherapeutic doses. Thiseffect is mediated by122
a subpopulation of u-receptors in the medullary areas of the brain stem
responsible for ventilary control.Respiratory depression represents a limitation
to the therapeutic use of opioid analgesics since human fatalities through
morphine poisoning is always a result of respiratory arrest.Other species, for
example dogs, are much less sensitive in this respect.
The neurobiological changes that are produced in the mammalian brain by
morphine addiction are very complex. Drug abuse alters the metabolism of both
opioid receptors and endogenous peptides. This interferes with a variety of other
physiological processes such as mood, learning, thermoregulation, ingestive
behavior, motor activity and the perception of reward. There is evidence that the
mesolimbic dopamine pathway and various y-aminobutyric acid (GABA)
interneurons are affected by morphine abuse.12
The genetic cloning and overexpression of opioid receptors is currentlyan
active area of investigation. Isolation and sequencing of all three receptor types
has now been accomplished.8 The technique makes macroscopic quantities of
the receptors available-for example NG108-15 cells expressca 300,000 S
receptors per cell- and this has created new opportunities in biological research,
particularly that involving endogenous peptide ligands.Biochemical and
molecular genetic studies are currently being conducted to assign structural
domains in these receptors to specific functions such as agonist and antagonist
binding, coupling to the G-proteins, and phosphorylation by kinases. With further
examination of these receptors more detailed structural information should
become obtainable which could eventually influence the design of analgesic
drugs.123
The numerous approaches that have been directed toward synthesis of
the molecular skeleton of morphine represent a vast area of synthetic chemistry
that cannot be covered here in any detail. A diverse array of synthetic concepts
and methods have been used to construct the carbocyclic and heterocyclic rings
of the molecule. Some of the more innovative approaches will be described
below.Most of them are racemic and, in fact, there have been very few
attempts to design chiral syntheses in this area.13 Only very recently has the first
asymmetric total synthesis of morphine been completed which did not involve
resolution.14
Early routes to morphine were often influenced by degradative studies
which all yielded phenanthrene derivatives (scheme 2). Before the structure of
morphine was fully elucidated, it was assumed that this hydrocarbon represented
the "primeval form" of morphine and was thus regarded as the appropriate
starting material for synthetic studies.In spite of extensive efforts along this line
very few examples can be found in the literature of successful morphine
syntheses in which carbon-carbon bond formation between carbon 13 and 15 is
used to construct the morphine ring system.15
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Several of the intermediates that were prepared following the
"phenanthrene approach" were useful in the identification of degradation
products obtained from morphine alkaloids.For example, in 1896 Pschorr124
developed a general method for the synthesis of phenanthrene derivatives that
was applied to a proof of the structure of morphenol (9) (scheme 3). 16
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The Pschorr synthesis of 14 was also used to determine the structure of
apomorphine (15), which can be obtained from morphine throughan acid
catalyzed rearrangement (scheme 4).It was believed by Pschorr that knowledge
of the structure of apomorphine would clarify the structure of morphine since it
was not recognized at the time that a rearrangement takes place in the
conversion of morphine (1) to apomorphine (15).
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Robinson who was first to propose the correct structure of morphine
reported the synthesis of an intermediate 17 which shares with morphinethe
phenanthrene skeleton and the quaternary carbon center (scheme 5).17
Although no further synthetic progress could be achieved with 17, itclosely
resembles certain degradation products of morphine.
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The elucidation of the detailed biosynthesis of morphine18 has prompted
many attempts to simulate the key biosynthetic transformation which converts
reticuline (18) to salutaridine (19) in the poppy plant (scheme 6).
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Salutaridine, the immediate precursor to the morphine alkaloids,is
produced inPapaver Somniferumby an intramolecular oxidative coupling that126
establishes the tetracyclic framework with great efficiency.By contrast, this
process when carried out under non enzymatic conditions in the laboratory has
proved to be an exceedingly difficult reaction. Chemical yields are often low and
the coupling frequently gives mixtures of all possible coupling products:
isosalutaridine (20), isoboldine (21), corytuberine (22) and only a minor quantity
of the desired salutaridine (19).Efforts to find efficient oxidative phenolic
coupling procedures have been a challenging problem for chemical synthesis,
although considerable progress has been made in the development of coupling
reagents19 as well as in the regio- and stereochemical control of the reaction.20
A total synthesis of (±)-codeine has been completed following this biomimetic
approach.21
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In spite of their diverse nature, almost all other successful synthetic
approaches toward the morphine nucleus have in common with the biosynthesis
the fact that the creation of a bond between carbons 12 and 13 is the crucialstep
which establishes the morphine ring system.127
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In formal analogy to the biosynthesis (although through avery different
mechanism), a variety of 1-benzylhydroisoquinoline derivatives suchas 23 have
been cyclized under acidic conditions to the morphinan nucleus (scheme 7).
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This approach is known as the Grewe cyclization22 and has proven to bea quite
flexible process and has provided access to some commercially important
morphinan derivatives.It has also permitted a formal total syntheses of (±)-
morphine.23 The hydroisoquinoline precursor can be resolvedon an industrial
scale to afford, after Grewe cyclization, levorphanol (24), an orally active
analgesic, and its enantiomer dextrorphan, a useful antitussive agent.
Using a quite different concept, Fuchs24 has reported a total synthesis of
(±)-morphine based on vinyl sulfone chemistry which connects the carbocyclic
framework as shown in scheme 8.The ether linkage of 25 becomes the
prospective hydrofuran oxygen of the morphine structure in this plan. The key
step here is an intramolecular conjugate addition of an aryloxy anion derived from128
25 to the vinyl sulfone, thereby providing an incipient a-sulfonyl anion which
undergoes intramolecular alkylation. The tetracyclic sulfone 26 is obtained in a
single operation as a beautifully crystalline material.
25
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Quite recently, studies by Parker have culminated in a formal total
synthesis of (±)-morphine which features a very elegant tandem radical
cyclization strategy (scheme 9).25
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As in the Fuchs strategy, the ether linkage in 27 serves as a tether to hold
the coupling partners in close proximity.In the second step, a reductive
detosylation effects concomitant formation of a carbon-nitrogen bond across the
styrene moiety of 28. This unprecedented cyclization is probably facilitated by129
the close proximity of the reactive nitrogenspecies (radical or anion) with the
styrene double bond.
Recent work by Tius has demonstrated thepracticality of a Diels -Alder
reaction between 30 and 31in an unconventional formal synthesis of (±)-
morphine (scheme 10).26
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The Diels -Alder adduct 32 was transformedin a number of steps that
involved hydroxylation and aromatization of the Aring and reduction of the C ring
to the intermediate 33 which condensed to the morphinenucleus through an
intramolecular Michael addition (scheme 11).
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In 1993 Overman reported the firstasymmetric total synthesis of( -)-
morphine by applying an intramolecular Heckarylation reaction to the130
enantiomerically pure octahydroisoquinoline34.13In terms of bond connection,
this approach is very similar to the traditional Grewe cyclization (scheme 7).
The Heck arylation has broad scope and tolerates a variety of functional
groups, so that potentially a wide range of previously unavailable morphinans
could be assembled by this route.
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A conceptuallydifferentapproachcentersontheuseof
aryldecahydroisoquinoline derivatives that have become available following the
methodological studies ofRapoport27andEvans.28Here, the crucial bond
connection is made between carbon 10 and 11 (scheme 13).An inherent
advantage of this strategy is the improved control over the regiochemical
outcome of the coupling step.
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Thus, Evans29 has reported the cyclization of the aryl substituted amino
aldehyde 37 to morphinan 38 which has been taken on to (±)-morphine (scheme
14).
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As can be seen from the examples shown above, morphine and its
derivatives continue to hold the fascination of chemists and neuroscientists alike.
Although many creative approaches have been reported, nature's ability to
synthesize this small but intrinsically complex molecule is still unsurpassed.
Apart from the academic challenge, any total synthesis of morphine provides a
source of interesting material for biological testing and pharmacological research.
As more information about the opioid receptors is gathered, synthesis of
biological probe molecules related to morphine (for example, for affinity labeling)
may become a useful tool in the study of these receptors.132
Results and Discussion
As outlined in the previous chapter, the successful synthetic routes to
morphine alkaloids most often involved bond formation between carbon atoms 12
and 13 (biomimetic, Grewe and Overman approaches) or between carbon atoms
10 and 11 (Evans and Rapoport approaches). By contrast, strategies which
envision bonding between carbon atoms 13 and 15 (the phenanthrene approach)
have so far not usually proven useful in spite of a long history of attempts along
this line (scheme 15).15
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Perhaps the most compelling reason for this failure is the high degree of
steric hindrance around carbon 13 in the "bay region" of the phenanthrene
skeleton which makes the formation of a carbon-carbon bond at this position a
difficult process. Aside from this fundamental problem, however, there are a
number of inherent advantages to this strategy. These include the fact that the
nitrogen can be introduced late in the synthesis and that a variety of potentially
useful phenanthrene templates can be constructed with relative ease.
It can be inferred from accounts in the older literature that attempts to
create a bond between the quarternary center at carbon 13 and carbon 15 by
conventional methods, for example using enolate chemistry, would most likely133
fail.Less conventional methods of carbon-carbon bond construction thatwere
developed in the recent past have not been examined in the context of this
particular problem.This led us to propose a "modernized" strategy for the
phenanthrene approach involving an intramolecular process where carbon-
carbon bond formation takes place in a highly reactive organic intermediate such
as a carbenoid species or a free radica1.30
Examination of a molecular model of morphine (1)conveys the fact that
the nitrogen-containing ring which bridges the phenanthrene nucleusrepresents
the most flexible part of an otherwise rigid framework.It was concluded that this
part of the molecule could arise from a more strained precursor suchas ketone
41 via Beckmann rearrangement31 and subsequent reduction of the lactam 40
(scheme 16).32
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Synthesis of ketone 41 was envisioned from a strained cyclopropyl ketone
intermediate 42 that would undergo ring fragmentation with concomitantclosure
of the furan ring of the morphine structure. Cyclopropyl ketonesare frequently
prepared by the decomposition of diazoketones. Cyclopropane ring formation
has been postulated to occur via the reaction between the intermediate
carbenoid species and the n-electrons of a carbon-carbon double bond (scheme
17).33H
MeO OR
41 42
scheme 17
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The diazoketone 43 could be obtained fromthe phenanthrenone-
carboxylic acid 44 which in turn arises from thetetralone 45 through a Robinson
annulation. The tetralone 45 can be prepared, in principle,from isovanillin (46)
and dialkyl succinate 47 (scheme 18) viaa Stobbe condensation, followed by
reduction of the resulting cinnamate anda Friedel-Crafts cyclization.
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While the steps leading to the phenanthrenonecarboxylicacid 44 can be
considered relatively straightforward, the intramolecularcyclopropanation of 43
has no direct precedent.It was surmised that diazoketone 43 couldbe induced135
to undergo a rhodium diacetate-catalyzed carbenoid addition to the olefinic bond
to afford the strained cyclopropyl ketone 40. This could subsequently suffer
homoconjugate addition of the free phenol (scheme 19).
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Many examples in the literature confirm that the addition of ketocarbenoid
species to n-bonds is a very general and direct entry to highly functionalized
cyclopropane-containing structures.For intramolecular cyclopropanation,
reactions which generate the [3.1.0] and the [4.1.0] bicyclic frameworks are the
most common. However, very strained [2.1.0] and [1.1.0] bicyclic systems are
also accessible via this pathway. The reaction appears to be insensitive toward
strain in the resultant ring system and the degree of substitution of the olefin
substrate (scheme 20).34
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The ring system present in the strainedcyclopropyl ketone 40 is not
known.However, Wenkert has reported the synthesisof an analogous
cyclopropanobicyclo[3.2.1]octanone49 from diazoketone 48.35The
cyclopropane of 49 underwent facile reductive ring openingto afford 50. A highly
selective cleavage of the bond most nearly parallelto the neighboring ketone7C-
orbital was observed (scheme 21).
48 49
scheme 21
Li
N H3
go %
50
The inherent strain associated with the cyclopropanering within a bicyclic
system such as 40 can lead to a variety of ring-openingtransformations after the
carbenoid insertion step.Apart from rearrangement,36 fragmentation37and137
reductive ring opening,38 there are a number of examples which demonstrate that
electrophilic cyclopropanes can undergo homoconjugate addition.In these
reactions ring opening occurs in the presence of an external or internal
nucleophile.In particular, doubly activated cyclopropanes, such as those
resulting from the reaction between an olefin and diazomalonate, react with
nitrogen, sulfur and oxygen nucleophiles in a homoconjugate fashion.This
reaction has been reviewed by Danishefsky,39 of which two examples are shown
below for oxygen nucleophiles (scheme 22).
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By contrast, monoactivated systems are much less reactive so that
powerful nucleophiles and electrophilic assistance are often needed to promote
homoconjugate addition.Intramolecular cleavage ofmonoactivated
cyclopropanes are rare, except in cases where a cyclopropyl cation is intercepted
through the involvement of a it- system. The latter is generally an aromatic ring or
a double bond. An example of such a process is found in a "polyene cyclization"
reported by Stork which proceeds in high yield and with good stereoselectivity
(scheme 23).40OMe
benzene
H2O, SnCI4
80%
scheme 23
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The synthetic approach towards morphine presented here is most
straightforward in its racemic form. However, a chiral version may be feasible.
This would involve preparation of the first chiral intermediate of the sequence 52
in enantiomerically pure form either through a resolution or via enantioselective
synthesis.
lsovanillin(46) was treated with diethyl succinate under Stobbe
condensation conditions to afford E-cinnamate half ester 51 a.41Racemic
acid 52 a was readily available through hydrogenation
24).
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lsovanillin (46) has not been previously studied in this context. However
both steps have been carried out in excellent yield with vanillin (3-methoxy-4-
hydroxybenzaldehyde) as a starting material. Protection of the phenolic hydroxy
group is not needed during the Stobbe condensation and the carboxylic acid
isomeric with 52 a can be readily resolved with a chiral amine.42 Thesame
compound is available in enantiomerically pure form through asymmetric139
hydrogenation using a chiral rhodium(I)-catalyst,43 thus suggesting two options
for obtaining 52 in a version suitable for asymmetric synthesis.
Carboxylic acid 52 a was subjected to concentrated sulfuric acid in order
to promote an intramolecular Friedel-Crafts acylation.Not unexpectedly, the
acylation was found to be completely para selective, affording the undesired
tetralone 53 in good yield (scheme 25). For steric and electronicreasons 53 is
strongly favored over the desired ortho coupled product 54.
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The outcome of this reaction necessitated the blockage of the reactive
para -position preferably by a group that could easily be removed at a later stage
in the synthesis. A para selective bromination reaction of N-norreticuline (19)
has been described in the literature where the product 55was taken forward to
morphine (scheme 26).20 The removal of the bromine from the alkaloid nucleus
has been successful under a number of conditions.
MeO
HO
HO
MeO
19
B r2
MeO
HO
HOAc HO
79%
MeO
55
scheme 26
morphine140
Hence, bromination of carboxylic acid 52 a followed by Friedel Crafts
acylation of 56 a yielded the bromo tetralone 57 a with the desired regiochemistry
(scheme 27).
Me0 OH
52 a
Br2
HOAc
81 %
H CO2Et H CO2Et
H2SO4
Me0 OH
56 a
CO2H
scheme 27
80%
Me00H
57 a
The tetralone 57 a was then to be subjected to a Robinson annulation,a
classical ring construction procedure which condensesa ketone with methyl vinyl
ketone to yield cyclohexenone derivatives." Attempts to effect the Robinson
annulation of 57 a directly by treating the compound with methyl vinyl ketone
under either acidic or basic conditions or with 5-diethylamino-2-pentanone failed.
The latter compound forms methyl vinyl ketone under basic conditions ata slow
rate.Presumably, the slow rate of formation of either the enol or the enolate
anion derived from 57 a put these species at a disadvantage in the Michael
addition step which therefore failed to compete effectively with polymerization of
the electrophile.
To circumvent this problem, a-formylation of tetralone 57a was carried out
using ethyl formate and sodium hydride.45 Purification of the resultinga- formyl
tetralone 58 a proved to be difficult due to lability of the compound. However,
the reaction of crude 58 a with methyl vinyl ketone in thepresence of
triethylamine resulted in smooth Michael addition and formation of the alkylated
product 59 a in high yield.Intramolecular aldol condensation, dehydration and
deformylation was achieved in one step by treating 59 a with refluxing sodium141
ethoxide in ethanol. The Robinson adduct 59 a was obtained in modestyield, but
as a single diastereomer (scheme 28).
CO2Et
P
MeO0H
57 a
NaH,
HCO2Et,
toluene
59 a
C 02Et
OH MVK, Et3N
CH2C12
86 %
MeO
NaOEt
0H
58a
EtOH, 47 %
scheme 28
60
59 a
The relative configuration of the latter was confirmed by X-ray diffraction
analysis of its acetate derivative 61. The crystal structure of 61 revealssome
interesting conformational features.For example, the carboethoxygroup is
pseudoaxially oriented, and the carbon-carbon bond of theenone is bent out of
the plane of the aromatic ring by 11.6 °.142
Figure 3.1: TELP Representation from X-ray Structure of 61.
With compounds 60 and 61in hand, an opportunity for examining
reduction of the enone became available.Our hope was that the existing
stereochemistry of 60 would direct reduction of the ketone to give a secondary
alcohol at C-15 corresponding in configuration to that of the morphine structure.
While the free phenol 60 was found to react very sluggishly with sodium
borohydride to give a hydroxy phenol in low yield, its acetate 61 could be reduced
more efficiently under a variety of conditions that included sodium borohydride, L-
selectride, lithium borohydride and lithium aluminum hydride.However, the
stereoselectivity was found to be disappointingly low. Changes in the protecting143
group of the phenol did not appear to have any effect on the selectivity of the
reduction (scheme 29).
H C 02Et H02Et
NaBH4,
EtOH,
70 % MeO OAc
61
scheme 29
Me() OAc
62
OH
The epimeric mixture of alcohols 62 proved to be unstable in the presence
of acid or base. Even after protection of the secondary alcohol in 62 as the tert-
butyldimethylsilyl ether 63 or the methoxyethoxymethyl ether 64, hydrolysis of the
carboethoxy group could not be accomplished without extensive decomposition
of the starting materials (scheme 30).
MeO OAc OR
R=H, 62
R=TBDMS, 63
R=MEM, 64
scheme 30
MeO OH OR
Saturation of the enone double bond in 60 could be accomplished
smoothly with sodium amalgam, but unfortunately, a 1:1 mixture of diastereomers
was obtained (scheme 31).It was originally intended to take 65 on to a
diazoketone that would have been capable of C-H insertion into the benzylic144
methine C13. However, the hydrolysis of 65 was found to be difficult.These
results made any approach to morphine from 65 unattractive, and this line of
attack was not pursued further.
NaHg,
NaOH,
H2O,
60 %
scheme 31
The difficulties encountered with the hydrolysis of the carboethoxygroup
in 61-63 and in 65 indicated that a more tractable esterwas needed, and for this
reason it was decided to replace this functionality by a methyl ester.Dimethyl
succinate was used in the Stobbe condensation leading to compound 59 b
through the steps previously described (scheme 32).
MeO OH
46
O C 02M e
Me02C
Me0H, LiOMe,
A 87 % Me() OH
C 02M e
MeO OH
52 a
51 b
C 02H Pd/C, H2
EtOH,
99%
1) Br2, HOAc, 81%
2) H2S 04, 80%
MeO
MeO0H
57 b
OH
52 bNaH,
HCO2Et,
toluene
scheme 32
59 b
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It was observed that during the Robinson annelation the hydrolysis ofthe
carbomethoxy group occurred as a side reaction.Following up on this
observation, we could obtain the phenanthrenonecarboxylic acid 66 directlyby
simple treatment of 59 b with a 1M potassium hydroxide solution. Compound66
was thus availablein much better yield than was the case when the
corresponding ester was isolated (scheme 33).
59 b
KOH
H2O
86%
scheme 33
66
Several attempts were made to transform this unusually polarand
insoluble material to a diazoketone of the type 68 thatwas envisioned in our
original plan (see retrosynthetic analysis scheme 15). While the reductionof 66
with sodium borohydride and the acetylation could be carriedout to afford 67 in
low yield, activation of the carboxyl group with oxalyl chlorideresulted in
decomposition (scheme 34).66
67
1) NaBH4
EtOH
2) Ac20
pyr
1) (C0C1)2
x
2) CH2N 2
MeO OAc
67
MeO
scheme 34
OH OR
68
OAc
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Although 66 was uncooperative it was hoped that structuralchanges could
be introduced which would lead to a more stable series ofcompounds and which
would allow for the elaboration of the diazoketone fromthe carboxylic acid.
Acetylation of 66 greatly improved the solubility and stability ofthe compound.
However, in an attempt to remove bromine from thetricyclic nucleus,
hydrogenation of the acetate 69 unexpectedly yielded 70(scheme 35).In
addition to debromination, conversion of theenone to a saturated C ring occurs,
presumably via 1,2-reduction of the ketone and hydrogenolysisof the resultant
allylic alcohol. The latter then undergoes further reductionof the trisubstituted
double bond.
69
H2, Pd/C
Me0H
85 % MeO OAc
70MeO OAc
H
MeO OAc
4
70
OH MeOMe0
scheme 35
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An analogous result was reported by Gates et al. 46whilestudying the
hydrogenation of the thebaine derived product 71 (scheme 36).
Me Me
HN H
H2, Pd/C
MeO OH
71
Me0H
100%
scheme 36
MeO OH
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After more experimentation with carboxylic acids 66and 70, it was
concluded that only protected carboxylic acid 69 could beconverted in a
satisfactory manner to a diazoketone.
66
MeO OAc
70
This was accomplished by treatment of 69 with oxalyl chloride,followed by
reaction of the unisolated acyl chloride with diazomethane. Thediazoketone 73
was found to be relatively stable (scheme 37).
69
1) (C0C1)2
C H2Cl2
2) CH2N2
Et20
70%
scheme 37
73
First experiments with 73 were not encouraging, forexposure of 73 to
rhodium acetate in toluene resulted in reaction with the solventto afford 74 as the
sole product (scheme 38). This intermolecular insertion into thebenzylic methyl
group is not without precedent47 but was surprising in view of the several
alternative pathways which appeared to be accessible to 73.O
Rh2(OAc)4
toluene
70% Me() OAc O MeO OAc
73
scheme 38
74
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By contrast, when diazoketone 73 was reacted indichloromethane,
intramolecular C-H insertion was the main pathway leadingto the cyclobutanone
75 as a beautifully crystalline material (scheme 39). Formation of75 was not the
desired outcome, and the insertion into the 7-hydrogen of theenone moiety was
unexpected.Although studies have shown that methineprotons are the
preferred site for rhodium (II) catalyzed intramolecular C-H insertions,48the
formation of a cyclobutanone is typically observed onlyas a minor side reaction
rather than the main reaction pathway.49
MeO OAc
73
Rh2(OAc)2
C H2C12
55 % 0
scheme 39
75
The identity of 75 was independently verified by X-ray diffractionanalysis
(figure 2.2).The crystal structure reveals interesting conformationaldetails
including the fact that the cyclobutanone ring standsout perpendicularly with
respect to the it- system of the aromatic ring and theenone.150
Figure 3.2: TELP Representation from X-ray Structure of75.
The C-H insertion process which leads to 75 andwhich creates a
quaternary carbon center, generates a new carbon-carbon bondbetween the
carbons 14 and 15 rather than carbon 13 and 15as had been hoped. Access to
the morphine skeleton thus appeared to be blocked bythe propensity of
diazoketone 73 to form a cyclobutanone rather thana cyclopentanone.151
This predicament led us to examine the prospects for a rearrangement of
75 involving a 1,2-alkyl shift of carbon 15 to carbon 13 (morphine numbering).
The geometry of 75, as revealed by its crystal structure is clearly conducive toa
rearrangement with the cyclobutanone placed perpendicular to theit- system of
the aromatic ring and the enone. This implies that the a-bond between carbon
14 and carbon 15 should be in position to overlap favorably with the vacantp-
orbital of carbon 13 during this Wagner-Meerwein rearrangement.50
MeO OAc
76
0- H
There should,inprinciple, be substantial driving force for this
rearrangement since it would relieve ring strain of the cyclobutanone, which is
approximately 30 kcal/mo1.51On the other hand, a well known skeletal
rearrangement of morphine offers precedence for the reverse event since it has
been noted that during the acid-catalyzed conversion of morphine (1) to
apomorphine (81), a ring contraction occurs in which carbon 15 migrates from
carbon 13 to 14.52 This would appear to be driven by the increased stability of
carbocation 80 relative to 79 (scheme 40).1
HO OH
81
HCI
77
Me,
HO OH
80
scheme 40
HO OH
79
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In the conversion of 1 to 80, where ring contraction of a piperidine to a
pyrrolidine takes place, ring strain clearly is less important than carbocationic
stability.On the other hand,relief of ring strain associated with the
rearrangement of 75 should be the dominant factor and should outweigh the
difference in stability of carbocations 76 and 83.Thus, expansion of the
cyclobutanone should provide significant thermodynamic driving force in the
direction of 83 (scheme 41).
75
H+
MeO OAc
76
scheme 41
0H
0
83153
Much to our disappointment, however, 75 didnot show any inclination to
undergo the expected rearrangement. A variety of mineral andLewis acids were
combined with 75 but to no avail. Cleavage of theacetate in 75 was the only
reaction observed after extended exposure to acids,including p-toluenesulfonic
acid in refiuxing toluene.
It was reasoned that, because the carbonylgroup of the cyclobutanone
decreases the migratory aptitude of carbon 15,rearrangement could be effected
if this ketone were reduced. While studying the reductionof 75 it was found that
the cyclobutanone is reduced at a faster rate than thecyclohexenone with
sodium borohydride in tetrahydrofuran.By this means, the alcohol 84was
available in modest yield and was subjected to thesame conditions as had been
explored with 75. Again, no rearrangement of 84 could beinduced (scheme 42).
75
NaBH4
THE
40 % MeO OAc
OH
scheme 42
84
Reduction of both keto groups of 75 could be carriedout under Luche
conditions53 and gave a diastereomeric mixture of four diols85 in variable yields
(scheme 42). The mixture of diols 85 was unstable andconsequently difficult to
handle. Chromatographic purification, for example, ledto decomposition and low
mass recovery.75
NaBH4
CeC13.6H20
Me0H
88 %
scheme 43
MeO OAc
85
OH
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When the diols 85 were treated with Lewis acids (boron trifluoride
etherate, titanium tetrachloride, stannic chlorideor, diethylaluminum chloride) at
low temperature in dichloromethane, slow decomposition of the startingmaterial
and no rearrangement was observed. Eventually, itwas found that 85 could be
rearranged in the presence of a catalytic amount of boron trifluorideetherate in
refluxing toluene. An epimeric mixture of dienyl alcohols 86was thus obtained in
36% yield (scheme 43).
MeO OAc
85
BF3.OEt2
toluene, A
OH MeO
36%
scheme 44
OAc
86
The mixture of alcohols 86 was oxidized toa single ketone 87 in good
yield (scheme 45).54 Tetracycle 87 possesses the completecarbon framework of
morphine and structurally resembles the ketone 41 which, accordingto our
original plan (scheme 16), was to be converted to lactam 40 viaBeckmann
rearrangement.MeO OAc
86
O
,1-0Ac
Ac0OAc
CH2Cl2
75%
MeO OR
41
scheme 45
MeO OAc
87
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Several unsuccessful attempts were made toobtain a crystalline sample
of 87 or a derivative suitable for X-ray analysis.It was decided therefore to
continue forward from 87, and its oxime derivative88 was prepared in the hope
that it could be subjected to the Beckmannrearrangement to yield the desired S-
lactam (scheme 45).
MeO OAc
87
HCINH2OH
NaOAc
Me0H
80 0/
scheme 46
MeO OAc
88
Tosylation of the hydroxyl group of oxime of 88proved difficult and gave
no useful result.However, an unstable mesylate 89was prepared in good
yield.55 Unfortunately, attemptedrearrangement of 89 under basic conditions led156
to hydrolysis of the oxime mesylate, resulting in recovery of 88 (scheme 47). The
oxime 88 was found to decompose after prolongedexposure to base. Attempts
to induce Beckmann rearrangement of 88 or its mesylate 89 under acidic
conditions, for example with trimethylsilyl iodide,were also unsuccessful.
N- OH MsCI,
Et3N,
CH2Cl2,
MeO MeO OAc
88 78%
OAc
89
scheme 47
Na2CO3
H2O, THE
88
Although a negative result has to be viewed with caution,we must
conclude that the Beckmann rearrangement of oxime 88 isnot feasible by
conventional methods and further experimentation is required to establisha route
from 87 to morphine. Changes in the structure of ketone 87, forexample, by
debromination or dihydrofuran ring closure, or a variation in the conditions ofthe
Beckmann rearrangement could lead to the desired product.
In a different approach to the morphine structure, it has been possibleto
perform a Curtius rearrangement at the stage of the tricyclicphenanthrenone
carboxylic acid 66.
66
(Ph0)2PON3
Me0H, Et3N, z,
60%
scheme 48
90157
Initial experiments with 66 have been promising and have led to 90
(scheme 48).Itis hoped that the urethane 90 can be transformed to the
tetracyclic morphinan skeleton along the lines of a radical cyclization strategy
shown in scheme 49.56
90
Me
11N
)
MeO OH O MeO OH
scheme 49
In summary, we have demonstrated that a new series of tetracyclic
"carbomorphinan" compounds are available from a phenanthrenone precursor
63. The route to these novel structures involves cyclobutanone formation by
intramolecular insertion of a diazoketone and a subsequent ring expansion via
Wagner-Meerwein rearrangement.
These tetracyclic compounds may ultimately be useful for a total synthesis
of morphine and related alkaloids.In addition, these intermediates provide
access to potentially valuable analogs of morphine which cannot easily be made
through synthetic modification of natural morphine alkaloids.57158
Experimental Section
General
General experimental techniques and instrumentation usedin this work are
outlined in part I chapter IV.
OMe
R = Me, Et
4-[3-Hydroxy-4-methoxyphenyI]-3-carbomethoxy-3-butenoic
acid (51 b).A solution of sodium methoxide was prepared fromsodium
metal (2.3 g, 0.10 mol) and methanol (100 mL). To that solutionwas added
isovanillin (46) (5.01 g, 0.032 mol) and dimethyl succinate (5.02g, 0.034 mol)
followed by lithium chloride (10 g, 0.23 mol). The resulting yellowsuspension
was refluxed for 18 h. The color of the mixture changed from yellow to dark
orange. The mixture was allowed to cool to room temperature andwas taken
up with aqueous 10% sulfuric acid (400 mL) and extracted with ether (4x 150
mL).The combined organic layers were washed with brine,dried, and
concentrated in vacuo. Recrystallization of the residue from methanolafforded
7.61 g (86%) of 51 b as a orange solid: mp 183°C;IR (KBr) 3347, 2883,
2939, 1733, 1687, 1606, 1588, 1511, 1444, 1278, 1212, 1163,1126, 1022,
811 cm-1; 1H NMR (300 MHz, CDCI3) 6 3.65 (2H, m), 3.82 (3H, s),3.90 (3H, s),
6.60-6.95 (3H, m), 7.81 (1H, s); 13C NMR (CDCI3, 75 MHz) 6 33.5,52.3, 55.9,
110.7, 115.3, 121.9, 123.4, 127.9, 142.4, 145.6, 147.5, 168.2,177.0; MS(EI)
m/z 266 (M+, 27), 222, 175, 167, 163, 162, 162, 147,131, 119, 103, 91;159
HRMS m/z calcd for C13H1406 (M+): 266.0790.Found: 266.0790.Anal.
Calcd for C13H1406 C; 58.65; H; 5.30. Found: C; 58.54;H; 5.27.
4-[3-Hydroxy-4-methoxyphenyl]-3-carboethoxy-3-butenoic
Acid (51 a). The ethyl ester 51 awas prepared in a manner analogous to
that used for the methyl ester 51 b described above:IR (KBr) 3343, 2883,
2939, 1734, 1687, 1606, 1588, 1511, 1441, 1278, 1212,1163, 1126, 1022,
812 cm-1; 1H NMR (300 MHz, CDCI3) 6 1.35 (3 H, t, J=7Hz),3.61 (2H, m), 3.80
(3H, s), 4.23 (2H, q, J=7Hz), 6.60-6.95 (3H, m), 7.81 (1H,s); 13C NMR (CDCI3,
75 MHz) 6 14.1, 28.9, 56.1, 60.8, 110.2, 114.1, 125.6,130.5, 146.1, 151.9,
145.6, 147.5, 172.2, 172.3, 177.0; MS(EI) m/z 280 (M+),236, 175, 162, 147,
131, 119, 103, 103, 91; HRMS m/z calcd for C14111606(M+): 280.0947.
Found: 280.0946.
R = Me, Et
OMe
4-[ 3-Hydroxy-4-methoxyphenyl]-3-carbomethoxybutanoic
Acid (52 b). To a solution of 51 b (5.50g, 0.020 mol) in ethanol (200 mL)
was added 10% palladium on carbon (300 mg, 1.4 mol%). The flaskwas
flushed with hydrogen gas and the mixturewas stirred vigorously.After 3 h
the mixture was filtered over Celite, and the filtercakewas washed with ether.
After evaporation of the filtrate therewas obtained 5.51g of crude 52 b:IR
(neat) 3447, 3234, 2980, 1724, 1715, 1513, 1274,1179 cm-1; 1H NMR (300
MHz, CDCI3) 6 2.40 (1H, m), 2.68 (2H, m), 3.05 (2H, m),3.46 (1H, s), 3.66 (3H,
s), 3.83 (3H, s), 6.65 (3H, m), 7.30 (1H, bs); 13C NMR(CDCI3, 75 MHz) 6 36.9,
42.8, 52.0, 55.9, 110.8, 115.2, 120.5, 131.1, 145.4,145.5, 174.7, 177.0;160
MS(EI) m/z 268 (M+), 208, 137, 131, 122, 103, 94, 77; HRMSm/z calcd for
C13111606 (M-9: 268.0947. Found: 268.0947.
4-[ 3- Hydroxy- 4- methoxyphenyl] -3- carboethoxybutanoicAcid
(52 a). The ethyl ester 52 a was prepared ina manner analogous to that
used for the methyl ester 52 b described above: IR (neat)3447, 3234, 2980,
1724, 1715, 1513, 1274, 1179 cm-1; 1H NMR (300 MHz, CDCI3) 61.22 (3 H, t,
J=7Hz), 2.4-3.0 (5H, m), 3.85 (3H, s), 4.14 (2H,q, J=7Hz), 6.60 (d, 1H, J=8Hz),
6.71 (d, 1H, J=1Hz), 6.75 (d, 1H, J=8Hz); 13C NMR (CDCI3,75 MHz) 6 14.0,
34.6, 37.0, 42.9, 56.0, 60.8; 110.7, 115.2, 120.5, 131.2, 145.4,145.6, 174.1,
177.4; MS(EI) m/z 282.2 (M+), 208, 191, 137, 122, 103, 94,77; HRMS m/z
calcd for C14111806 (M+): 282.1103. Found: 282.1102.
3-Carboethoxy-6-hydroxy-7-methoxy-1-tetralone(53). To a
solution of 52 a (10 mg, 0.035 mmol) in ether (1 mL)was added 100%
sulfuric acid (30 ML). The resulting mixturewas stirred at room temperature for
2 h and diluted with water (3 mL).The phases were separated, and the
aqueous layer was back extracted with ether (2 x 2 mL).The combined
organic layers were washed with brine, dried, andconcentrated in vacuo.
Column chromatography of the residue (hexane-ethylacetate, 1:1) afforded 5
mg (53%) of 53: IR (neat) 3385, 3380, 2996, 1730, 1669, 1610, 1580,1308,
1280, 1213, 1188 cm-1; 1H NMR (300 MHz, CDCI3) 6 2.80 (3H,t, J=7Hz), 3.13
(3H, m), 3.92 (3H, s), 4.16 (1H, q, J=7Hz), 6.13 (1H, bs),6.77 (1H, s), 7.51 (1H,
s); 13C NMR (CDCI3, 75 MHz) 8 194.8, 173.2, 151.0,145.9, 137.2, 125.0,
113.9, 108.3, 61.0, 56.2, 40.5, 40.2, 31.5, 14.1; MS (El) m/z264 (M+), 192,161
191, 131, 103, 91. HRMS m/z calcd for C14H1605(M+): 264.0998. Found:
264.0997.
R = Me, Et
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4-[6-bromo-3-Hydroxy-4-methoxypheny1]-3-carbomethoxy-3-
butanoic Acid (56 b). To a stirred solution of52 b (2.50 g, 9.33 mmol) in
glacial acetic acid (50 mL)was added dropwise a solution of bromine (0.50
mL, 9.4 mmol) in acetic acid (1 mL).The mixture was stirred atroom
temperature for 0.5 h, after which aqueous sodium thiosulfate(50 mL) and
water (200 mL) were added. The resulting mixturewas extracted with ether (4
x 50 mL). The combined organic layers were washed with brine,dried, and
concentrated in vacuo. There was obtained 2.10g (65%) of crude 56 b. Due
its very polar nature, 56 bwas used without further purification:IR (neat)
3315, 3238, 2983, 1715, 1502, 1441, 1277, 1230,1183, 1161 cm-1; 1H NMR
(400 MHz, CDCI3) 6 2.49 (1H, s), 2.75 (2H, m),3.15 (2H, m), 3.68 (3H, s), 3.86
(3H, s), 6.00 (1H, s), 6.75 (1H, s); 13C NMR(CDCI3, 100 MHz) 6 34.7, 37.0,
41.4, 52.1, 56.2, 113.5, 115.2, 116.7, 130.2,145.0, 146.1, 174.4, 177.4;
MS(EI) m/z 348, 346 (Mt), 269, 267, 271, 216,215, 214, 191, 159, 127, 118;
HRMS m/z calcd for C131-11506Br (M+): 346.0052.Found: 346.0054.
4-[6-bromo-3-Hydroxy-4-methoxypheny1] -3-carboethoxy-3-
butanoic Acid (56 a).The ethyl ester 56 a was preparedin a manner
analogous to that used for the methyl ester 56 bdescribed above:IR (neat)
3315, 3238, 2983, 1715, 1502, 1441, 1277,1230, 1183, 1161 cm-1; 1H NMR
(300 MHz, CDCI3) 8 1.17 (3 H, t, J=7Hz), 2.4 (2H,m), 2.80 (1H, m), 3.10 (2H,162
m); 3.88 (3H, s), 4.14 (2H, q, J=7Hz), 6.75 (s, 1H), 6.98 (s, 1H); MS(EI) m/z
(rel. intensity) 362, 360 (M+), 288, 281, 271, 235, 217, 193, 172, 162, 147,
131, 103, 91; HRMS m/z calcd for C14E11706 Br (M+): 360.0209.Found:
360.0208.
0,
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5-Bromo-3-carbomethoxy-8-hydroxy-1-oxo-7-methoxy-1,2,
3, 4-tetrahydronaphthalene (57 b). To crude 57 b (11.50 g, 34.0 mmol)
was added 100% sulfuric acid (30 mL). The resulting syrup was stirred at
room temperature for 4 h, cooled to 0°C, diluted with methanol (100 mL), and
stirred at room temperature for 2 h. The mixture was diluted with brine (200
mL) and extracted with ether (6 x 50 mL). The combined organic layers were
washed with brine, dried, and concentrated in vacuo. Recrystallization of the
residue from methanol afforded 7.40 g (65%) of 57 b as a yellow solid: mp
95°C;IR (KBr) 2928, 1731, 1643, 1465, 1435, 1281, 1245, 1181, cm-1; 1H
NMR (300 MHz, CDCI3) 6 2.85-3.30 (5H, m), 3.74 (3H, s), 3.87 (3H, s), 7.20
(1H, s), 12.7 (1H, s); 13C NMR (CDCI3, 75 MHz) 6 31.8, 39.0, 39.9, 52.3, 56.3,
111.4, 116.9, 121.3, 131.0, 147.6, 152.7, 172.9, 202.9; MS(EI) m/z (rel.
intensity) 330, 328 (Mt), 298, 296, 271, 269, 253, 239, 191, 189, 175, 119;
HRMS m/z calcd for C13H1305Br (M+): 327.9946. Found: 327.9946. Anal.
Calcd for C13H1305Br C; 47.44; H; 3.98. Found: C; 47.52; H; 3.76.
5-Bromo-3-carboethoxy-8-hydroxy-1-oxo-7-methoxy-1, 2,3,
4-tetrahydronaphthalene (57 a). The ethyl ester 57 a was prepared in a
manner analogous to that used for the methyl ester 57 b described above: IR
(KBr) 2928, 1731, 1643, 1465, 1435, 1281, 1245, 1181, cm-1; 1H NMR (300163
MHz, CDC13) 6 1.26 (3H, t, J=7Hz), 2.90-3.20 (5H, m), 3.88 (3H, s), 4.17 (2H, t,
J=7Hz), 7.20 (1H, s), 12.7 (1H, s); 130 NMR (CDCI3, 75 MHz) 6 14.1, 32.0,
39.3, 40.1, 56.4, 61.3, 111.4, 117.0,123.3,131.1, 151.4,152.9, 172.5, 203.0;
MS(EI) m/z 344, 342 (Mt), 298, 296,282,280, 269, 255,192, 190, 159, 127;
HRMS m/z calcd for C14H1505Br (M+): 342.0103. Found: 342.0103.
MeO
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5-Bromo-3-carbomethoxy-2-formy1-8-hydroxy-1-oxo-7-
methoxy-1, 2 ,3, 4-tetrahydronaphthalene (58 b).To a suspension of
60% sodium hydride dispersion in mineral oil (38 mg, 1.0 mmol) in toluene
(0.5 mL) was added methyl formate (1 mL, 12.4 mmol).To the foamy
suspension was added 57 b (101 mg, 0.31 mmol) in toluene (3 mL). The
resulting mixture was stirred at room temperature for 18 h, after which
aqueous 0.1 N hydrochloric acid (10 mL) was added.The layers were
separated, and the aqueous layer was back extracted with ether (3x 5 mL).
The combined organic layers were washed withbrine,dried, and
concentrated in vacuo. There was obtained 110 mg of crude 58 b. Due to its
oxygen sensitivity, 58 b was used directly without further purification:IR
(neat) 2928, 1726, 1613, 1467, 1439, 1409, 1356, 1242, 1215, 1182 cm-1; 1H
NMR (300 MHz, CDCI3) 6 2.90 (1H, dd, J=4.0, 1 Hz), 3.60 (2H, m), 3.74 (3H, s),
3.94 (3H, s), 7.16 (1H, s), 7.53 (1H, d, J=10Hz), 12.18 (1H, s).
5-B romo-3-ca rboethoxy-2-f ormy1-8-hydroxy-1-oxo-7-
methoxy-1, 2 ,3, 4-tetrahydronaphthalene (58 a).The ethyl ester 58
a was prepared in a manner analogous to that used for the methyl ester 58 b164
described above: IR (neat) 2928, 1726, 1613, 1467, 1439, 1409, 1356, 1242,
1215, 1182 cm-1; 1H NMR (300 MHz, CDCI3) 6 1.20 (3H, t, J=7Hz), 2.90 (1H,
dd, J=4.0, 1 Hz), 3.62 (2H, m), 3.87 (3H, s), 4.10 (2H, m), 7.16 (1H, s), 7.53
(1H, d, J=10Hz), 12.18 (1H, s).
Me01.0
O. ,-0
H
C 02R
R = Me, Et
5-Brorno-3-carbornethoxy-2-[1-(3-butanone)]-2-formy1-8-
hydroxy-1-oxo-7-methoxy-1, 2 ,3, 4-tetrahydronaphthalene (59 b).
To a cold (0°C) solutionof crude 58 b (110 mg, 0.28 mmol)in
dichloromethane (4 mL) was added freshly distilled methyl vinyl ketone (300
5 mmol) followed by triethylamine (10 lit, 0.14 mmol).The resulting
mixture was stirred at room temperature for 5 h, after which the volatile
components were evaporated in vacuo.Chromatography of the residue
afforded 116 mg (86%) of 59 b:IR (neat) 2928, 1721, 1638, 1465, 1435,
1311, 1258, 1206, cm-1; 1H NMR (300 MHz, CDCI3) 6 2.02 (1H, s), 2.10 (3H,
s), 2.90 (1H, m), 3.15 (1H, m),3.45 (1H, m), 3.60-3.80 (3H, m), 3.94 (3H, s),7.20
(1H, s), 10.31 (1H, s); 13C NMR (CDCI3, 75 MHz) 6 21.0, 28.7, 30.0, 36.9, 45.6,
52.8, 56.4, 57.0, 60.4, 111.8, 121.8, 127.8, 148.2, 153.5, 171.1, 173.2, 200.0,
202.1; MS(CI) m/z 428, 426 (Mt), 383, 381, 368, 366, 343, 341, 283, 281;
HRMS m/z calcd for C18H1907Br (M +): 426.0314. Found: 426.0313.
5-Bromo-3-carboethoxy-2-[1 -(3-butanone)]-2-formy1-8-
hydroxy-1-oxo-7-methoxy-1, 2,3, 4-tetrahydronaphthalene (59 a).
The ethyl ester 59 a was prepared in a manner analogous to that used for the
methyl ester 59 b described above: IR (neat) 2928, 1721, 1638, 1465, 1435,165
1311, 1258, 1206, cm-1; 1H NMR (300 MHz, CDCI3) 6 1.20 (3H, t, J=7Hz), 2.07
(3H, s), 2.41 (2H, m), 2.80 (1H, m), 3.01 (2H, m), 3.45 (2H, m), 3.85 (3H, s),
4.02 (1H, m), 4.20 (2H, m), 3.94 (3H, s),7.20 (1H, s), 10.31 (1H, s); 130 NMR
(CDCI3, 75 MHz) 6 14.0, 26.5, 29.9, 30.0, 37.0, 37.8, 45.9, 56.9, 61.7, 111.8,
115.8, 121.8, 128.0, 148.2, 153.5, 172.6, 200.0, 202.1, 202.7.
8-Bromo-10-carboethoxy-5-hydroxy-6-methoxy-3-oxo-1,2,9,
10-tetrahydrophenanthrene(60). To a solution of sodium ethoxide
prepared from sodium (200 mg, 8.70 mmol) and ethanol (50 mL) was added a
solution of 59 a (1.20 g, 2.72 mmol) in ethanol (20 mL), and the mixture was
refluxed for 1h.Most of the ethanol was carefully evaporated in vacuo, and
the residue was acidified by addition of aqueous 10 % hydrochloric acid (50
mL). The mixture was extracted with ether (3 x 40 mL) and ethyl acetate (4x
40 mL ), and the combined organic layers were washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 1:1) afforded 512 mg (47%) of 60 as a colorless solid:IR (KBr) 2919,
2850, 1728, 1657, 1466, 1284, 1181, cm-1; 1H NMR (400 MHz, CDCI3) 8 1.31
(3H, t, J=7Hz), 1.81 (1H, m), 2.20
dd, J=16, 6Hz), 3.91 (3H, s), 4.19
(1H, m), 2.55
(2H, m), 6.62
(3H, m), 2.95
(1H, s), 7.10
(2H, m), 3.14
(1H, s), 7.38
(1H,
(1H,
d, J=2Hz); 130 NMR (CDCI3, 100 MHz) 6 14.2, 27.7, 33.6, 36.6, 38.6, 46.3,
56.6, 61.0, 113.5, 115.9, 120.2, 128.7, 129.1, 145.3, 145.6, 152.4, 174.0,
200.3; MS(EI) m/z 396, 394 (M+), 368, 366, 323, 321, 294, 292, 265, 263, 241,
186, 171, 143, 115, 89; HRMS m/z calcd for Ci8H1905Br (M+): 394.0416.166
Found: 394.0416. Anal. Calcd for 018H1905 Br C; 54.70; H; 4.85. Found: C;
54.58; H; 4.66.
H CO2Et
MeO0-H
8-Bromo-10-carboethoxy-5-hydroxy-6-methoxy-3-oxo-1, 2,4,
4a, 9, 10-hexahydrophenanthrene (65). To a solution of 60 (220mg,
0.55 mmol) in aqueous 0.1 N sodium hydroxide (50 mL) was added 2%
sodium amalgam (6 g, 0.6 mmol), and the mixture was stirred atroom
temperature until the red color of the solution disappeared. The mixture was
filtered and the filtrate was acidified by careful addition ofaqueous 1 N
hydrochloric acid.The mixture was extracted with ether (3 x 40 mL), and the
combined organic layers were washed with brine, dried, and concentrated in
vacuo. There was obtained 180 mg (84%) of 65: IR (KBr) 3389, 3383, 2938,
1722, 1702, 1478, 1435, 1285, 1239, 1179, 1095 cm-1; 1H NMR (400 MHz,
CDCI3) 6 1.3 (3H, m), 1.65 (1H, m), 2.01-2.25 (3H, m), 2.31-2.65 (2H, m), 2.81-
3.20 (3H, m), 3.60 (1H, m), 3.87 (3H, s), 3.90 (1H, m), 4.23 (2H, m), 5.90 (1H,
bs), 6.98 (1H, s); 130 NMR (CDCI3, 75 MHz) 6 14.2, 27.8, 28.4, 33.3, 34.3,
34.9, 36.3, 36.7, 38.9, 41.0, 42.1, 42.3, 42.8, 45.2, 45.6, 56.3, 60.7, 60.8,
113.3, 113.5, 124.9, 125.7, 126.4, 127.9, 141.8, 143.4, 144.9, 145.2, 171.7,
174.8, 210.4, 211.0; MS(EI) m/z 398, 396 (M+), 324, 322, 318, 317, 307, 305,
227, 226, 213, 201, 187, 183, 175, 167, 160, 149,
103, 84; HRMS m/z calcd for 018H2105Br (M+):
396.0572. Found: 396.0572.
279,267,265,244,243,
144,143,131,128,115,167
0
5-Acetoxy-8-bromo-10-carboethoxy-6-methoxy-3-oxo-1,2,9,
10-tetrahydrophenanthrene(61). To a solution of 60 (90 mg, 0.23
mmol) in dichloromethane (4 mL) was added acetic anhydride (30 mg, 0.30
mmol), triethylamine (40 pi, 0.4 mmol), and a catalytic amount of 4-
(dimethylamino)pyridine. The mixture was stirred at room temperature for 5 h,
after which aqueous 0.1 N hydrochloric acid (20 mL) was added and the
mixture was extracted with ether (3 x 15 mL). The combined organic layers
were washed with brine,dried, and concentrated in vacuo.Column
chromatography of the residue (hexane-ethyl acetate, 3:1) afforded 81 mg
(80%) of 61: IR (KBr) 2942, 1770, 1730, 1670, 1601, 1558, 1472, 1287, 1262,
1124, 912, 713 cm-1; 1H NMR (300 MHz, CDCI3) 8 1.21 (3H, t, J=7Hz), 1.85
(1H, m), 2.18 (1H, s), 2.26 (3H, s), 2.50 (2H, m), 2.71 (1H, m), 2.98 (2H, m),
3.20 (1H, dd, J=16, 10Hz), 3.80 (3H, s), 4.15 (2H, q, J=7Hz), 6.55 (1H, s), 7.18
(1H, s); 13C NMR (CDCI3, 75 MHz) 8 14.1, 15.2, 20.7, 27.5, 31.9, 36.0, 37.3,
45.7, 56.4, 61.1, 117.6, 121.0, 128.0, 128.6, 129.3, 136.9, 150.5, 152.6, 168.2,
173.2, 199.0; MS(EI) m/z 438, 436 (M-F), 396, 394, 323, 321, 279, 277, 265,
263, 242, 240, 214, 213, 185, 128; HRMS m/z calcd for C201-12106Br (M+):
436.0521. Found: 436.0521.
Compound 61 crystallized in the tetragonal space group I4(1)/a with
a=26.878 (4) A, b=26.878 (4) A, c=10.870 (3) A, V=7852.78 A3, Z=16,
Dcalc=1.479 g/cm3.All 2187 nonequivalent reflections in the range of 3.5° <
20 < 95° were measured on a Siemens P4 diffractometer with graphite
monochromated Cu Ka radiation (X=1.54178 A).The structure was solved168
with direct methods (SHELXTL) using 1536 unique reflections with F> 4 a(F).
Full matrix least squares refinement with anisotropic temperature factors for all
non-hydrogen atoms and calculated hydrogen atom positions led to the final
discrepancy indices of R=0.0749 and wR =0.0776.
H CO2Et
Me0 OH
0
5-Acetoxy-8-bromo-10-carboethoxy-6-methoxy-3-hydroxy-1,
2, 3, 9, 10-tetrahydrophenanthrene (62). To a solution of 61 (150mg,
0.34 mmol) in methanol (4 mL) was added sodium borohydride (20mg, 0.4
mmol) in small portions. The mixture was stirred at room temperature for 15
min, treated with aqueous 0.1 N hydrochloric acid, and extracted with ether (3
x 15 mL). The combined organic layers were washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 1:1) afforded 111 mg (75%) of 62:IR (KBr) 3426, 2938, 1761, 1728,
1471, 1437, 1371, 1286, 1190, 1127, 1103, 732 cm-1, 1H NMR (300 MHz,
CDCI3) 8 1.21 (3H, m), 1.65 (m, 1H), 1.82 (m, 2H), 2.08 (m, 1H), 2.26 (s, 3H),
2.30, 2.51 (m, 1H), 2.70 (m, 1H), 3.00 (m, 2H), 3.30 (m, 1H),3.39, 3.79 (s, 3H),
3.80, 4.15 (m, 2H), 6.32, 6.41 (s, 1 H), 7.07 (s, 1 H), 7.09; 13C NMR (CDCI3, 75
MHz) 8 14.2, 20.7, 20.9, 21.0, 25.0, 28.6, 29.9, 32.5, 32.8, 35.9, 36.0, 46.4,
47.7, 56.3, 60.4, 60.8, 66.1, 66.8, 115.4, 115.6, 121.4, 127.4, 127.5, 130.5,
130.6, 132.8, 134.2, 136.2, 150.2, 150.2, 168.7, 173.2, 174.3, MS(EI) m/z 440,
438 (Mt), 422,420,402,380,378,348,307,306,305,304,303,291,289,
287, 280, 279,278,227,226,225,224,211,210,208,198,194,193,183,169
165, 153, 152, 139, 128, 115; HRMS m/z calcd for C20H23O6Br (M+):
438.0678. Found: 438.0678.
8-Bromo-5-hydroxy-6-methoxy-3-oxo-1,2,9,10-tetrahydro
phenanthrene-10-carboxylic Acid (66). A solution of 59 b (2.0g, 4.54
mmol) in aqueous 1.0 M potassium hydroxide (100 mL)was stirred at room
temperature for 7 h.The mixture was acidified with aqueous 10 %
hydrochloric acid (50 mL) during which the red color of thesolution
disappeared and a white precipitate formed. Filtration of the mixture througha
Buchner funnel provided 1.40 g (86%) of crude 66as a colorless solid: mp
264°C; IR (KBr)2928, 1702, 1609, 1466, 1245, 1181, cm-1; 1H NMR (400
MHz, D6 -DMSO) 6 1.75 (1H, m), 2.11 (1H, m), 2.41 (2H, m), 2.85 (2H, m),3.82
(3H, s), 7,15 (1H, s), 7.27 (1 H, s), 9.71 (1H, 5); 13C NMR (D6-DMSO,100
MHz) 6 27.6, 32.8, 36.3, 37.8, 45.2, 56.5, 112.0, 116.5, 120.9, 127.5,128.4,
145.9, 146.9, 153.2, 174.9, 199.2,; MS(EI) m/z 368, 366 (Mt), 323, 321,242,
240, 215, 214, 209, 199, 186, 185, 153, 152, 139, 119; HRMS m/z calcdfor
C16H1505Br (M+): 366.0103. Found: 366.0103. Anal. Calcd for C16H15O5Br
C; 52.34; H; 4.12. Found: C; 52.74; H; 4.00.
5-Acetoxy-8-bromo--6-methoxy-3-oxo-1,2,9,10-tetrahydro
phenanthrene-10-carboxylic Acid (69). To a suspension of 66(238170
mg, 0.65 mmol) in dichloromethane (20 mL) was added acetic anhydride (200
mL, 2.0 mmol), triethylamine (0.5 mL, 7 mmol), and a catalytic amount of 4-
(dimethylamino)pyridine. The mixture was stirred at room temperature for 12 h
after which aqueous 0.1 N hydrochloric acid (50 mL) was added and the
mixture was extracted with ether (4 x 40 mL). The combined organic layers
were washed with brine, dried, and concentrated in vacuo. Recrystallisation of
the residue from ether afforded 250 mg (92%) of 69 as a colorless solid:mp:
196°C; IR (KBr) 2946, 1769, 1733, 1664, 1470, 1436, 1284, 1263, 1185, 713
cm-1; 1H NMR (300 MHz, CDCI3) 6 1.95 (1H, m), 2.18 (1H, m), 2.50 (2H, m),
2.28 (3H, s), 3.05 (2H, m), 2.78 (1H, m), 3.20 (1H, dd, J=16, 7Hz), 3.82 (3H, s),
6.62 (1H, s), 7.22 (1H, s); 130 NMR (CDCI3, 75 MHz) 6 20.7, 27.4, 32.0, 36.4,
39.9, 45.6, 56.4, 117.9, 121.3, 128.1, 128.4,129.0, 137.1, 150.6, 152.6, 168.3,
178.0, 199.4; MS(EI) m/z 410, 408 (M+), 368, 366, 323, 321, 214, 212, 186,
185, 171, 169; HRMS m/z calcd for 018H -17068r (M+): 408.0208.Found:
408.0207.
5-Acetoxy-6-methoxy-3-oxo-1,2,9,10-tetrahydrophen-
anthrene-10-carboxylic Acid (70). To a suspension of 69 (250 mg, 0.61
mmol) in methanol (10 mL) was added 10% palladium on carbon (9 mg, 1.4
mol %). The flask was flushed with hydrogen gas and the mixture was stirred
vigorously. After 3 h the mixture was filtered over Celite, and the filtercakewas
washed with ether. After evaporation of the filtrate, there was obtained 165mg
(85%) of crude 70: IR (KBr) 2931, 1765, 1740, 1705, 1490, 1283, 1193, 1090,
732 cm-1; 1H NMR (300 MHz, CDCI3) 8 0.91 (3H, m), 1.65 (1H, m), 1.90 (1H,171
m), 2.31 (3H, s), 2.45 (2H, m), 2.71 (1H, m), 2.91 (1H, m), 3.10 (2H,m), 3.78
(3H, s), 6.92 (1H, d, J=8Hz), 6.94 (1H, d, J=8Hz); 13C NMR (CDCI3,75 MHz) 6
20.7, 26.5, 27.3, 31.2, 31.9, 34.1, 43.4, 45.0, 45.6, 56.0, 110.2, 126.7,128.5,
132.4, 138.8, 149.7, 168.7, 181.4; MS(CI) m/z 408 (M+), 301, 276,231; HRMS
m/z calcd for C18H2205 (M±): 318.1467. Found: 318.1467.
5-Acetoxy-8-bromo-10-[2'-diazoacetyI]-6-methoxy-3-oxo-1,
2, 9, 10-tetrahydrophenanthrene (73). Toa solution of 69 (85 mg, 0.21
mmol) in dichloromethane (2 mL) was added oxalyl chloride (504, 0.60
mmol). The mixture was stirred at room temperature for 18 h.Solvent and
residual oxalyl chloride were evaporated in vacuo, and the residuewas taken
up in ether (3 mL) and treated with diazomethane solution in ether (1 mL).
The resulting yellow solution was stirred for 1 h atroom temperature and the
solvent was evaporated. Column chromatography of the residue(hexane-
ethyl acetate, 1:1) afforded 63 mg (70%) of 73:IR (neat) 2918, 2108, 1769,
1666, 1640, 1469, 1375, 1288, 1260, 1184, 1123, 1019, 713 cm-1; 1HNMR
(300 MHz, CDCI3) 6 1.80 (1H, m), 2.20 (1H, m), 2.28 (3H, s),2.49 (2H, m), 2.61
(1H, m), 3.05 (3H, m), 3.81 (3H, s), 5.39 (1H, s), 6.66 (1H, s),7.21 (1H, s); 13C
NMR (CDCI3, 75 MHz) 6 20.8, 27.1, 33.1, 35.9, 37.4, 50.7,55.5, 56.4, 117.8,
121.3, 128.2, 128.6, 128.7, 137.3, 150.6, 152.8, 168.2,194.3, 199.1;Anal.
Calcd for C19H1705BrN2 C; 52.77; H; 3.97; N; 6.48. Found: C;52.59; H; 3.94;
N; 5.78.172
0
5-Acetoxy-8-bromo-1043-phenylpropanoy1]-6-methoxy-3-
oxo-1,2,9,10-tetrahydrophenanthrene (74). To a suspension of
rhodium (II) acetate dimer (3 mg, 0.007 mmol) in toluene (1 mL)was added
dropwise over a period of 4 h a solution of 73 (50 mg, 0.11 mmol) in toluene
(20 mL).After the addition was complete, the solventwas evaporated in
vacuo. Column chromatography of the residue (hexane-ethyl acetate, 1:1)
afforded 40 mg (70%) of 74: IR (neat) 2920, 1769, 1714, 1671,1601, 1470,
1436, 1369, 1331, 1262, 1186, 1124, 1020, 732 cm-1; 1H NMR (300 MHz,
CDCI3) 6 1.75 (2H, m), 2.0 (2H, m), 2.15 (1H, m), 2.28 (3H, s), 2.35 (1H, m),
2.50 (2H, m), 3.11 (3H, m), 3.80 (3H, s), 4.13 (1H, m), 6.01-6.30 (4H, m),6.56
(1H, s), 7.17 (1H, s); 13C NMR (CDCI3, 75 MHz) 6 15.2, 20.7, 23.0,23.1, 27.6,
32.0, 36.2, 36.7, 51.4, 56.4, 65.8, 117.6, 120.9, 126.3, 126.4, 127.1,127.6,
127.9, 128.0, 128.4, 129.4, 150.6, 153.2, 168.2, 199.0, 199.1; MS(EI) m/z498,
496 (M+), 456, 454, 410, 408, 364, 362, 324, 323, 322, 321, 320,263, 242,
128, 119, 106, 105, 91; HRMS m/z calcd for C26H2505Br (M+):496.0885.
Found: 496.0885.173
0
8-Acetoxy-11-bromo-2, 3,4,5,6, 7-hexadehydro-9-methoxy-
4-oxo-15-oxo-tetracyclo[12.2.01,6.07,12.01,14]-5-hexadecene(75).
To a suspension of rhodium(II) acetate dimer (10 mg, 0.02 mmol) in
dichloromethane (20 mL) was added dropwise over a period of 4 ha solution
of 73 (340 mg, 0.78 mmol) in dichloromethane (60 mL). After the additionwas
complete, the solvent was evaporated in vacuo. Column chromatography of
the residue (hexane-ethyl acetate, 1:1) afforded 170 mg (53%) of 75: IR (neat)
2925, 1781, 1668, 1470, 1187 cm-1; 1H NMR (300 MHz, CDCI3) 52.20 (3H, s),
2.50 (4H, m), 2.92 (1H, m), 3.20 (1H, dd, J=18, 4Hz), 3.55 (2H, m), 3.83 (3H,s),
6.38 (1H, s), 7.22 (1H, s); 130 NMR (CD013, 75 MHz) 6 20.6, 27.3, 34.1,34.7,
35.3, 56.4, 56.6, 63.9, 118.0, 121.0, 127.9, 128.7, 129.3, 137.4, 150.9,153.4,
168.5, 198.2, 206.9; MS(EI) m/z 406, 404 (M+), 364, 362, 322, 320, 307,305,
279, 277, 265, 263, 261, 242, 240, 213, 211, 198, 197, 169, 167,116, 113;
HRMS m/z calcd for C19H1705Br (M+): 404.0259. Found: 404.0259.
Compound 75 crystallized in the triclinic space group P-1 witha=9.489
(2) A, b=11.102 (2) A, c=16.969 (3) A, V=1786.28 A3, Z=2,Dcalc=1.507 g/cm3.
All 2340 nonequivalent reflections in the range of 3.5°< 20 < 95° were
measured on a Siemens P4 diffractometer with graphite monochromatedCu
Ka radiation (X=1.54178 A). The structure was solved with directmethods
(SHELXTL) using 2155 unique reflections with F> 4 a(F).Full matrix least
squares refinement with anisotropic temperature factors for all non-hydrogen
atoms and calculated hydrogen atom positions led to the final discrepancy
indices of R=0.1093 and wR =0.1051.174
HOH
8-Acetoxy-11-bromo-2,3,4,5,6,7-hexadehydro-15-
hydroxy-4-oxo-9-methoxy-tetracyclo[12.2.01,6.07,12.01,14].5.
hexadecene(84).To a solution of 75(52 mg, 0.13 mmol)in
tetrahydrofuran (2.5 mL) at -78°C was added sodium borohydride (10 mg, 0.27
mmol) in small portions. The mixture was stirred at -78°C for 15 min, treated
with aqueous 0.1 N hydrochloric acid (5 mL), and extracted with ether (3 x 15
mL).The combined organic layers were washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue (hexane-ethyl
acetate, 1:4) afforded 21 mg (40%) of 85 and 13 mg (25%) of recovered
starting material: IR (neat) 3444, 3426, 3414, 2928, 1766, 1662, 1471, 1436,
1280, 1191, 1145, 1118, 732 cm-1; 1H NMR (300 MHz, CDCI3) 81.64 (1H, m),
2.21 (3H, s), 2.32-2.60 (5H, m), 2.80 (2H, m), 3.42 (1H, m), 3.83 (3H, s), 4.50
(1H, m), 6.27 (1H, s), 7.12 (1H, s); 130 NMR (CDCI3, 75 MHz) 6 6.4, 14.1, 21.0,
26.5, 33.1, 34.1, 34.5, 41.1, 43.1, 56.2, 56.3, 58.3, 60.4, 64.4, 67.4, 115.6,
117.7, 120.6, 129.3, 130.9, 132.2, 137.4, 150.4, 154.8, 168.6, 199.1; MS(EI)
m/z 408, 406 (M+), 366, 365, 364, 348, 346, 322, 320, 307, 305, 279, 241,
225, 213, 198, 182, 169, 165, 153, 115, 91; HRMS m/z calcd for 019H1905Br
(M+): 406.0416. Found: 406.0416.175
8-Acetoxy-11-bromo-2, 3,4,5,6, 7-hexadehydro-4-hydroxy-
15-hydroxy-9-methoxytetracyclo[12.2.01,6.07,12.01,14.] ..5.
hexadecene (85). To a solution of 75 (95mg, 0.23 mmol) in 0.4 M cerium
chloride (0.5 mL) was added sodium borohydride (20mg, 0.54 mmol) in small
portions. The mixture was stirred at room temperature for15 min, treated with
aqueous 0.1 N hydrochloric acid (5 mL), and extracted with ether (3x 15 mL).
The combined organic layers were washed withbrine,dried, and
concentrated in vacuo. There was obtained 83mg (88%) of crude product.
Column chromatography of the crude residue (hexane-ethylacetate, 1:4)
afforded 58 mg (60%) of 85: IR (neat) 3392, 2927, 1760,1469, 1198 cm-1; 1H
NMR (300 MHz, CDCI3) 8 1.57 (2H, m), 2.02 (2H, m), 2.27(4H, m), 2.47 (1H,
m), 2.69 (1H, m),3.35 (1H, m), 3.40 (1H, m), 3.82 (3H,s), 4.35 (1H, m), 6.00
(1H, s), 7.11, 7.13 (1H, s); 13C NMR (CDCI3, 75 MHz) 8168.9, 150.5, 150.4,
137.0, 135.5, 133.1, 130.5, 130.4, 129.1, 120.0, 119.9, 115.4,115.2, 67.1, 66,
64.8, 64.7, 56.2, 46.5, 43.5, 43.0, 35.0, 34.7, 34.1, 32.5, 29.6, 29.4,26.9, 26.6,
20.8, 20.6; MS(EI) m/z 410, 408 (M+), 392, 390, 366, 364,350, 287, 251, 226,
224, 193, 192, 181, 178, 153, 152, 115, 197, 169, 167, 116,113; HRMS m/z
calcd for C19H2105Br (Mt): 408.0572. Found: 408.0572.MeO
ocs-
176
3-Acetoxy-6-bromo-2, 3,4,5,6, 7-hexadehydro-15-hydroxy-
4-methoxytetracyclo[7.5.2.02,7.01,10]..10,13-hexadecadiene(86).
To a solution of 85 (21 mg, 0.05 mmol) in refluxingtoluene (2 mL) was added
a0.1M solutionofboron trifluoridediethyletherate (10I_IL)in
dichloromethane.After 30 sec the mixture was poured into icewater, the
layers were separated, and the aqueous layerwas back extracted with ether
(2 x 10 mL). The combined organic layerswere washed with brine, dried, and
concentrated in vacuo. Column chromatography of the residue(hexane-ethyl
acetate, 3:1) afforded 7 mg (36 %) of 86:IR (neat) 3312, 2927, 1761, 1472,
1198, 1169, 1143, 1017 cm-1; 1H NMR (300 MHz, CDCI3)6 2.02 (3H, s), 2.52-
2.80 (3H, m), 3.01 (1H, m), 3.30 (1H, m), 3.80 (3H, s),3.82 (2H, m), 5.74 (3H,
m), 7.13 (1H, s); 130 NMR (CDCI3, 75 MHz) 6 20.6,20.8, 27.0, 27.4, 29.3, 31.4,
38.3, 38.5, 45.7, 46.0, 47.7, 48.5, 56.2, 56.3, 65.2, 115.8,123.5, 124.1, 125.7,
129.4, 130.8,132.9,133.6, 137.1,137.4,150.3, 151.3,168.2, 168.8; MS(EI)
m/z 392, 390(M+),330, 304, 258,207,178, 165, 152,139, 131, 120, 117,
107, 106, 105; HRMS m/z calcd for 019H -1904r (M+):390.0467.Found:
390.0457.Me0-
177
3-Acetoxy-6-bromo-2, 3,4,5,6, 7-hexadehydro-4-methoxy-
15-oxo-tetracyclo-[7.5.2.02,7.01,10].10,13-hexadecadiene(87).To
a solution of 86 (7 mg, 0.018 mmol) in dichloromethane (1 mL) was added
Dess-Martin periodinane (15 mg, 0.054 mmol). The mixture was stirred at
room temperature for 0.5 h and was diluted with ether (2 mL) and aqueous
sodium thiosulfate (2 mL).After separation of the layers, the aqueous layer
was back extracted with ether (3 x 2 mL). The combined organic layers were
washed withbrine,dried,and concentratedinvacuo.Column
chromatography of the residue (hexane-ethyl acetate, 3:1) afforded 5mg
(72%) of 87: IR (neat) 2971, 2933, 2929, 1768, 1752, 1477, 1195, 1175 cm-1;
1H NMR (300 MHz, CDCI3) 6 2.02 (3H, s), 2.80-3.25 (4H, m), 3.75 (3H, s), 3.80
(1H, m), 5.80 (3H, m), 6.97 (1H, s); 130 NMR (CDCI3, 75 MHz) 6 20.5, 27.5,
34.7, 44.4, 57.8, 60.4, 60.7, 115.0, 115.7, 116.4, 120.0, 124.8, 126.4, 127.6,
135.4, 139.4, 151.6, 168.2, 216; MS(EI) m/z 390, 388 (M+), 348, 346, 306,
304, 267, 225, 224; 223, 207, 165, 152, 139, 115, 91; HRMS m/z calcd for
Ci9H1704Br (M+): 388.0310. Found: 388.0310.
Me0
3-Acetoxy-6-bromo-2,3,4,5,6,7-hexadehydro-15-
hydroxyimino-4-methoxytetracyclo-[7.5.2.02,7.01,1c]_10,13-
hexadecadiene (88).To a solution of 87 (20 mg, 0.05 mmol) in methanol178
(0.5 mL) was added ammonium chloride (20 mg, 0.38 mmol) followed by
hydroxylamine hydrochloride (11 mg, 0.15 mmol). The mixturewas stirred at
room temperature for 3 h, after which the methanol was evaporated in vacuo.
Column chromatography of the residue (hexane-ethyl acetate, 3:1) afforded
15 mg (71 %) of 88 as a colorless amorphous solid:IR (neat) 3312, 2971,
2933, 2861, 1767, 1476, 1192, 1171, 1153 cm-1; 1H NMR (300 MHz, CDCI3) 8
2.21 (3H, s), 2.32 (2H, m), 2.60-2.98 (2H, m), 3.01-3.25 (2H, m), 3.49 (1H, m),
3.80 (m, 1H), 5.75 (3H, m), 6.99 (1H, s); 13C NMR (CDCI3, 75 MHz) 8 20.9,
21.0, 26.1, 33.8, 37.2,37.4,56.3, 56.5, 58.3, 114.7, 115.5,116.2,116.5,119.0,
124.1, 124.5, 125.2,126.3,126.6, 127.8, 135.9, 136.2,139.5,151.4,164.5,
168.2; MS(EI) m/z 405, 403 (M+), 363, 361, 346, 345, 344, 343, 330, 306, 305,
304, 302, 165, 153, 151, 139; HRMS m/z calcd for Ci 9H 18NO4Br (M+):
403.0419. Found: 403.0419.
MeOO
3,4,5,6,7-hexadehydro-15-
methansulfonyloxyimino-4-methoxytetracyclo-[7.5.2.02,7.01,10]-
10,13-hexadecadiene (89).To a solution of 88 (5 mg, 0.012 mmol) in
dichloromethane (1 mL) and triethylamine (10 pl, 0.05 mmol)was added
methanesulfonyl chloride (10 pl, 0.062 mmol). The mixturewas stirred at 0°C
for 3 h, after which it was diluted with aqueous 0.1 N hydrochloric acid (2 mL)
and extracted into ether (3 x 2 mL). Column chromatography of the residue
(hexane-ethyl acetate, 3:1) afforded 4 mg (67 %) of 89as a colorless oil:IR
(neat) 3170, 3165, 3020, 2924, 2853, 1764, 1477, 1437,1192, 1171,1110,179
1083 cm-1; 1H NMR (300 MHz, CDCI3) 5 2.21 (3H, s), 2.82 (2H, m),3.05 (1H,
m), 3.10 (3H, s), 3.20-3.51 (4H, m), 3.77 (m, 1H), 5.80 (m, 3H),7.01 (s, 1 H).
0
H 11
H NC)Me
MeOO-H
8-Bromo-10-methoxycarbonylamino-5-hydroxy-6-methoxy-3-
oxo-1, 2,9, 10-tetrahydro-phenanthrene (90).To a solution of 8-
bromo-10-carboxy1-5-hydroxy-6-methoxy-3-oxo-1,2,9,10-tetrahydro-
phenanthrene 89 (20 mg, 0.055 mmol) in dry methanol (1.5 mL)was added
diphenylphosphoryl azide (35 0.16 mmol) and triethylamine (20 IA, 0.10
mmol). The mixture was heated to reflux for 2 h after which itwas diluted with
aqueous 0.1 N hydrochloric acid (2 mL) and extracted into ether (3 x 2 mL).
Column chromatography of the residue (hexane-ethylacetate, 1:4) afforded
13 mg (60 `)/0) of 90 as a white solid:IR (KBr) 3992, 3316, 3290, 2941, 1768,
1689, 1642, 1466, 1287, cm-1; 1H NMR (300 MHz, CDCI3) 5 1.90 (1H,m),
2.41-2.80 (5H, m), 3.20 (1H, dd, J=16, 6 Hz), 3.70 (3H, s), 3.77 (1H, m),3.92
(3H, s), 4.65 (1H, bd, J=9Hz), 6.55 (1H, s), 7.10 (1 H, s), 7.30 (1H, s); 13CNMR
(CDCI3, 75 MHz) 6 26.2, 29.69, 36.5, 37.1, 42.8, 51.3, 56.6, 113.7,115.8,
120.5, 128.9, 129.0, 145.0, 145.7, 152.4, 156.5, 200.3; MS(CI) m/z397, 395
(M+1), 380, 322, 320, 243, 241, 169, 158,152, 142, 124, 106, 100, 95, 83;
HRMS m/z calcd for C17H18NO5Br (M+1): 395.0368. Found:395.0369.180
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Chapter IV. General Conclusion
This dissertation describes the synthetic approaches toward two complex
alkaloids, koumine, a herbal drug used in China, and morphine, an important
analgesic widely used in the practice of medicine throughout the world.
CH3
I
N
(-)-Koumine (-)-Morphine
NCH3
Although structurally unrelated, both substances have been used to
alleviate pain.Leitmotiv for the synthetic planning has been to approach these
complex structures starting from simple heterocyclic or aromatic compounds. We
then sought to gain entry to the appropriate ring system by applying organic
transformations that have precedence in the literature (for example, the Diels-
Alder Reaction or Robinson annulation).Further study is needed to complete
both syntheses.
Although both koumine and morphine occur innature as single
enantiomers, the synthetic approaches described here are racemic. However,
both routes are potentially amenable to asymmetric synthesis.185
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